User Image Cart Icon 0 Search Image

Dynorphin

  1. DYNORPHIN 1–8 and DYNORPHIN 1–9 are ligands for the κ-subtype of opiate receptor
  2. Behavioral effects and in vivo degradation of intraventricularly administered DYNORPHIN-(1-13) and D-Ala2-DYNORPHIN-(1-11) in rats
  3. DYNORPHIN is a specific endogenous ligand of the kappa opioid receptor
  4. Specific receptor for the opioid peptide DYNORPHIN: structure–activity relationships
  5. DYNORPHIN-(1-13), an extraordinarily potent opioid peptide
  6. Enhancement of DYNORPHIN gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor …
  7. Dopamine differentially regulates DYNORPHIN, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis
  8. Cloning and sequence analysis of cDNA for porcine β-neo-endorphin/DYNORPHIN precursor
  9. Porcine pituitary DYNORPHIN: complete amino acid sequence of the biologically active heptadecapeptide
  10. Effect of low-and high-frequency TENS on Met-enkephalin-Arg-Phe and DYNORPHIN A immunoreactivity in human lumbar CSF
  11. DYNORPHIN and vasopressin: common localization in magnocellular neurons
  12. Altered patterns of DYNORPHIN immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy
  13. Distribution of DYNORPHIN and enkephalin peptides in the rat brain
  14. DYNORPHIN immunocytochemistry in the rat central nervous system
  15. Cocaine-induced c-fos messenger RNA is inversely related to DYNORPHIN expression in striatum
  16. Dopamine D1 receptor mutant mice are deficient in striatal expression of DYNORPHIN and in dopamine-mediated behavioral responses
  17. DYNORPHIN is contained within hippocampal mossy fibers: immunochemical alterations after kainic acid administration and colchicine-induced neurotoxicity
  18. Differential activation of spinal cord DYNORPHIN and enkephalin neurons during hyperalgesia: evidence using cDNA hybridization
  19. In situ hybridization histochemistry and immunocytochemistry reveal an increase in spinal DYNORPHIN biosynthesis in a rat model of peripheral inflammation and …
  20. The opioid peptide DYNORPHIN mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation
  21. Opioid receptor selectivity of DYNORPHIN gene products.
  22. Comparison of the distribution of DYNORPHIN systems and enkephalin systems in brain
  23. Nonopiate effects of DYNORPHIN and des-Tyr-DYNORPHIN
  24. Antinociception and paralysis induced by intrathecal DYNORPHIN A.
  25. Optimization of solid-phase synthesis of [Ala8]-DYNORPHIN A
  26. DYNORPHIN expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons
  27. Pathway-specific patterns of the co-existence of substance P, calcitonin gene-related peptide, cholecystokinin and DYNORPHIN in neurons of the dorsal root ganglia of …
  28. Intrathecal DYNORPHIN A1–13 and DYNORPHIN A3–13 reduce rat spinal cord blood flow by non-opioid mechanisms
  29. Vasopressin, oxytocin, DYNORPHIN, enkephalin and corticotrophin‐releasing factor mRNA stimulation in the rat.
  30. Predominance of the amino-terminal octapeptide fragment of DYNORPHIN in rat brain regions
  31. DYNORPHIN increases in the dorsal spinal cord in rats with a painful peripheral neuropathy
  32. Immunoreactive DYNORPHIN in pituitary and brain
  33. DYNORPHIN A selectively reduces a large transient (N-type) calcium current of mouse dorsal root ganglion neurons in cell culture
  34. Involvement of DYNORPHIN and the kappa opioid receptor in feeding
  35. DYNORPHIN opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters
  36. DYNORPHIN-immunoreactive neurons in the central nervous system of the rat
  37. DYNORPHIN‐related peptides cause motor dysfunction in the rat through a non‐opiate action
  38. Stimulation of hypothalamic β-endorphin and DYNORPHIN release by corticotropin-releasing factor (in vitro)
  39. Cocaine selectively increases striatonigral DYNORPHIN levels by a dopaminergic mechanism
  40. Regional distribution of DYNORPHIN and neo-endorphin peptides in rat brain, spinal cord, and pituitary
  41. DYNORPHIN: potent analgesic effect in spinal cord of the rat
  42. DYNORPHIN A decreases voltage‐dependent calcium conductance of mouse dorsal root ganglion neurones.
  43. DYNORPHIN A and related peptides administered intrathecally in the rat: a search for putative kappa opiate receptor activity.
  44. DYNORPHIN-A-(1-8) is contained within vasopressin neurosecretory vesicles in rat pituitary
  45. DYNORPHIN-(1–13) induces spontaneous feeding in rats
  46. DYNORPHIN increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism
  47. β-Endorphin and DYNORPHIN control serum luteinizing hormone level in immature female rats
  48. Demonstration of a specific DYNORPHIN receptor in guinea pig ileum myenteric plexus
  49. Isolation and amino acid sequence analysis of a 4,000-dalton DYNORPHIN from porcine pituitary
  50. Stress-induced changes in brain Met-enkephalin, Leu-enkephalin and DYNORPHIN concentrations
  51. Immunohistochemical distribution of DYNORPHIN B in rat brain: relation to DYNORPHIN A and alpha-neo-endorphin systems
  52. The mechanism of action for the block of NMDA receptor channels by the opioid peptide DYNORPHIN
  53. Immunoreactive DYNORPHIN in mammalian spinal cord and dorsal root ganglia
  54. The opioid peptide DYNORPHIN, circadian rhythms, and starvation
  55. Extensive co‐occurrence of substance P and DYNORPHIN in striatal projection neurons: an evolutionarily conserved feature of basal ganglia organization
  56. Suppressive effect of DYNORPHIN-(1–13) on luteinizing hormone release in conscious castrated rats
  57. DYNORPHIN immunocytochemical localization in brain and peripheral nervous system: preliminary studies
  58. Immunohistochemical distribution of alpha-neo-endorphin/DYNORPHIN neuronal systems in rat brain: evidence for colocalization
  59. The opioid peptide DYNORPHIN directly blocks NMDA receptor channels in the rat.
  60. Spinal kappa receptor-mediated analgesia of E-2078, a systemically active DYNORPHIN analog, in mice.
  61. DYNORPHIN-containing pathways in the substantia nigra and ventral tegmentum: a double labeling study using combined immunofluorescence and retrograde tracing
  62. 17β-estradiol and progesterone positively modulate spinal cord DYNORPHIN: relevance to the analgesia of pregnancy
  63. Distribution of opiate receptor subtypes and enkephalin and DYNORPHIN immunoreactivity in the hippocampus of squirrel, guinea pig, rat, and hamster
  64. Analgesia produced by E-2078, a systemically active DYNORPHIN analog, in mice.
  65. DYNORPHIN: important mediator for electroacupuncture analgesia in the spinal cord of the rabbit
  66. Sequential expression of c-fos protooncogene, TNF-alpha, and DYNORPHIN genes in spinal cord following experimental traumatic injury
  67. The comparative distribution of enkephalin, DYNORPHIN and substance P in the human globus pallidus and basal forebrain
  68. Elevated DYNORPHIN in the hippocampal formation of aged rats: relation to cognitive impairment on a spatial learning task
  69. Striato-nigral DYNORPHIN and substance P pathways in the rat
  70. Co-expression of neuropeptides in the cat’s striatum: an immunohistochemical study of substance P, DYNORPHIN B and enkephalin
  71. Seizures induce dramatic and distinctly different changes in enkephalin, DYNORPHIN, and CCK immunoreactivities in mouse hippocampal mossy fibers
  72. The striatonigral DYNORPHIN pathway of the rat studied with in vivo microdialysis—II. Effects of dopamine D1 and D2 receptor agonists
  73. Mixed opioid/nonopioid effects of DYNORPHIN and DYNORPHIN related peptides after their intrathecal injection in rats
  74. β-endorphin and DYNORPHIN abnormalities in rats subjected to exercise and restricted feeding: relationship to anorexia nervosa?
  75. DYNORPHIN: a possible modulatory peptide on morphine or β-endorphin analgesia in mouse
  76. Self-administration of DYNORPHIN-[1–13] and D-ala2-DYNORPHIN-[1–11](kappa opioid agonists) in morphine (mu opioid agonist)-dependent rats
  77. DYNORPHIN A and cAMP-dependent protein kinase independently regulate neuronal calcium currents.
  78. DYNORPHIN opioid inhibition of cocaine‐induced, D1 dopamine receptor‐mediated immediatem‐early gene expression in the striatum
  79. L-type calcium channels mediate DYNORPHIN neuropeptide release from dendrites but not axons of hippocampal granule cells
  80. Pro-DYNORPHIN peptides are found in the same neurons throughout rat brain: immunocytochemical study
  81. A novel interaction between DYNORPHIN (1–13) and an N-methyl-D-aspartate site
  82. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, DYNORPHIN and …
  83. Suppression of withdrawal symptoms by DYNORPHIN in heroin addicts
  84. Brain DYNORPHIN and enkephalin systems in Fischer and Lewis rats: effects of morphine tolerance and withdrawal
  85. The distribution of substance P-, enkephalin-and DYNORPHIN-immunoreactive neurons in the medulla of the rat and their contribution to bulbospinal pathways
  86. Peripheral inflammation is associated with increased DYNORPHIN immunoreactivity in both projection and local circuit neurons in the superficial dorsal horn of the rat …
  87. Immunoreactive DYNORPHIN-(1-8) and corticotropin-releasing factor in subpopulation of hypothalamic neurons
  88. Effects of cocaine on extrapyramidal and limbic DYNORPHIN systems.
  89. No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) DYNORPHIN A and Met-enkephalin-Arg6-Phe7
  90. Striatonigral GABA, DYNORPHIN, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms
  91. A role for neuropeptide-Y, DYNORPHIN, and noradrenaline in the central control of food intake after food deprivation
  92. Evidence that DYNORPHIN-(1–13) acts as an agonist on opioid κ-receptors
  93. DYNORPHIN, a preferential ligand for κ-opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the rat
  94. Coordinate expression of hypothalamic pro-DYNORPHIN and pro-vasopressin mRNAs with osmotic stimulation
  95. The effects of morphine treatment and morphine withdrawal on the DYNORPHIN and enkephalin systems in Sprague-Dawley rats
  96. A subset of β-endorphin-or DYNORPHIN-containing neurons in the medial basal hypothalamus accumulates estradiol
  97. Isolation and structure of DYNORPHIN, an opioid peptide, from porcine duodenum
  98. DYNORPHIN A-(1-13) potently improves the impairment of spontaneous alternation performance induced by the mu-selective opioid receptor agonist DAMGO in mice.
  99. Co-localization of neuropeptide Y, vasoactive intestinal polypeptide and DYNORPHIN in non-noradrenergic axons of the guinea pig uterine artery
  100. Differential modulation of striatal dopamine release by intranigral injection of γ-aminobutyric acid (GABA), DYNORPHIN A and substance P
  101. Regulation of the metabolism of striatal DYNORPHIN by the dopaminergic system.
  102. DYNORPHIN and neoendorphin peptides decrease dorsal root ganglion neuron calcium-dependent action potential duration.
  103. Absorptive-mediated endocytosis of a DYNORPHIN-like analgesic peptide, E-2078 into the blood-brain barrier.
  104. Possible regulatory role of DYNORPHIN on morphine-and beta-endorphin-induced analgesia.
  105. Differential modulation of striatonigral DYNORPHIN and enkephalin by dopamine receptor subtypes
  106. Spinal DYNORPHIN immunoreactivity increases bilaterally in a neuropathic pain model
  107. DYNORPHIN-related immunoreactive peptides in rat brain and pituitary
  108. A specific radioimmunoassay for the novel opioid peptide DYNORPHIN
  109. Multiple opioid peptides and the modulation of pain: immunohistochemical analysis of DYNORPHIN and enkephalin in the trigeminal nucleus caudalis and spinal cord of …
  110. CSF-endorphin and DYNORPHIN in bulimia nervosa
  111. Preferred conformation, orientation, and accumulation of DYNORPHIN A-(1-13)-tridecapeptide on the surface of neutral lipid membranes
  112. Suppression by DYNORPHIN A-(1–13) of the expression of opiate withdrawal and tolerance in mice
  113. Behavioral changes induced by stressful situations: effects of enkephalins, DYNORPHIN, and their interactions.
  114. LOW AND HIGH FREQUENCY ELECTROCU-PUNCTURE STIMULATIONS RELEASE (Met~ 5) ENKEPHALIN AND DYNORPHIN A IN RAT SPINAL CORD
  115. Des-tyrosine-DYNORPHIN antagonizes morphine analgesia
  116. Striato-nigral DYNORPHIN and substance P pathways in the rat
  117. Synaptosomal Membrane‐Bound Form of Endopeptidase‐24.15 Generates Leu‐Enkephalin from DYNORPHIN 1‐8, α‐ and β‐Neoendorphin, and Met‐Enkephalin from Met‐Enkephalin‐Arg …
  118. Selective potentiation of NMDA-induced activity and release of excitatory amino acids by DYNORPHIN: possible roles in paralysis and neurotoxicity
  119. The degradation of DYNORPHIN A in brain tissue in vivo and in vitro
  120. Estimated conformation, orientation, and accumulation of DYNORPHIN A-(1-13)-tridecapeptide on the surface of neutral lipid membranes
  121. Increased DYNORPHIN immunoreactivity in spinal cord after traumatic injury
  122. Beta-endorphin and DYNORPHIN mimic the circadian immunoenhancing and anti-stress effects of melatonin
  123. DYNORPHIN induces partially reversible paraplegia in the rat
  124. Primary structure and functional expression of a guinea pig kappa opioid (DYNORPHIN) receptor
  125. DYNORPHIN A-(1-13) attenuates withdrawal in morphine-dependent rats: Effect of route of administration
  126. Selectivity of DYNORPHIN for κ opioid receptors
  127. DYNORPHIN gene expression and release in the myocardial cell.
  128. Morphine and DYNORPHIN (1–13) microinjected into the medial preoptic area and nucleus accumbens: effects on sexual behavior in male rats
  129. A new opioid octapeptide related to DYNORPHIN from porcine hypothalamus
  130. [N-methyl-Tyr1, N-methyl-Arg7-D-Leu8]-DYNORPHIN-A-(1-8) ethylamide, a stable DYNORPHIN analog, produces diuresis by kappa-opiate receptor activation in the rat.
  131. The effects of stress on central nervous system concentrations of the opioid peptide, DYNORPHIN
  132. Use of the 4-Methoxy-2, 6-dimethylbenzenesulfonyl (Mds) Group to Synthesize DYNORPHIN [1-13] and Related Peptides
  133. DYNORPHIN‐immunoreactive neurons in the rat nucleus accumbens: Ultrastructure and synaptic input from terminals containing substance P and/or DYNORPHIN
  134. Neurological dysfunction after intrathecal injection of DYNORPHIN A (1-13) in the rat. II. Nonopioid mechanisms mediate loss of motor, sensory and autonomic function.
  135. Microinjection of DYNORPHIN into the hippocampus impairs spatial learning in rats
  136. Induction of the gene encoding pro-DYNORPHIN by experimentally induced arthritis enhances staining for DYNORPHIN in the spinal cord of rats
  137. Pharmacology of DYNORPHIN
  138. The effect of morphine tolerance dependence and abstinence on immunoreactive DYNORPHIN (1–13) levels in discrete brain regions, spinal cord, pituitary gland and …
  139. Influence of nigrostriatal dopaminergic tone on the biosynthesis of DYNORPHIN and enkephalin in rat striatum
  140. Ultrastructural analysis of DYNORPHIN B–immunoreactive cells and terminals in the superficial dorsal horn of the deafferented spinal cord of the rat
  141. DYNORPHIN A-(1–13) markedly improves scopolamine-induced impairment of spontaneous alternation performance in mice
  142. In vivo transport of a DYNORPHIN-like analgesic peptide, E-2078, through the blood–brain barrier: An application of brain microdialysis
  143. ATP release, adenosine formation, and modulation of DYNORPHIN and glutamic acid release by adenosine analogues in rat hippocampal mossy fiber synaptosomes
  144. Effects of DYNORPHIN A-(1–13) on carbon monoxide-induced delayed amnesia in mice studied in a step-down type passive avoidance task
  145. DYNORPHINs other than DYNORPHIN A (1-17) lack spinal antianalgesic activity but do act on DYNORPHIN A (1-17) receptors.
  146. DYNORPHIN reduces calcium-dependent action potential duration by decreasing voltage-dependent calcium conductance
  147. Rimorphin, a unique, naturally occurring [Leu] enkephalin-containing peptide found in association with DYNORPHIN and alpha-neo-endorphin
  148. Opioid peptides (DAGO-enkephalin, DYNORPHIN A (1–13), BAM 22P) microinjected into the rat brainstem: comparison of their antinociceptive effect and their effect on …
  149. Effects of adrenal steroid manipulations and repeated restraint stress on DYNORPHIN mRNA levels and excitatory amino acid receptor binding in hippocampus
  150. Sites of analgesic action of DYNORPHIN
  151. DYNORPHIN (1–13) improves survival in cats with focal cerebral ischaemia
  152. Distribution of immunoreactive DYNORPHIN in the central nervous system of the rat
  153. Cellular substrates for interactions between DYNORPHIN terminals and dopamine dendrites in rat ventral tegmental area and substantia nigra
  154. Regional Distribution of Calcitonin Gene‐Related Peptide‐, Substance P‐, Cholecystokinin‐, Met5‐Enkephalin‐, and DYNORPHIN A (1–8)‐Like Materials in the Spinal …
  155. DYNORPHIN-(1–13), dopamine and feeding in rats
  156. Spinal cord DYNORPHIN may modulate nociception via a ℵ-opioid receptor in chronic arthritic rats
  157. U-50,488 H inhibits DYNORPHIN and glutamate release from guinea pig hippocampal mossy fiber terminals
  158. Immunoreactive DYNORPHIN in human brain and pituitary
  159. Suppression by DYNORPHIN A and [des-Tyr1] DYNORPHIN A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice.
  160. Immunoreactive DYNORPHIN in rat tissues and plasma
  161. Met-enkephalin and morphine but not DYNORPHIN inhibit noxious stimuli-induced release of substance P from rabbit dorsal horn in situ
  162. Effects of traumatic injury on DYNORPHIN immunoreactivity in spinal cord
  163. Changes in DYNORPHIN, enkephalin and cholecystokinin content of hippocampus and substantia nigra after amygdala kindling
  164. ProDYNORPHIN peptide distribution in the forebrain of the Syrian hamster and rat: a comparative study with antisera against DYNORPHIN A, DYNORPHIN B, and the C …
  165. Glutamate and DYNORPHIN release from a subcellular fraction enriched in hippocampal mossy fiber synaptosomes
  166. Feeding elicited by DYNORPHIN (1–13) microinjections into the ventral tegmental area in rats
  167. DYNORPHIN A inhibits and naloxone increases the electrically stimulated release of oxytocin but not vasopressin from the terminals of the neural lobe
  168. Elevated CSF DYNORPHIN A [1–8] in Tourette’s syndrome
  169. DYNORPHIN reduces voltage-dependent calcium conductance of mouse dorsal root ganglion neurons
  170. Analgesic effects of μ-, δ-and κ-opiate agonists and, in particular, DYNORPHIN at the spinal level
  171. Characterization of DYNORPHIN A-converting enzyme in human spinal cord. An endoprotease related to a distinct conversion pathway for the opioid …
  172. High density of zinc-containing and DYNORPHIN B-and substance P-immunoreactive terminals in the marginal division of the rat striatum
  173. Intrathecally administered DYNORPHIN-(1–17) modulates morphine-induced antinociception differently in morphine-naive and morphine-tolerant rats
  174. DYNORPHIN-selective inhibition of adenylyl cyclase in guinea pig cerebellum membranes.
  175. Opioid peptide levels in gerbil brain after transient ischemia: lasting depletion of hippocampal DYNORPHIN.
  176. Head group and structure specific interactions of enkephalins and DYNORPHIN with liposomes: investigation by hydrophobic photolabeling
  177. DYNORPHIN (1–17): lack of analgesia but evidence for non-opiate electrophysiological and motor effects
  178. Spinal DYNORPHIN involvement in the analgesia of pregnancy: effects of intrathecal DYNORPHIN antisera
  179. Parallel distribution of immunoreactive α-neo-endorphin and DYNORPHIN in rat and human tissue
  180. Effect of DYNORPHIN on insulin and somatostatin secretion, calcium uptake, and c-AMP levels in isolated rat islets of Langerhans
  181. Upregulation of HIV-1 expression in cocultures of chronically infected promonocytes and human brain cells by DYNORPHIN
  182. Alterations in mRNA of enkephalin, DYNORPHIN and thyrotropin releasing hormone during amygdala kindling: an in situ hybridization study
  183. Immunoreactive DYNORPHIN B in sacral primary afferent fibers of the cat
  184. Intrathecal DYNORPHIN (1–13) results in an irreversible loss of the tail-flick reflex in rats
  185. The effects of intranigral GABA and DYNORPHIN A injections on striatal dopamine and GABA release: evidence that dopamine provides inhibitory regulation of striatal …
  186. Enhancement of phagocytosis by DYNORPHIN A in mouse peritoneal macrophages
  187. Decreased glutamate release correlates with elevated DYNORPHIN content in the hippocampus of aged rats with spatial learning deficits
  188. Characterization and localization of immunoreactive DYNORPHIN, α-neo-endorphin, met-enkephalin and substance P in human spinal cord
  189. DYNORPHIN-A-(1–13) antagonizes morphine analgesia in the brain and potentiates morphine analgesia in the spinal cord
  190. Antinociceptive action of intracerebroventricularly administered DYNORPHIN and other opioid peptides in the rat.
  191. Characterization of DYNORPHIN A-induced antinociception at spinal level
  192. Role of DYNORPHIN and GABA in the inhibitory regulation of NMDA-induced dopamine release in striosome-and matrix-enriched areas of the rat striatum
  193. Analgesic effects of DYNORPHIN-A and morphine in mice
  194. Selective inactivation of opioid receptors in rat hippocampus demonstrates that DYNORPHIN-A and-B may act on μ-receptors in the CA1 region
  195. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal DYNORPHIN expression in the 6-hydroxydopamine lesioned rat
  196. DYNORPHIN A and substance P in the cerebrospinal fluid of schizophrenic patients
  197. Kainic acid alters the metabolism of Met5-enkephalin and the level of DYNORPHIN A in the rat hippocampus
  198. DYNORPHIN-and enkephalin-like immunoreactivity is altered in limbic-basal ganglia regions of rat brain after repeated electroconvulsive shock
  199. Influence of DYNORPHIN A antibodies on the formation of edema and cell changes in spinal cord trauma
  200. Characterization of methamphetamine effects on the striatal-nigral DYNORPHIN system
  201. Sympathetic noradrenergic neurons containing DYNORPHIN but not neuropeptide Y innervate small cutaneous blood vessels of guinea-pigs
  202. Modulation of central nervous system actions of corticotropin-releasing factor by DYNORPHIN-related peptides
  203. N-methyl-D-aspartate (NMDA) and opioid receptors mediate DYNORPHIN-induced spinal cord injury: behavioral and histological studies
  204. DYNORPHIN-immunoreactive neurons in the autonomic nervous system
  205. Distribution of immunoreactive DYNORPHIN B in discrete areas of the rat brain and spinal cord
  206. Competitive and non-competitive NMDA antagonists limit DYNORPHIN A-induced rat hindlimb paralysis
  207. Spinal DYNORPHIN A (1–17): possible mediator of antianalgesic action
  208. DYNORPHIN: potent analgesic effect in spinal cord of the rat.
  209. A DYNORPHIN-like opioid in the central nervous system of an amphibian
  210. Degradation of DYNORPHIN‐related peptides by the puromycin‐sensitive aminopeptidase and aminopeptidase M
  211. Increased spinal cord DYNORPHIN mRNA during peripheral inflammation
  212. Localization of DYNORPHIN B-like and alpha-neoendorphin-like immunoreactivities in the guinea pig organ of Corti
  213. Distribution of immunoreactive DYNORPHIN A1–8 in discrete nuclei of the rat brain: comparison with DYNORPHIN A
  214. DYNORPHIN A-(1–13) potently prevents memory dysfunctions induced by transient cerebral ischemia in mice
  215. Evidence for the occurrence of the opioid octapeptide DYNORPHIN-(1–8) in the neurointermediate pituitary of rats
  216. The influence of chronic stress on multiple opioid peptide systems in the rat: pronounced effects upon DYNORPHIN in spinal cord
  217. DYNORPHIN is located throughout the CNS and is often co-localized with alpha-neo-endorphin
  218. Immunohistochemical localization of DYNORPHIN (1–8) in hypothalamic magnocellular neurons: evidence for absence of proenkephalin
  219. DYNORPHIN converting enzyme with unusual specificity from rat brain
  220. Release of DYNORPHIN, somatostatin and substance P from the vascularly perfused small intestine of the guinea‐pig during peristalsis
  221. Blockade of the glycine modulatory site of NMDA receptors modifies DYNORPHIN-induced behavioral effects
  222. DYNORPHIN and related opioid peptides enhance tumoricidal activity mediated by murine peritoneal macrophages
  223. DYNORPHIN‐(1–13). I. Structure‐function relationships of Ala‐containing analogs
  224. Release of immunoreactive-DYNORPHIN from the isolated guinea-pig small intestine is reduced during peristaltic activity
  225. L (+)-2-amino-4-phosphonobutyrate inhibits the release of both glutamate and DYNORPHIN from guinea pig but not rat hippocampal mossy fiber synaptosomes
  226. DYNORPHIN A-(1-17) induces alterations in free fatty acids, excitatory amino acids, and motor function through an opiate-receptor-mediated mechanism
  227. DYNORPHIN A-induced rat spinal cord injury: evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury.
  228. The co-occurrence of substance P-like immunoreactivity and DYNORPHIN-like immunoreactivity in striatopallidal and striatonigral projection neurons in birds and reptiles
  229. Neuropeptide Y and DYNORPHIN‐immunoreactive large dense‐core vesicles are strategically localized for presynaptic modulation in the hippocampal formation and …
  230. Metabolism of DYNORPHIN A 1-13 in human blood and plasma
  231. Spinal cord DYNORPHIN: positive region-specific modulation during pregnancy and parturition
  232. Blockade of the 3, 4-methylenedioxymethamphetamine-induced changes in neurotensin and DYNORPHIN A systems
  233. Degradation of DYNORPHIN-(1–13) by membrane-bound rat brain enzymes
  234. Comparison of DYNORPHIN-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency.
  235. Presence of DYNORPHIN-like immunoreactivity in rat pituitary gland and hypothalamus
  236. The conformation of DYNORPHIN A-(1–13) in aqueous solution as studied by fourier transform infrared spectroscopy
  237. Synthesis using a Fmoc-based strategy and biological activities of some reduced peptide bond pseudopeptide analogs of DYNORPHIN A
  238. Influence of DYNORPHIN (1-13) on spinal reflexes in the rat.
  239. A novel bovine spinal cord endoprotease with high specificity for DYNORPHIN B
  240. DYNORPHIN-(1–13): Effects in nontolerant and morphine-dependent rhesus monkeys
  241. Morphological characterization of marginal (lamina I) neurons immunoreactive for substance P, enkephalin, DYNORPHIN and gamma-aminobutyric acid in the rat spinal …
  242. Analgesia induced by intrathecal injection of DYNORPHIN B in the rat
  243. A comparison of the role of DYNORPHIN in the hippocampal mossy fiber pathway in guinea pig and rat
  244. Amygdaloid kindling increases enkephalin-like immunoreactivity but decreases DYNORPHIN-A-like immunoreactivity in rat hippocampus
  245. Increased staining of immunoreactive DYNORPHIN cell bodies in the deafferented spinal cord of the rat
  246. Regulation of the concentration of DYNORPHIN A1–8 in the striatonigral pathway by the dopaminergic system
  247. Stimulation by corticotropin-releasing factor of the release of immunoreactive DYNORPHIN A from mouse spinal cords in vitro
  248. Comparison of met‐enkephalin‐, DYNORPHIN A‐, and neurotensin‐immunoreactive neurons in the cat and rat spinal cords: I. Lumbar cord
  249. Met-enkephalin-like and DYNORPHIN-like immunoreactivities of the basal ganglia of the cat
  250. Pro-DYNORPHIN is endogenous to the anterior pituitary and is co-localized with LH and FSH in the gonadotrophs
  251. Increased β-endorphin and DYNORPHIN concentrations in discrete hypothalamic regions of genetically obese (ob/ob) mice
  252. Kappa opioid properties of DYNORPHIN and its peptide fragments on the guinea-pig Ileum.
  253. Levels of DYNORPHIN-(1–13) immunoreactivity in rat neurointermediate pituitaries are concomitantly altered with those of leucine enkephalin and vasopressin in …
  254. Mild footshock stress dissociates substance P from substance K and DYNORPHIN from Met-and Leu-enkephalin
  255. Apomorphine-susceptible and apomorphine-unsusceptible Wistar rats differ in novelty-induced changes in hippocampal DYNORPHIN B expression and two-way active …
  256. Characterization of kappa opioid binding using DYNORPHIN A1-13 and U69, 593 in the rat brain.
  257. Rostrocaudal subregional differences in the response of enkephalin, DYNORPHIN and substance P synthesis in rat nucleus accumbens to dopamine depletion
  258. Antinociceptive profile of DYNORPHIN in the rat
  259. DYNORPHIN A-induced rat hindlimb paralysis and spinal cord injury are not altered by the κ opioid antagonist nor-binaltorphimine
  260. Behavioral effects of DYNORPHIN—a novel opioid neuropeptide
  261. DYNORPHIN‐immunoreactive terminals in the rat nucleus accumbens: Cellular sites for modulation of target neurons and interactions with catecholamine afferents
  262. MK-801 blocks DYNORPHIN A (1–13)-induced loss of the tail-flick reflex in the rat
  263. DYNORPHIN A modulates acute and chronic opioid effects.
  264. Matrix-assisted laser desorption mass spectrometry of biotransformation products of DYNORPHIN A in vitro
  265. Colocalization of α-neo-endorphin and DYNORPHIN immunoreactivity in hypothalamic neurons
  266. A subclassification of κ-sites in human brain by use of DYNORPHIN 1–17
  267. Sensitivity to DYNORPHIN-(1–13) of the presynaptic inhibitory opiate receptors of the guinea-pig heart
  268. Vasopressin and oxytocin in the rat spinal cord: distribution and origins in comparison to [Met] enkephalin, DYNORPHIN and related opioids and their irresponsiveness to …
  269. Increased enkephalin and DYNORPHIN immunoreactivity in the hippocampus of seizure sensitive Mongolian gerbils
  270. Neonatal capsaicin treatment attenuates spinal Fos activation and DYNORPHIN gene expression following peripheral tissue inflammation and hyperalgesia
  271. DYNORPHIN effects on plasma concentrations of anterior pituitary hormones in the nonhuman primate.
  272. Corticotropin-releasing factor stimulates the release of methionine-enkephalin and DYNORPHIN from the neostriatum and globus pallidus of the rat: in vitro and in vivo …
  273. Differential release of substance P and somatostatin in the rat spinal cord in response to noxious cold and heat; effect of DYNORPHIN A (1-17).
  274. Plasma extravasation induced by DYNORPHIN-(1–13) in rat skin
  275. Central cardiovascular effects of κ agonists DYNORPHIN-(1–13) and ethylketocyclazocine in the anaesthetized rat
  276. Central and peripheral sites for cardiovascular actions of DYNORPHIN-(1–13) in rats
  277. Conformation of DYNORPHIN A (1-17) bound to dodecylphosphocholine micelles
  278. Measurement of CSF DYNORPHIN A 1–8 immunoreactivity in anorexia nervosa and normal-weight bulimia
  279. DYNORPHIN A content in the rat brain and spinal cord after a localized trauma to the spinal cord and its modification with p-chlorophenylalanine: An experimental study …
  280. Differential modulation by [D-Pen2, D-Pen5] enkephalin and DYNORPHIN A-(1-17) of the inhibitory bladder motility effects of selected mu agonists in vivo.
  281. Deprivation of REM sleep in the rat and the opioid peptides β-endorphin and DYNORPHIN
  282. Synthesis and structure-activity relationships of DYNORPHIN A-(1-8) amide analogs
  283. Treatment of stroke with opiate antagonists—effects of exogenous antagonists and DYNORPHIN 1–13
  284. Colocalization of prolactin-and DYNORPHIN-like substances in a neuronal population of the rat lateral hypothalamus
  285. Possible interactions between DYNORPHIN and dopaminergic systems in rat basal ganglia and substantia nigra
  286. DYNORPHIN prolongs the action potential of mouse sensory ganglion neurons by decreasing a potassium conductance whereas another specific kappa opioid does so …
  287. The distribution of neuropeptide Y and DYNORPHIN immunoreactivity in the brain and pituitary gland of the platyfish, Xiphophorus maculatus, from birth to sexual maturity
  288. Lithium increases DYNORPHIN A (1–8) and proDYNORPHIN mRNA levels in the basal ganglia of rats
  289. Role of DYNORPHIN-containing neurons in the presynaptic inhibitory control of the acetylcholine-evoked release of dopamine in the striosomes and the matrix of the cat …
  290. Increased immunoreactive DYNORPHIN and leu-enkephalin in posterior pituitary of obese mice (ob/ob) and super-sensitivity to drugs that act at kappa receptors
  291. Characterization of the aminopeptidase activity of epidermal leukotriene A4 hydrolase against the opioid DYNORPHIN fragment 1–7
  292. The striatonigral DYNORPHIN pathway of the rat studied with in vivo microdialysis—I. Effects of K+-depolarization, lesions and peptidase inhibition
  293. Unlike β-endorphin, DYNORPHIN 1–13 does not cause retrograde amnesia for shuttle avoidance or inhibitory avoidance learning in rats
  294. Effect of intranigral injections of DYNORPHIN, DYNORPHIN fragments and α-neoendorphin on rotational behaviour in the rat
  295. Preparation of brain membranes containing a single type of opioid receptor highly selective for DYNORPHIN
  296. [3H] DYNORPHIN a binding and κ selectivity of proDYNORPHIN peptides in rat, guinea-pig and monkey brain
  297. DYNORPHIN (1–8) inhibits stimulated release of oxytoxin but not vasopressin from isolated neurosecretory endings of the rat neurohypophysis
  298. DYNORPHIN (1–13), a long-lasting inhibitor of opiate receptor binding invitro
  299. Electrophysiological effects of DYNORPHIN peptides on hippocampal pyramidal cells in rat
  300. Agonist and antagonist effects of DYNORPHIN A-(1-13) in a thermal antinociception assay in rhesus monkeys.
  301. Chronic haloperidol and clozapine differentially affect DYNORPHIN peptides and substance P in basal ganglia of the rat
  302. DYNORPHIN potentiation of [3H] CGP-39653 binding to rat brain membranes
  303. The influence of foot-shock stress upon brain, pituitary and spinal cord pools of immunoreactive DYNORPHIN in rats
  304. Spinal involvement of both DYNORPHIN A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in …
  305. Biology and chemistry of the DYNORPHIN peptides
  306. … on the 3, 4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and DYNORPHIN A …
  307. Evidence that Inhibition of Nicotine‐Mediated Catecholamine Secretion from Adrenal Chromaffin Cells by Enkephalin, β‐Endorphin, DYNORPHIN (1‐13), and Opiates is …
  308. Invivo cellular responses to electrophoretically applied DYNORPHIN in the rat hippocampus
  309. Syntheses, opioid binding affinities, and potencies of DYNORPHIN A analogues substituted in positions 1, 6, 7, 8 and 10
  310. Highly. kappa. receptor-selective DYNORPHIN A analogs with modifications in position 3 of DYNORPHIN A (1-11)-NH2
  311. Localization of DYNORPHIN gene product-immunoreactivity in neurons from spinal cord and dorsal root ganglia
  312. A specific radioimmunoassay for the opioid peptide DYNORPHIN B in neural tissues
  313. Dopamine receptors mediate alterations in striato-nigral DYNORPHIN and substance P pathways
  314. Comparison of acute effects of DYNORPHIN and beta-endorphin on prolactin release in the rat
  315. Mimicking the membrane-mediated conformation of DYNORPHIN A-(1-13)-peptide: Circular dichroism and nuclear magnetic resonance studies in methanolic solution
  316. N-Terminal alkylated derivatives of [D-Pro10] DYNORPHIN A-(1-11) are highly selective for. kappa.-opioid receptors
  317. Lateral olivocochlear neurons contain both enkephalin and DYNORPHIN immunoreactivities: immunocytochemical co-localization studies.
  318. DYNORPHIN A (1–17) mediates midazolam antagonism of morphine antinociception in mice
  319. Introduction of guest peptides into Escherichia coli alkaline phosphatase. Excision and purification of a DYNORPHIN analogue from an active chimeric protein.
  320. DYNORPHIN levels in parkinsonian patients: Leu5-enkephalin production from either proenkephalin A or proDYNORPHIN in human brain
  321. Synthesis and opioid activity profiles of cyclic DYNORPHIN analogs
  322. In vitro stability of some reduced peptide bond pseudopeptide analogues of DYNORPHIN A
  323. Behavioral and neurochemical effects of the new opioid peptide DYNORPHIN-(1–13): Comparison with other neuropeptides
  324. The opioid peptide DYNORPHIN modulates AMPA and kainate responses in acutely isolated neurons from the dorsal horn
  325. Rectal Absorption of E‐2078 (DYNORPHIN Analogue Peptide) in Rats
  326. DYNORPHIN agonist therapy of Parkinson’s disease.
  327. Localization of immunoreactive DYNORPHIN in neurons cultured from spinal cord and dorsal root ganglia
  328. Dual effects of DYNORPHIN-(1-13) on cholinergic and substance P-ergic transmissions in the rabbit iris sphincter muscle.
  329. Demonstration of DYNORPHIN A 1–8 immunoreactive axons contacting spinal cord projection neurons in a rat model of peripheral inflammation and hyperalgesia
  330. DYNORPHIN A (1–13) peptide NH groups are solvent exposed: FT-IR and 500 MHz 1H NMR spectroscopic evidence
  331. PC12 rat pheochromocytoma cells synthesize DYNORPHIN. Its secretion is modulated by nicotine and nerve growth factor
  332. Effect of DYNORPHIN-(1–13) and related peptides on respiratory rate and morphine-induced respiratory rate depression
  333. Peptide models of DYNORPHIN A (1-17) incorporating minimally homologous substitutes for the potential amphiphilic. beta. strand in residues 7-15
  334. DYNORPHIN A: in vivo release in the spinal cord of the cat
  335. Immunoreactive DYNORPHIN in the rat adenohypophysis consists exclusively of 6000 dalton species
  336. Rostral and caudal ventricular infusion of antibodies to DYNORPHIN A (1–17) and DYNORPHIN A (1–8): effects on electrically-elicited feeding in the rat
  337. DYNORPHIN, naloxone, and overflow of norepinephrine during cardiac nerve stimulation in dogs
  338. The effect of various opiate receptor agonists on the seizure threshold in the rat. Is DYNORPHIN an endogenous anticonvulsant?
  339. Opioids in myocardial ischaemia: potentiating effects of DYNORPHIN on ischaemic arrhythmia, bradycardia and cardiogenic shock following coronary artery occlusion in …
  340. DYNORPHIN induces task-specific impairment of memory
  341. The histamine-releasing effect of DYNORPHIN and other peptides possessing Arg-Pro sequences
  342. Comparative structure-function studies with analogs of DYNORPHIN-(1–13) and [Leu5] enkephalin
  343. Solution conformations of the pituitary opioid peptide DYNORPHIN-(1–13)
  344. Presynaptic modulation of glutamate and DYNORPHIN release by excitatory amino acids in the guinea-pig hippocampus
  345. Comparative effects of intrahippocampal injection of DYNORPHIN A (1–8), DYNORPHIN A (1–13), DYNORPHIN A (1–17), U-50,488 H, and DYNORPHIN B on blood pressure and …
  346. DYNORPHIN (1–13): Analgesia, hypothermia, cross-tolerance with morphine and β-endorphin
  347. … physostigmine-induced analgesia: enhancement by naloxone, beta-funaltrexamine and nor-binaltorphimine and antagonism by DYNORPHIN A (1-17).
  348. Cerebrospinal fluid activity of DYNORPHIN-converting enzyme at term pregnancy.
  349. Selective involvement of kappa opioid and phencyclidine receptors in the analgesic and motor effects of DYNORPHIN-A-(1–13)-Tyr-Leu-Phe-Asn-Gly-Pro
  350. Sympathetic noradrenergic fibers as the source of immunoreactive alpha-neoendorphin and DYNORPHIN in the guinea pig heart
  351. Allosteric interaction of DYNORPHIN and myelin basic protein with muscarinic receptors
  352. Comparison of in vitro potencies in pharmacological and binding assays after inhibition of peptides reveals that DYNORPHIN (1–9) is a potent κ-agonist
  353. Significance of testosterone in regulating hypothalamic content and in vitro release of β‐endorphin and DYNORPHIN
  354. The comparison between enkephalin-like and DYNORPHIN-like immunoreactivity in both monkey and human globus pallidus and substantia nigra
  355. Kappa binding sites in guinea-pig brain membranes: evidence for a DYNORPHIN-resistant subtype
  356. Repeated electroconvulsive shocks alter the biosynthesis of enkephalin and concentration of DYNORPHIN in the rat brain
  357. [125I] DYNORPHIN (1–8) produces a similar pattern of κ-opioid receptor labelling to [3H] DYNORPHIN (1–8) and [3H] etorphine in guinea pig brain: A quantitative …
  358. Presence of DYNORPHIN-like immunoreactivity in pheochromocytomas
  359. Central non-opioid physiological and pathophysiological effects of DYNORPHIN A and related peptides.
  360. k‐Binding and Degradation of [3H]DYNORPHIN A (1–8) and [3H]DYNORPHIN A (1–9) in Suspensions of Guinea Pig Brain Membranes
  361. Striatal neurochemistry of DYNORPHIN-(1–13): In vivo electrochemical semidifferential analyses
  362. Studies in vivo with DYNORPHIN-(1–9): analgesia but not gastrointestinal effects following intrathecal administration to mice
  363. Cardiovascular effects of DYNORPHIN A-(1–8), DYNORPHIN A-(1–13) and DYNORPHIN A-(1–17) microinjected into the preoptic medialis nucleus of the rat
  364. DYNORPHIN A-(1–13) potently improves scopolamine-induced impairment of passive avoidance response in mice
  365. A re-examination of the localization of immunoreactive DYNORPHIN (1–8),[Leu] enkephalin and [Met] enkephalin in the rat neurohypophysis
  366. Beta-endorphin and DYNORPHIN participate in the stress-induced release of prolactin in the rat
  367. Antagonism of μ-opioid receptor-mediated inhibitions of nociceptive neurones by U50488H and DYNORPHIN A1–13 in the rat dorsal horn
  368. Clonidine stimulated the release of DYNORPHIN in the spinal cord of the rat: a possible mechanism for its depressor effects
  369. Design, Synthesis, and Biological Properties of highly Potent Cyclic DYNORPHIN A Analogs. Analogs Cyclized between Positions 5 and 11
  370. Intranigral DYNORPHIN-1-13 suppresses kindled seizures by a naloxone-insensitive mechanism
  371. The role of amino-terminal sequence of β-endorphin and DYNORPHIN in the determination of opiate receptor type selectivity
  372. Synthesis and biological activities of DYNORPHIN A analogues with opioid antagonist properties
  373. Potency of three opiate antagonists to reverse the inhibitory activity of DYNORPHIN, enkephalins and opioid-like alkaloids on the guinea pig ileum
  374. Effects of β-endorphin, met-enkephalm, and DYNORPHIN a on basal and stimulated insulin secretion in the mouse
  375. Histamine release induced by DYNORPHIN-(1-13) from rat mast cells
  376. Subcellular localization of immunoreactive DYNORPHIN and vasopressin in rat pituitary and hypothalmus
  377. Electrophysiological changes in substantia nigra after DYNORPHIN administration
  378. DYNORPHIN-(1-13) is a potent in vivo suppressor of vasopressin levels in the rat
  379. Increased Sensitivity to Insulin-Releasing and Glucoregulatory Effects of DYNORPHIN A 1–13 and U 50488h in ob/ob Versus Lean Mice
  380. Demonstration of calcitonin gene-related peptide immunoreactive axons contacting DYNORPHIN A (1–8) immunoreactive spinal neurons in a rat model of peripheral …
  381. Naloxone reverses the inhibitory effects of DYNORPHIN A on motor activity in the mouse
  382. N-methyl-d-aspartate receptors mediate dopamone-induced changes in extrapyramidal and limbic DYNORPHIN systems
  383. Effect of neonatal hypoxia-ischemia on nigro-striatal dopamine receptors and on striatal neuropeptide Y, DYNORPHIN A and substance P concentrations in rats
  384. DYNORPHIN in bovine adrenal medulla: I. Detection in glandular and cellular extracts and secretion from isolated chromaffin cells
  385. Immunocytochemical demonstration of DYNORPHIN (PH‐8P)‐like immunoreactive elements in the human hypothalamus
  386. Immunoreactive DYNORPHIN is regulated by estrogen in the rat anterior pituitary
  387. DYNORPHIN A-(1–13) attenuates basal forebrain-lesion-induced amnesia in rats
  388. DYNORPHIN 1–8 binds to opiate kappa receptors in the neurohypophysis
  389. Intrathecal somatostatin, somatostatin analogs, substance P analog and DYNORPHIN A cause comparable neurotoxicity in rats
  390. Synthesis and Opioid Activity of Conformationally Constrained DYNORPHIN A Analogs. 1. Conformational Constraint in the” Message” Sequence
  391. Effects of DYNORPHIN A (1–13) and of fragments of β-endorphin on blood pressure and heart rate of anesthetized rats
  392. Functional studies with the opioid peptide DYNORPHIN: Acute effects of injections into the substantia nigra reticulata of naive rats
  393. Changes in hippocampal immunoreactive DYNORPHIN and-neoendorphin content following intra-amygdalar kainic acid-induced seizures
  394. Distinct distribution of immunoreactive DYNORPHIN and leucine enkephalin in various populations of isolated adrenal cromaffin cells
  395. Treatment of pain in cancer patients by intrathecal administration of DYNORPHIN
  396. Decreased [3H]-naloxone binding and elevated DYNORPHIN-A (1–8) content in Zucker rat brain
  397. Cardiovascular effects of DYNORPHIN A (1–13) in conscious rats and its modulation of morphine bradycardia over time
  398. Clonidine, administered intracerebroventricularly in mice, produces an anti-analgesic effect which may be mediated spinally by DYNORPHIN A (1–17)
  399. Hypothalamic DYNORPHIN and vasopressin mRNA expression in normal and Brattleboro rats.
  400. Levels of immunoreactive DYNORPHIN in brain and pituitary of Brattleboro rats
  401. DAKLI: a multipurpose ligand with high affinity and selectivity for DYNORPHIN (kappa opioid) binding sites
  402. Effect of modification of the basic residues of DYNORPHIN A-(1-13) amide on opioid receptor selectivity and opioid activity
  403. Chronic administration of morphine decreases level of DYNORPHIN A in the rat nucleus accumbens
  404. Stimulation of prolactin secretion in the rat by α-neo-endorphin, β-neo-endorphin and DYNORPHIN
  405. Distribution of immunoreactive DYNORPHIN in discrete brain nuclei; comparison with vasopressin
  406. Evidence for the corelease of DYNORPHIN and glutamate from rat hippocampal mossy fiber terminals
  407. Enkephalin, DYNORPHIN and substance P in postmortem substantia nigra from normals and schizophrenic patients
  408. Separate origins for the DYNORPHIN and enkephalin immunoreactive fibers in the inferior mesenteric ganglion of the guinea pig
  409. Design and synthesis of highly potent and selective cyclic DYNORPHIN A analogs
  410. DYNORPHIN-A alters the excitability of pyramidal neurons of the rat hippocampus in vitro
  411. [Des-Tyr1] DYNORPHIN A-(2-17) has naloxone-insensitive antinociceptive effect in the writhing assay.
  412. Modulation of acute morphine tolerance by corticotropin-releasing factor and DYNORPHIN A in the mouse spinal cord
  413. 1-Aminocyclopropanecarboxylic acid protects against DYNORPHIN A-induced spinal injury
  414. Central nervous system injection of DYNORPHIN-(1-13) overrides gastric satiety factors in sheep
  415. Lower CSF level of DYNORPHIN (1–8) immunoreactivity in schizophrenic patients
  416. Immunoreactive DYNORPHIN and α-neo-endorphin in rat hypothalamo-neurohypophyseal system
  417. Synthesis and biological activity of DYNORPHIN‐(1‐13) and analogs substituted in positions 8 and 10
  418. A 35 kDa Fos-related antigen is co-localized with substance P and DYNORPHIN in striatal neurons
  419. Intracerebroventricular morphine produces diuresis 24 h after previous DYNORPHIN/morphine treatment
  420. Cerebrospinal fluid DYNORPHIN 1-17 and β-endorphin in late pregnancy and six months after delivery
  421. DYNORPHIN A (1–8) immunoreactive cell bodies, dendrites and terminals are postsynaptic to calcitonin gene-related peptide primary afferent terminals in the monkey …
  422. Corelease of DYNORPHIN-Like Immunoreactivity, Luteinizing Hormone, and Follicle-Stimulating Hormone from Rat Adenohypophysis in Vitro
  423. Bestatin potentiates the antinociception but not the motor dysfunction induced by intracerebrally administered DYNORPHIN-B in mice
  424. DYNORPHIN A [1–17] induces “reward” in rats in the place conditioning paradigm
  425. Analysis of opioid and non-opioid end products of pro-DYNORPHIN in the substantia nigra of the rat
  426. Kappa‐selective opioid receptor agonists leumorphin and DYNORPHIN inhibit supraoptic neurons in rat hypothalamic slice preparations
  427. Modulation of morphine-induced EEG and behavioral effects by DYNORPHIN A-(1-13) in non-tolerant and morphine-tolerant rats
  428. Comparison of the substance P-and DYNORPHIN-containing projections to the substantia nigra: a radioimmunocytochemical and biochemical study
  429. Immunoreactive pro‐enkephalin and pro‐DYNORPHIN products are differentially distributed within the nucleus of the solitary tract of the rat
  430. Design and synthesis of highly potent and selective cyclic DYNORPHIN A analogs. 2. New analogs
  431. Nerve fibers surrounding intracranial and extracranial vessels from human and other species contain DYNORPHIN-like immunoreactivity
  432. Rehydration process from salt-loading: recovery of vasopressin and its coexisting galanin, DYNORPHIN and tyrosine hydroxylase immunoreactivities in the supraoptic …
  433. Effects of antibodies to DYNORPHIN A and β-endorphin on lateral hypothalamic self-stimulation in ad libitum fed and food-deprived rats
  434. DYNORPHIN B-containing perivascular axons and sensory neurotransmitter mechanisms in brain blood vessels
  435. Subcellular localization, partial purification, and characterization of a DYNORPHIN processing endopeptidase from bovine pituitary
  436. Conversion of Leumorphin (DYNORPHIN B‐29) to DYNORPHIN B and DYNORPHIN B‐14 by Thiol Protease Activity
  437. Fluorescence study on the solution conformation of DYNORPHIN in comparison to enkephalin
  438. Neuropeptide processing by single-step cleavage: Conversion of leumorphin (DYNORPHIN B-29) to DYNORPHIN B
  439. Localization of DYNORPHIN-induced neurotoxicity in rat spinal cord
  440. Co-expression of vasopressin with β-endorphin and DYNORPHIN in individual cells from the ovaries of Brattleboro and Long-Evans rats: immunocytochemical studies
  441. Opioid peptides, particularly DYNORPHIN, after amygdaloid-kindled seizures
  442. The effects of DYNORPHIN A (1–13) and U50, 488H on free intracellular calcium in guinea pig cerebellar synaptosomes
  443. A DYNORPHIN peptide induces hypotension by stimulating the release of atrial natriuretic peptide from rat atrium
  444. Early changes in proDYNORPHIN mRNA and ir‐DYNORPHIN A levels after kindled seizures in the rat
  445. On the origin of DYNORPHIN A and α-neo-endorphin in the substantia nigra
  446. Specificity of action of human brain alanyl aminopeptidase on Leu-enkephalin and DYNORPHIN-related peptides
  447. Binding of [3H] DYNORPHIN a to apparent [kappa] opioid receptors in deep layers of guinea pig cerebral cortex
  448. Behavioral effects of centrally administered DYNORPHIN and [D-ala2-D-leu] enkephalin (DADLE) in rats
  449. Immunohistochemical distribution of cholecystokinin, DYNORPHIN A and Met-enkephalin neurons in sheep hypothalamus
  450. Comparison of met‐enkephalin, DYNORPHIN a, and neurotensin immunoreactive neurons in the cat and rat spinal cords: II. Segmental differences in the marginal zone
  451. Reduced cerebrospinal fluid DYNORPHIN A1–8 in Alzheimer’s disease
  452. Antibodies to DYNORPHIN A (1–13) but not β-endorphin inhibit electrically elicited feeding in the rat
  453. Attenuation of the inhibitory effect of DYNORPHIN on dopamine release in the rat nucleus accumbens by repeated treatment with methamphetamine
  454. Intrathecal administration of beta-endorphin and DYNORPHIN-(1-13) for the treatment of intractable pain
  455. Inhibiting a spinal DYNORPHIN A component enhances intrathecal morphine antinociception in mice.
  456. Electrophysiological evidence for κ-agonist activity of DYNORPHIN in rat brain
  457. Effects of a Mixture of Peptidase Inhibitors (Amastatin, Captopril and Phosphoramidon) on Met-Enkephalin-, β-Endorphin-, DYNORPHIN-(1-13) and Electroacupuncture …
  458. DYNORPHIN peptides in human substantia nigra
  459. Multiple forms of immunoreactive DYNORPHIN in rat pituitary and brain
  460. Electrophysiological evidence for a non-opioid interaction between DYNORPHIN and GABA in the substantia nigra of the rat
  461. Different effects of DYNORPHIN A on in vitro guinea pig hippocampal CA3 pyramidal cells with various degrees of paired-pulse facilitation
  462. Enzymic synthesis of DYNORPHIN (1-8)
  463. Localization and quantitation of DYNORPHIN B in the rat hippocampus
  464. Centrally mediated cardiovascular actions of DYNORPHIN A (1-8) on rat hippocampal formation.
  465. Chronic pain in the rat: selective alterations in CNS and pituitary pools of DYNORPHIN as compared to vasopressin
  466. Morphine-like discriminative stimulus effects of opioid peptides: possible modulatory role of d-Ala 2-d-Leu 5-enkephalin (DADL) and DYNORPHIN A (1-13)
  467. Effects of DYNORPHIN (1–8) on movement: Non-opiate effects and structure-activity relationship
  468. Neurological dysfunction after intrathecal injection of DYNORPHIN A (1-13) in the rat. I. Injection procedures modify pharmacological responses.
  469. Biochemical mapping of cholecystokinin-, substance P-,[Met] enkephalin-,[Leu] enkephalin-and DYNORPHIN A (1–8)-like immunoreactivities in the human cerebral …
  470. Identification of DYNORPHIN 1–8 in human placenta by mass spectrometry
  471. DYNORPHIN immunoreactivity in pituitary.
  472. Levels of pro-neo-endorphin/DYNORPHIN-derived peptides in the hypothalamo-posterior pituitary system of male and female Brattleboro rats
  473. Some projections of DYNORPHIN-immunoreactive neurons in the rat central nervous system
  474. Tissue distribution of a DYNORPHIN-processing endopeptidase
  475. Effects of calcium antagonists on the evoked release of DYNORPHIN A (1–8) and availability of intraterminal calcium in rat hippocampal mossy fiber synaptosomes
  476. The hypothalamic paraventricular nucleus: relationship to brain and pituitary pools of vasopressin and oxytocin as compared to DYNORPHIN, β-endorphin and related …
  477. Steady-state levels of pro-DYNORPHIN-related end-products from the brain of the amphibian, Xenopus laevis
  478. The effect of food and water deprivation on post-stress analgesia in mice and levels of beta-endorphin and DYNORPHIN in blood plasma and hypothalamus
  479. In Vitro-Peritused Rat Testes Secrete β-Endorphin and DYNORPHIN: Their Effect on Testosterone Secretion
  480. Purification and identification of multiple forms of DYNORPHIN in human placenta
  481. Effects of DYNORPHIN A (1–17), DYNORPHIN A (1–13) and D-Ala2-D-Leu5-enkephalin on the excitability of pyramidal cells in CA1 and CA2 of the rat hippocampus invitro
  482. Cerebrospinal fluid DYNORPHIN-converting enzyme activity is increased by voluntary exercise in the spontaneously hypertensive rat
  483. Synaptosomal free [Ca2+] is reduced by clonidine and DYNORPHIN A-(1–13) and increased by idazoxan
  484. ICI 174864, a putative δ opioid antagonist, reverses endotoxemic hypotension: Pretreatment with DYNORPHIN 1–13, a κ agonist, blocks this action
  485. Ontogeny of DYNORPHIN-like immunoreactivity in the hippocampal formation of the rat
  486. Enterochromaffin (EC-) cells of the mammalian gastro-entero-pancreatic (GEP) endocrine system: cellular source of pro-DYNORPHIN-derived peptides
  487. Adrenocorticotropin, vasoactive intestinal polypeptide, growth hormone-releasing factor, and DYNORPHIN compete for common receptors in brain and adrenal
  488. A putative processing enzyme from Aplysia that cleaves DYNORPHIN A at the single arginine residue
  489. DYNORPHIN receptor in the blood vessel
  490. [3H] DYNORPHIN A binds selectively to guinea pig brain
  491. Regulation of hypothalamic-endorphin and DYNORPHIN release by corticotropin-releasing factor (CRF)
  492. Formation of [Leu5]Enkephalin from DYNORPHIN A(1–8) by Rat Central Nervous Tissue In Vitro
  493. Release of DYNORPHIN-like immunoreactivity of rat neurohypophysis in comparison to vasopressin after various stimuli in vitro and in vivo
  494. Placental kappa binding site: interaction with DYNORPHIN and its possible implication in hCG secretion
  495. The antagonistic effects of naloxone on hypermotility in mice induced by DYNORPHIN-(1-13) using a multi-dimensional behavioral analysis
  496. Gi proteins and calcium in DYNORPHIN-induced hypothermia and behaviour
  497. Synthesis and biological activity of analogs of DYNORPHIN-A(1–13) substituted in positions 2 and 4: Design of [Ala2,Trp4]-Dyn-A(1–13) as a putative selective opioid …
  498. Lithium and haloperidol differentially alter the DYNORPHIN A (1–8) and enkephalin levels in the neurointermediate lobe of rat pituitary
  499. A Large-Scale Synthesis of [MeTry1, MeArg7, D-Leu8] DYNORPHIN A-(1-8)-NHEt (E-2078) by Application of the Trifluoroacetic Acid-Pentamethylbenzene Deprotecting …
  500. Stimulation by DYNORPHIN of prolactin and growth hormone secretion in the rat
  501. Heterogeneity of immunoreactive DYNORPHIN B-like material in human, rat, rabbit and guinea-pig heart
  502. DYNORPHIN A-(1–10) amide stimulates the release of atrial natriuretic polypeptide (ANP) from rat atrium
  503. Inactivation of DYNORPHIN-(1-8) in isolated preparations by three peptidases
  504. DYNORPHIN A (1–13) modulates apomorphine-induced behaviors using multidimensional behavioral analyses in the mouse
  505. Distribution of DYNORPHIN B and methionine-enkephalin in the mouse hippocampus: influence of genotype
  506. Immunocytochemical identification of DYNORPHIN-containing vesicles in Brattleboro rats
  507. Intrathecal DYNORPHIN A administration causes pressor responses in rats associated with an increased resistance to spinal cord blood flow
  508. Effect of DYNORPHIN microinjection in the paraventricular nucleus on the hemodynamic response to hemorrhage in the rat.
  509. Nigrostriatal dopamine mediates the stimulatory effects of corticotropin releasing factor on methionine-enkephalin and DYNORPHIN release from the rat neostriatum
  510. Coexistence of enkephalin and DYNORPHIN immunoreactivities in neurons in the dorsal gray commissure of the sixth lumbar and first sacral spinal cord segments in rat
  511. Autoradiographic localization of supraspinal kappa-opioid receptors with [125I-Tyr1, D-Pro10] DYNORPHIN A-(1-11)
  512. Effects of intracerebroventricular injection of DYNORPHIN, leumorphin and α neo-endorphin on operant feeding in pigs
  513. A low hippocampal DYNORPHIN A (1–8) immunoreactivity in spontaneously hypertensive rats
  514. Multiple forms of immunoreactive DYNORPHIN in human pituitary and pheochromocytoma
  515. Presence of a DYNORPHIN-like peptide in a restricted subpopulation of catecholaminergic neurons in rat nucleus tractus solitarii
  516. Spinal cord DYNORPHIN precursor intermediates decline during late gestation
  517. Consequence of DYNORPHIN-A administration on anterior pituitary hormone concentrations in the adult male rhesus monkey
  518. Concomitant neonatal development and in vitro release of DYNORPHIN and α-neo-endorphin
  519. Possible modulatory role of DYNORPHIN on the excitation by neurotensin on the guinea pig myenteric plexus
  520. Conformational features of DYNORPHIN A-(1-13), Laser Raman spectroscopic studies.
  521. DYNORPHIN inhibition of the neurotensin contractile activity on the myenteric plexus.
  522. Evidence for DYNORPHIN-A as a neurotransmitter in rat hippocampus
  523. DYNORPHIN-containing pilomotor neurons in the superior cervical ganglion of guinea pigs
  524. A strychnine-sensitive site is involved in DYNORPHIN-induced paralysis and loss of the tail-flick reflex
  525. Levels of DYNORPHIN peptides, substance P and CGRP in the spinal cord after subchronic administration of morphine in the rat
  526. Competitive binding of DYNORPHIN-(1-13) and beta-endorphin to cerebroside sulfate in solution.
  527. N,N‐diallyl‐tyrosyl substitution confers antagonist properties on the κ‐selective opioid peptide [D‐Pro10]DYNORPHIN A(1–11)
  528. DYNORPHIN modulates prolactin secretion in the turkey
  529. Dopaminergic involvement in the improving effects of DYNORPHIN A-(1–13) on scopolamine-induced impairment of alternation performance
  530. Systemic single dose morphine pretreatment desensitizes mice to the spinal antianalgesic action of DYNORPHIN A (1-17).
  531. [3H] DYNORPHIN binding to guinea pig and rat brain
  532. DYNORPHIN converting enzyme in the rat spinal cord. Decreased activities during acute phase of adjuvant induced arthritis
  533. Synthesis and opioid activity of DYNORPHIN A-(1-13) NH2 analogs containing cis-and trans-4-aminocyclohexanecarboxylic acid
  534. Expression of enkephalin and DYNORPHIN precursor mRNAs in brain areas of hypo-and hyperthyroid rat: effect of kainic acid injection
  535. Opioid peptide DYNORPHIN-(1–13): Adsorptive losses and potency estimates
  536. Evidence for the expression of DYNORPHIN gene in the prolactin-immunoreactive neurons of the rat lateral hypothalamus
  537. [3H]-DYNORPHIN A (1–9): binding characteristics and degradation profile in brain homogenates
  538. Actions of D-Ala2-D-Leu5-enkephalin and DYNORPHIN A (1–17) on neocortical neurons invitro
  539. DYNORPHIN A immunoreactivity in human cerebrospinal fluid
  540. A glutamate antagonist blocks perforant path stimulation-induced reduction of DYNORPHIN peptide and proDYNORPHIN mRNA levels in rat hippocampus
  541. Effects of dehydration on pro-DYNORPHIN derived peptides in the neuro-intermediate lobe of the rat pituitary
  542. DYNORPHIN in bovine adrenal medulla: II. Isolation, partial characterization and biological activity of two distinct molecules
  543. Aquaretic effect of the stable DYNORPHIN-A analog E2078 in the human.
  544. Pressor, tachycardic and feeding responses in conscious rats following icv administration of DYNORPHIN. Central blockade by opiate and α1-receptor antagonists
  545. Levallorphan and DYNORPHIN improve motor dysfunction in mongolian gerbils with unilateral carotid occlusion: The first application of the inclined plane method in the …
  546. Inhibition of cardiac Na+, K+-ATPase activity by DYNORPHIN-A and ethylketocyclazocine
  547. α‐N‐Acetyl β‐Endorphins in the Pituitary: Immunohistochemical Localization Using Antibodies Raised Against DYNORPHIN (1‐13)
  548. Purification and Characterization of a DYNORPHIN-processing Endopeptidase (∗)
  549. Specific binding and clearance of [3H]DYNORPHIN (1–13) in the perfused rat lung: an application of the multiple-indicator dilution method
  550. Mass spectrometric identification of various molecular forms of DYNORPHIN in bovine adrenal medulla
  551. Cataleptic effects of DYNORPHIN-(1–13) in rats made tolerant to a mu opiate receptor agonist
  552. Method for isolation of kappa‐opioid binding sites by DYNORPHIN affinity chromatography
  553. Changes in the content of immunoreactive DYNORPHIN in dorsal and ventral spinal cord of the rat in three different conditions
  554. [D-Pro10]-DYNORPHIN (1-11) is a kappa-selective opioid analgesic in mice.
  555. Regional distribution of immunoreactive DYNORPHIN A in the human gastrointestinal tract
  556. Enkephalin is liberated from metorphamide and DYNORPHIN A1-8 by endo-oligopeptidase A, but not by metalloendopeptidase EC 3.4.24.15
  557. Ultrastructural demonstration of synaptic connections between calcitonin gene-related peptide immunoreactive axons and DYNORPHIN A (1–8) immunoreactive dorsal …
  558. Assay and biochemical characterization of a DYNORPHIN converting enzyme in human cerebrospinal fluid
  559. Ontogenetic development of the pro-enkephalin B (= pro-DYNORPHIN) opioid peptide system in the rat pituitary
  560. Immunohistochemistry ofβ-neoendorphin and DYNORPHIN in the endocrine pancreas of rat and man
  561. Systemic administration of DYNORPHIN A (1–13) markedly inhibits different behavioural responses induced by cocaine in the mouse
  562. Synthesis and opioid activity of 2–substituted DYNORPHIN A‐(1‐13) amide analogues1
  563. DYNORPHIN-A (1–8) is contained within perikarya, nerve fibres and nerve terminals of rat duodenum
  564. Analgesic efficacy of E2078 (DYNORPHIN analog) in patients following abdominal surgery
  565. DYNORPHIN (1–13) impairs memory formation for aversive and appetitive learning in chicks
  566. Cardiovascular effects of microinjection of DYNORPHIN-A (1-8) into the hippocampus in conscious, spontaneously hypertensive and normotensive Wistar-Kyoto rats
  567. DYNORPHIN A1-13 administration causes elevation of serum levels of prolactin in human subjects
  568. Characterization of cysteine proteases functioning in degradation of DYNORPHIN in neuroblastoma cells: evidence for the presence of a novel enzyme with strict …
  569. DYNORPHIN A: Inhibitory effect on other opiate ligand bindings in the mouse brain
  570. Inhibition of DYNORPHIN Converting Enzymes from Human Spinal Cord by N-Peptidyl-O-Acyl Hydroxylamines
  571. Microinjection of DYNORPHIN into the supraoptic and paraventricular nuclei produces antidiuretic effects through vasopressin release
  572. DYNORPHIN-(1–13) restores the potency of morphine on the tolerant guinea pig ileum
  573. DYNORPHIN (1–10) amide: a potent and selective analog of DYNORPHIN (1–13)
  574. Atrial natriuretic polypeptide secretion via selective activation of kappa-opioid receptor: role of DYNORPHIN
  575. Steady state levels of pro-DYNORPHIN-related end products in the striatum and substantia nigra of the adult rhesus monkey
  576. Sensitivity to morphine-evoked bradycardia in rats is modified by DYNORPHIN (1-13), Leu-and Met-enkephalin.
  577. DYNORPHIN A-containing neural elements in the nucleus of the solitary tract of the rat. Light and electron microscopic immunohistochemistry
  578. Effects of DYNORPHIN 1–13 on opiate binding and dopamine and GABA uptake in stroked cat brain
  579. Specific N-or C-terminus modified DYNORPHIN and β-endorphin peptides can selectively block excitatory opioid receptor functions in sensory neurons and unmask …
  580. Heterogeneous distribution of cytochrome oxidase activity in the rat substantia nigra: correlation with tyrosine hydroxylase and DYNORPHIN immunoreactivities
  581. Modulation of striatal aspartate and DYNORPHIN B release by cholecystokinin (CCK-8) studied in vivo with microdialysis.
  582. Lesions of the hypothalamic arcuate nucleus modify discrete brain and pituitary pools of DYNORPHIN in addition to β-endorphin in the rat
  583. Effect of DYNORPHIN microinjection in the anterior hypothalamus (AV3V) region on the hemodynamic response to hemorrhage in the rat.
  584. Effects of D-amino acid substitution in DYNORPHIN A (1–9) on binding at the μ-, δ-and κ-sites
  585. Hypothalamo-posterior pituitary system in Brattleboro rats: Immunoreactive levels of leucine-enkephalin, DYNORPHIN (1–17), DYNORPHIN (1–8) and α-neo-endorphin
  586. Elimination of the antianalgesic action of DYNORPHIN A by spinal transsection in barbital-anesthetized mice.
  587. Comparative study of the analgesic and paralytic effects induced by intrathecal DYNORPHIN A in rats
  588. Rimorphin (DYNORPHIN B) exists together with α-neo-endorphin and DYNORPHIN (DYNORPHIN A) in human hypothalamus
  589. Multidimensional behavioral analyses show DYNORPHIN A-(1–13) modulation of methamphetamine-induced behaviors in mice
  590. A review of some nonopioid actions of DYNORPHIN.
  591. Inhibitory effects of rimorphin and DYNORPHIN on insulin secretion from the isolated, perfused rat pancreas
  592. Opiate and alpha receptor antagonists block the pressor responses of conscious rats given intravenous DYNORPHIN
  593. [D-Ala2,(F5) Phe4]-DYNORPHIN1–13-NH2 (DAFPHEDYN): a potent analog of DYNORPHIN 1–13
  594. The immunostaining for the hypothalamic vasoactive intestinal peptide, but not for β-endorphin, DYNORPHIN-A or methionine-enkephalin, is affected by the …
  595. Central administration of the endopeptidase 24.15 inhibitor cFP-AAF-pAB suggests DYNORPHIN as the endogenous ligand underlying behavioral effects of milk in the …
  596. DYNORPHIN-(1–13)-like immunoreactivity in central nervous system and pituitary gland of spontaneously hypertensive rats
  597. Synthesis and opioid activities of [D-Leu8] DYNORPHIN (1-8) analogs containing a reduced peptide bond, Ψ (CH2NH)
  598. Appearance of DYNORPHIN in the spinal trigeminal nucleus complex following experimental tooth movement in the rat
  599. Top concentrations of DYNORPHIN-like immunoreactivity in fractions of rat anterior pituitary cells enriched in gonadotrophs
  600. Differential modulation of the beta-endorphin and DYNORPHIN systems by serotonergic stimulation in the rat
  601. DYNORPHIN A (1–13) preferentially inhibits behaviors induced by the D2 dopamine agonist RU 24213 but not by the D1 dopamine agonist SK&F 38393
  602. DYNORPHIN receptor changes in hippocampus of the spontaneously hypertensive rat
  603. Proton NMR and CD solution conformation determination and opioid receptor binding studies of a DYNORPHIN A (1–17) model peptide
  604. A 1 H nuclear magnetic resonance study of the opioid peptide DYNORPHIN-(1–13) in aqueous solution
  605. DYNORPHIN 1–17 delays the vasopressin induced mobilization of intracellular calcium in cultured astrocytes from the rat neural lobe
  606. DYNORPHIN, an endogenous stimulator of feeding.
  607. Ventricular expression and circulating levels of immunoreactive DYNORPHIN in heart transplant recipients
  608. Intranigral injection of DYNORPHIN in combination with substance P on striatal dopamine metabolism in the rat
  609. Diethylstilbesterol-and pregnancy-induced changes in rat neurointermediate lobe oxytocin, arginine vasopressin, methionine enkephalin and DYNORPHIN
  610. 125I-DPDYN, monoiodo [D-Pro10] DYNORPHIN (1–11): A highly radioactive and selective probe for the study of kappa opioid receptors
  611. Levels of immunoreactive DYNORPHIN in brain and pituitary of hyperthyroid and hypothyroid rats
  612. Opioid and non-opioid behavioral actions of DYNORPHIN A and the DYNORPHIN analogue DAKLI
  613. Application of an irreversible opiate antagonist (β-FNA, β-funal-trexamine) to demonstrate DYNORPHIN selectivity for K-opioid sites
  614. DYNORPHIN A (1–13) in the brain suppresses epinephrine-induced ventricular premature complexes and ventricular tachyarrhythmias
  615. “Immunoreactive DYNORPHIN” in Escherichia coli: Tracer degradation by a heat-stable endopeptidase
  616. … administered intracerebroventricularly antagonize spinal morphine-induced antinociception in mice through the antianalgesic action of spinal DYNORPHIN A (1-17 …
  617. Chromatographic characterization of DYNORPHIN and [Leu5] enkephalin immunoreactivity in guinea pig and rat testis
  618. Analgesic actions of DYNORPHIN A (1–13) antiserum in the rat brain stem
  619. Beta endorphin and DYNORPHIN levels in rat pituitary and hypothalamus: age studies
  620. Opioid-like properties of seven DYNORPHIN (1–10) analogs
  621. Immunoreactive DYNORPHIN-like material in rat pituitary after ovariectomy
  622. Conversion of DYNORPHIN-(1-9) to [Leu5] enkephalin by the mouse vas deferens in vitro
  623. Alterations of heart DYNORPHIN-A in the development of spontaneously hypertensive rats
  624. The endogenous kappa agonist, DYNORPHIN (1–13), does not alter basal or morphine-stimulated dopamine metabolism in the nigrostriatal pathway of the rat
  625. Colocalization of DYNORPHIN-A (1–17) and DYNORPHIN-A (1–8) within some perikarya of rat duodenum: immunohistochemical evidence for the presence of two separate …
  626. DYNORPHIN‐Related Opioid Peptides in the Neurointermediate Pituitary of Rats Are Not α‐N‐Acetylated
  627. Serotonergic regulation of the brain and gut beta-endorphin and DYNORPHIN content in the rat.
  628. DYNORPHIN A-(1-13)-Tyr14Leu15-Phe16-Asn17-Gly18-Pro19: a potent and selective κ opioid peptide
  629. Response of brain and pituitary pools of DYNORPHIN as compared to vasopressin to acute stress in the rat
  630. Intrathecal DYNORPHIN A (1-13) and (3-13) reduce spinal cord blood flow by non-opioid mechanisms
  631. DYNORPHIN-A and vasopressin release in the rat: a structure-activity study
  632. Effects of DYNORPHIN on the PHA-induced lymphocyte proliferation in vitro
  633. Intrathecal DYNORPHIN-A infusion in rat spinal cord causes energy depletion, edema and neurologic dysfunction
  634. Possible involvement of beta endorphin (1–31) and DYNORPHIN (1–13) in the central hypotensive mechanism of action of alpha methyldopa
  635. Effects of food deprivation and high fat diet on immunoreactive DYNORPHIN A (1–8) levels in brain regions of Zucker rats
  636. Receptor preference of DYNORPHIN A fragments in the mouse vas deferens determined by different techniques.
  637. Characterization of non-opioid [3H] DYNORPHIN A-(1-13) binding sites in the rat heart
  638. DYNORPHIN‘in plasma: enzymatic artifact and authentic immunoreactivity
  639. Intrathecal administration of DYNORPHIN A and its fragments increase heart rate and arterial pressure in the urethane anesthetized rat: mediation by a nonopioid …
  640. Immunoreactive peptides related to DYNORPHIN B (= rimorphin) in the rat brain
  641. Interaction of DYNORPHIN with kappa opioid receptors in bovine adrenal medulla
  642. Reward and its control by DYNORPHIN peptides
  643. Hippocampal levels of DYNORPHIN A (1–8) in neonatal and 16-week-old spontaneously hypertensive rats: comparisons with DOCA-salt hypertension
  644. Ultrastructure of the DYNORPHIN-immunoreactivity in rat brain hippocampal mossy fiber system.
  645. Release of DYNORPHIN-Like Immunoreactivity from Rat Adenohypophysis in Vitro during Inhibition of Anterior Pituitary Hormone Secretion from Individual Cell Types
  646. DYNORPHIN A (1–13), microinjected into the preoptic area, stimulates water intake in rats
  647. Inhibition of the antianalgesic action of DYNORPHIN A in mice by cholera toxin
  648. Effects of high intravenous doses of DYNORPHIN A (1–13) on tail flick latency and central nervous system histology in rats
  649. DYNORPHIN-processing endopeptidase in the rat anterior pituitary lactotrophic cell line, GH4C1
  650. Non-neuronal excitatory neurotensin receptors on the taenia coli of the guinea pig: lack of influence of tetrodotoxin and DYNORPHIN
  651. Cardiovascular effects of DYNORPHIN A-(1-13) and arginine vasopressin in fetal lambs
  652. DYNORPHIN A-(1-13) potently improves galanin-induced impairment of memory processes in mice
  653. A monoclonal antibody specific for a DYNORPHIN precursor
  654. A non-opioid pattern characterizes inhibition of growth hormone releasing peptide binding by DYNORPHIN-related peptides
  655. Clinical effect of DYNORPHIN on heroin addicts.
  656. A characterization of DYNORPHIN-(1-13) on the guinea pig ileal longitudinal muscle.
  657. Degradation of DYNORPHIN-(1–13) and DYNORPHIN-(1–17) by the neuroblastoma cell membrane. Evidence for the involvement of a cysteine protease
  658. … -assisted receptor subtype selection: synthesis, membrane structure, and opioid receptor affinity of [Phe8, 12]-and [Phe8, 12, Lys10] DYNORPHIN-(1–13)-tridecapeptide
  659. DYNORPHIN-induced depression of the dorsal root potential in rat spinal cord: a possible mechanism for potentiation of the C-fiber reflex.
  660. Cardiovascular responses to intra-hippocampal DYNORPHIN A-(1–8) in spontaneously hypertensive rats
  661. Characteristics of β-endorphin-induced histamine release from rat serosal mast cells Comparison with neurotensin, DYNORPHIN and compound 48/80
  662. DYNORPHIN blocks opioid inhibition of macrophage-colony stimulating factor-induced proliferation of bone marrow cells
  663. Comparative effects on blood pressure and heart rate of DYNORPHIN A (1–13) in anterior hypothalamic area, posterior hypothalamic area, nucleus tractus solitarius, and …
  664. [D-Met2, Pro5] enkephalinamide and DYNORPHIN-(1–13) inhibit the cholinergic contraction induced in the guinea-pig ileum by substance P
  665. DYNORPHIN B is present in sensory and parasympathetic nerves innervating pial arteries
  666. DYNORPHIN binds to neuropeptide Y and peptide YY receptors in human neuroblastoma cell lines
  667. Morphine addiction does not alter brain or pituitary immunoreactive DYNORPHIN level
  668. Effect of human growth hormone-releasing hormone on the release of DYNORPHIN-like immunoreactivity, luteinizing hormone, and follicle-stimulating hormone from rat …
  669. Synthesis and Structure-Activity Relationships of [MeTyr1, MeArg7]-DYNORPHIN A (1-8)-OH Analogues with Substitution at Position 8
  670. Opioid and other peptides as inhibitors of leumorphin (DYNORPHIN B-29) converting activity
  671. Presence of immunoreactive DYNORPHIN in human cerebrospinal fluid
  672. DYNORPHIN (1–13) effects on thyrotrophin-releasing hormone and thyrotrophin secretion in rats
  673. Interaction of DYNORPHIN with neurotensin on the guinea pig ileum myenteric plexus
  674. Unmyelinated primary afferent fiber stimulation depletes DYNORPHIN A (1–8) immunoreactivity in rat ventral horn
  675. Mesencephalic grafts partially restore normal nigral DYNORPHIN levels in 6-hydroxydopamine-lesioned rats treated chronically withl-dihydroxyphenylalanine
  676. The role of DYNORPHIN in narcotic tolerance mechanisms
  677. Effects of hypothalamic lesions on the content of DYNORPHIN immunoreactivity in pituitary
  678. DYNORPHIN-(1–13): the effect of in vivo treatment on opiate bindings in vitro
  679. Membrane-bound trypsin-like enzyme functioning in degradation of DYNORPHIN in neuroblastoma cells. Purification and characterization
  680. Morphine and the Endogenous Opioid DYNORPHIN in the Brain Attenuate Digoxin‐Induced Arrhythmias in Guinea Pigs
  681. Study of DYNORPHIN A (1-17) in vivo processing in rat brain by microdialysis and matrix-assisted laser desorption mass spectrometry
  682. Involvement of DYNORPHIN A and not substance P in the spinal antianalgesic action of capsaicin against morphine-induced antinociception in mice.
  683. The Effect of DYNORPHIN on Placental Pulsatile Human Chorionic Gonadotropin Secretion in Vitro
  684. Lack of effect of DYNORPHIN on consummatory behaviors in obese and normal rats
  685. CNS tissue levels of DYNORPHIN-A immunoreactivity and the anorexia associated with sodium chloride imbibition in the rat
  686. Independent origin and modulation of vasopressin as compared to DYNORPHIN and α-neo-endorphin in the medulla-pons of the rat
  687. Opioid antagonists: indirect antagonism of morphine analgesia by spinal DYNORPHIN A
  688. Heterogeneity of [3H] neurotensin binding: studies with DYNORPHIN, L-156,903 and levocabastine
  689. DYNORPHIN A (1–8) in human placenta: amino acid sequence determined by tandem mass spectrometry
  690. … interactions of the locus coeruleus as compared to the ventral noradrenergic bundle with CNS and pituitary pools of vasopressin, DYNORPHIN and related opioid …
  691. Effect of hypertonic saline infusion on the level of immunoreactive DYNORPHIN in extracted human plasma
  692. Tritiated porcine DYNORPHIN (1–17): Synthesis and characterization
  693. Evidence that the agonist action of DYNORPHIN A (1-8) in the guinea-pig myenteric-plexus may be mediated partly through conversion to [Leu5] enkephalin.
  694. An ultrastructural study of DYNORPHIN-immunoreactive nerve fibers and terminals in the celiac-superior mesenteric ganglion of the guinea pig
  695. Blockade of DYNORPHIN A (1–13) overt psychomotor effects by naloxone
  696. Identification of the tridecapeptide DYNORPHIN B (rimorphin) within perikarya of rat duodenum
  697. Physical dependence liability of DYNORPHIN A analogs in rodents
  698. Isolation and characterization of an endogenous C-terminal fragment of the alpha-neo-endorphin/DYNORPHIN precursor from bovine caudate nucleus
  699. DYNORPHIN A (1–13) potentiates DYNORPHIN a (1–17) on loss of the tail-flick reflex after intrathecal injection in the rat
  700. Studies of specificity and inhibition of human cerebrospinal fluid DYNORPHIN converting enzyme
  701. Characterization of DYNORPHIN A (1-17)-induced place preference in rats
  702. Effects of ketamine on the DYNORPHIN levels and the ethylketocyclazocine (EKC) receptor binding in discrete regions of rat brains
  703. Receptors mediating depressor responses to intrahippocampal injection of L-glutamate and DYNORPHIN-A (1-8) in conscious, spontaneously hypertensive and …
  704. Effects of β-endorphin and DYNORPHIN A on cholinergic neurotransmission in canine airway smooth muscle
  705. Possible regulatory role of DYNORPHIN A in the urinary bladder
  706. Different functional roles for substance P and DYNORPHIN in the striato-nigral pathways of the rat
  707. Influence of monoamine oxidase inhibitors on striatonigral DYNORPHIN system: a study with deprenyl and clorgyline
  708. Changes in the processing of pro-DYNORPHIN end products in the substantia nigra during neonatal development
  709. The in vitro release of immunoreactive DYNORPHIN and alpha-neoendorphin from the perfused rat duodenum
  710. Inhibitory effect of DYNORPHIN on the secretory activity of isolated rat adrenocortical cells
  711. Secretion of atrial and brain natriuretic peptides from human cardiac atrial explants in culture: effect of DYNORPHIN.
  712. Binding of DYNORPHIN A and related peptides to κ-and μ-opioid receptors: sensitivity to Na+ ions and Gpp (NH) p
  713. The effect of U-50,488 H tolerance-dependence and abstinence on the levels of DYNORPHIN (1–13) in brain regions, spinal cord, pituitary gland and peripheral tissues …
  714. DYNORPHIN (1-8) immunoreactivity in brainstem and hypothalamic nuclei of normotensive and age-matched hypertensive rat strains
  715. Conversion of DYNORPHIN A (1–8) to [Leu5]-enkephalin in rat central nervous tissue during development
  716. DYNORPHIN B-29: Chemical synthesis and pharmacological properties in opioid systems invitro
  717. Immunoreactive DYNORPHIN A-like material in extracted human hypothalamic-hypophysial plasma
  718. Nocturnal depletion of hypothalamic DYNORPHIN in anorexic Walker-256 tumor-bearing rats
  719. Expression of nitric oxide synthase in enkephalin and DYNORPHIN systems of the rat hypothalamus
  720. Subcellular distribution of DYNORPHIN-like immunoreactivity in rat adenohypophysis in comparison with luteinizing hormone and follicle-stimulating hormone
  721. Opiate sensitive DYNORPHIN conversion in SH-SY5Y human neuroblastoma cells: Evidence for inhibition by DYNORPHIN related peptides
  722. Endogenous DYNORPHIN modulates calcium-mediated antinociception in mice
  723. Immunoreactive DYNORPHIN-A in ovine anterior pituitary and effects of estradiol-17β administration
  724. Biphasic response of hippocampal DYNORPHIN expression following recurrent limbic seizure
  725. Molecular biology of DYNORPHIN gene expression in relationship to spinal cord processing of pain
  726. Immunoreactive DYNORPHIN-A in bovine anterior pituitary and its in vitro release
  727. DYNORPHIN-(1-13): antinociceptive action and its effects on morphine analgesia and acute tolerance
  728. High-performance liquid chromatographic system for the separation of DYNORPHIN A (1-17) fragments and its application in enzymolysis studies with rat nerve terminal …
  729. DYNORPHIN A-(1–17) and DYNORPHIN B are released from in vitro superfused rat hypothalami. Effects of depolarizing agents and ovariectomy
  730. Differential regulation of the brain and gut immunoreactive DYNORPHIN by the serotonin system
  731. DYNORPHIN A-(1–13)-morphine interactions: quantitative and qualitative EEG properties differ in morphine-naive vs. morphine-tolerant rats
  732. Cholinergic modulation and effects of DYNORPHIN on the non-adrenergic inhibitory potentials in the guinea-pig duodenum
  733. Study on the Mechanism Underlying DYNORPHIN Spinal Neurotoxicity.
  734. Release of DYNORPHIN-like immunoreactivity from rat anterior pituitary gland in vitro
  735. TRH fails to antagonize the acute paralytic effects of intrathecal DYNORPHIN A and substance P antagonists in the rat
  736. Role of the ventromedial hypothalamus in the regulation of adenohypophyseal immunoreactive DYNORPHIN in the rat
  737. Two different types of DYNORPHIN-A-immunoreactive terminals in rat substantia nigra
  738. Intrastriatal injections of DYNORPHIN A fragments potentiate the dorsal immobility response in rats
  739. Distribution of DYNORPHIN A (1-17) in the cat brainstem: an immunocytochemical study.
  740. Synthesis and properties of β‐endorphin analogs containing the DYNORPHIN‐(1–13) sequence
  741. Effects of ligusticum wallichii on the plasma and CSF levels of DYNORPHIN A1-13 in rabbits under acute experimental cerebral ischemia
  742. Inhibitory effects of DYNORPHIN-A on norepinephrine uptake by cardiac synaptosomal-mitochondrial fractions.
  743. DYNORPHIN immunoreactivity in the toad neurointermediate lobe
  744. Pharmacological characterization of DYNORPHIN A (1-17)-induced effects on spinal cord-evoked potentials.
  745. Analgesic, receptor binding, and peripheral opioid activities of synthetic dermorphin‐DYNORPHIN hybrid peptides
  746. β‐Endorphin. Biological activity of analogs containing dermorphin and DYNORPHIN sequences: ileum and vas deferens assays
  747. Synthesis of the Heptadecapeptide corresponding to the Full Sequence of DYNORPHIN
  748. [Biocytin 13] DYNORPHIN A 1-13 Amide: A Potential Probe for the κ-Opioid Receptor
  749. DYNORPHIN: Specific binding to opiate receptors
  750. Mechanism of DYNORPHIN inhibition on vasoconstriction in vitro
  751. Assessment of DYNORPHIN-A depletion in the anorexia of Walker-256 tumor bearing rats
  752. DYNORPHIN A: a rectifying peptide
  753. The effects of dopamine D-1 and D-2 receptor subtype agonists on nigrostriatal opioid DYNORPHIN and enkephalin immunostaining in 6-hydroxydopamine lesioned rats …
  754. The analgesic effect of DYNORPHIN A in spinal cord of the rat potentiated by DYNORPHIN B
  755. Bridge peptide is a cleavage product of pro-DYNORPHIN processing in the rat anterior pituitary
  756. Potent inhibition of thermal edema in rat by des-Tyr-DYNORPHIN A
  757. Cardiovascular effects of microinjection of DYNORPHIN fragments into the nucleus of the solitary tract (NTS) are mediated by non-opioid mechanisms
  758. DYNORPHIN-A (1–8) and γ-melanotropin exist within different myenteric plexus neurons of rat duodenum
  759. Intrinsic activity and effects of guanyl-5′-yl imidodiphosphate, Gpp (NH) p and sodium ion on the affinity of DYNORPHIN 1-13, nalorphine and nalorphine-7, 8-oxide to …
  760. Positive Inotropic Action of к Opiate Agonists, Ethylketocyclazocine and DYNORPHIN-A (1–13), in Isolated Rat Atrium
  761. INVOLVEMENT OF SPINAL MET-ENKEPHALINN AND DYNORPHIN IN DESCENDING MORPHINE ANALGESIA
  762. Adenosine modulation of DYNORPHIN B release by hippocampal synaptosomes
  763. Pressor responses in rats following intravenous DYNORPHIN A (1–13) administration are blocked by AVP-V1 receptor antagonism
  764. Synthesis and Biological Activity of [MeTyr1, MeArg7, D-Leu8]-DYNORPHIN A (1-9)-NHEt and [D-Cys2-Cys5, MeArg7, D-Leu8]-DYNORPHIN A (1-9)-NH2
  765. Effect of discrete brain lesions on hypothalamic and pituitary immunoreactive DYNORPHIN
  766. Decreased dihydromorphine and D-ala2-D-leu5-enkephalin binding invitro after DYNORPHIN pretreatment in mice invivo
  767. Effect of antiserum against DYNORPHIN A administered intrathecally on spinal cord injury (SCI) of rats and its significance
  768. DYNORPHIN-induced spinal cord injury in rats
  769. D-Ala2, F5Phe4-DYNORPHIN amide, an opiate with analgesic and toxic properties.
  770. Solution Syntheses of Two Enkephalin-Containing Peptides, Peptide E and DYNORPHIN (1-24), Using Nin-(2, 4, 6-Triisopropylphenylsulfonyl) tryptophan
  771. ProDYNORPHIN processing by rat CNS fractions and purified enzymes: Formation of DYNORPHIN A 1–8 by sulfhydryl-activated carboxypeptidase and peptidyl dipeptidase
  772. Increase in spinal cord DYNORPHIN biosynthesis during peripheral inflammation: behavioral, neuropeptide and mRNA studies
  773. Characterization of DYNORPHIN receptor specificity in the guinea pig ileum
  774. The Membrane Mediated Conformation of DYNORPHIN A (1-13) as Studied by Transferred Nuclear Overhauser Effect Spectroscopy
  775. Effect of Hemorrhage on Vasopressin, DYNORPHIN A, and Leu5-Enkephalin in the Hypothalamo-Pituitary System of the Rat
  776. Kainic acid depresses the ex vivo release of DYNORPHIN B and glutamate from rat hippocampal mossy fiber synaptosomes
  777. Possible regulatory role of DYNORPHIN-(1–13) on narcotic-induced changes in naloxone efficacy
  778. Characterization of DYNORPHIN-containing neurons on dissociated dentate gyrus cell cultures
  779. Isolation of DYNORPHIN-like peptide from gut extract
  780. Influence of microinjection of DYNORPHIN antibody into periaqueductal gray (PAG) on analgesia induced by electroacupuncture of different frequencies in rats
  781. Effects of the DYNORPHIN derivative” E2078″ on hemodynamics and plasma catecholamines in dogs
  782. Effect of endometriosis pill No. 2 on beta-endorphin and DYNORPHIN in endometriosis
  783. Molecular basis for DYNORPHIN A selectivity: a chimeric study
  784. Polymer-supported biopolymer synthesis: 4. Synthesis of DYNORPHIN (1–13) by condensation of protected peptide segments prepared by high-load solid (gel) phase …
  785. Involvement of DYNORPHIN in the antinociception induced by intrathecal injection of neurotensin in the rat
  786. DYNORPHIN-degrading cysteine protease is highly specific for paired arginine residues
  787. Gonadal steroids and anterior lobe DYNORPHIN in the male rat
  788. Intracerebroventricular (ICV) Clonidine Produces an Antianalgesic Effect Through Spinal DYNORPHIN A (1-17) Mediation
  789. CHANGES IN IMMUNOREACTIVE SUBSTANCE DYNORPHIN A1-13 LEVELS IN PITUITARY AND BRAIN AREAS IN BURNED RATS [J]
  790. Study of DYNORPHIN A peptides in vitro processing in human blood by matrix-assisted laser desorption mass spectrometry
  791. Effects of intraventricular DYNORPHIN treatment on brain monoamines
  792. EFFECTS OF DYNORPHIN A AND CCK-8 ON SYNAPTOSOMAL~(45) Ca UPTAKE OF THE RAT SPINAL CORD [J]
  793. Inhibitory effect of DYNORPHIN on the secretory activity of rat adrenal cortex in vivo
  794. Differential release of substance P and somatostatin in the rat spinal cord in response to noxious cold and heat: effect of DYNORPHIN A (1-17)
  795. DYNORPHIN Prolongs the Action Potential Duration of Mouse Sensory Ganglion Neurons by Decreasing a K+ Conductance Whereas the Specific Kappa Opioid, U …
  796. Effect of DYNORPHIN A (1–13) on cardiomyocytes in culture: modulation of the response to increased extracellular calcium, but no effect on intrinsic cardiac contractile …
  797. Technical aspects of opioid receptor localization: detection of opioid receptor proteins by immunocytochemistry or with a biotinylated DYNORPHIN analog
  798. DYNORPHIN B inhibits thymidine incorporation into DNA in fetal rat and guinea pig brain cell aggregates
  799. DESIGN AND SYNTHESIS OF HIGHLY POTENT AND SPECIFIC DYNORPHIN DERIVATIVES FOR AFFINITY LABELING OF K OPIOID RECEPTORS
  800. Synthesis and biological evaluation of DYNORPHIN a analogues as pharmacological probed of opioid receptors
  801. DIFFERENTIAL INTERACTIONS OF DYNORPHIN (1–13), β-ENDORPHIN, AND ENKEPHALIN-RELATED PEPTIDES AT μ AND δ SITES IN DIFFERENT BRAIN …
  802. Design and Synthesis of Metabolically Stable Analogue of DYNORPHIN-A
  803. Nerve fibers containing DYNORPHIN A in cerebral arteries.
  804. Cerebrospinal alterations of immunoreactive DYNORPHIN A after unilateral dorsal rhizotomy in the rat
  805. 125I-DPDYN, monoiodo [D-Pro10]-DYNORPHIN (1-11), is an effective and useful tool for the study of kappa opioid receptors.
  806. THE EFFECT OF DYNORPHIN A ON IMMUNE FUNCTION OF BURNED RATS
  807. The effect of DYNORPHIN A on intracellular cAMP and cGMP contents in spleen cells of burn rats and its relation to immune function
  808. THE EFFECT OF DYNORPHIN B ON SPATIAL LEARNING AND MEMORY WHEN MICROINJECTED INTO THE HIPPOCAMPUS OF THE RAT
  809. α-Neo-endorphin coexists with DYNORPHIN-A (1–8) within intramurally lying perikarya of rat duodenum
  810. Changes of β-endorphin, DYNORPHIN A1-13, atrial natriuretic factor and substance P in the cerebro-spinal fluid of the patients with acute brain injury and their chinieal …
  811. Role of central endogenous DYNORPHIN in control of ACTH and prolactin release during resting and stress
  812. Presence of DYNORPHIN-like immunoreactivity but not opiate binding in Walker-256 tumors
  813. … THE ACTION OF ACETYLCHOLINE ON PERISTALSIS IN VITRO. RELEASE STUDIES POINT TO A POSSIBLE ROLE FOR DYNORPHIN IN THE CONTROL OF …
  814. DYNORPHIN B-like immunoreactivity in gastroduodenal biopsy specimens from gallstone patients
  815. Effects of Foot-shock, Cold and Scalding on DYNORPHIN B Neurons in Rat Hypothalamus [J]
  816. Glucocorticosteroids decreases the activity of a DYNORPHIN-converting endopeptidase in rat cerebrospinal fluid
  817. Effects of DYNORPHIN A (1-8) on cell cycle and total cellular protein during neuronal aging in vitro
  818. The content of DYNORPHIN, Met-enk-Arg6-Phe7 and substance P (1-11) in the brain of mice with different levels of ethanol consumption
  819. DYNORPHIN-(2-17) Suppressed Withdrawal in Morphine-Dependent Rhesus Monkeys
  820. Evidence that Intracerebroventricular (ICV) Calcium Stimulates Spinal DYNORPHIN Release to Inhibit Morphine Analgesia in Mice
  821. Computer analysis of the effect of beta-endorphin and DYNORPHIN and related compounds on opioid binding to mouse brain membrane
  822. DYNORPHIN AND ATRIOPEPTIN MAY BE INVOLVED IN THE DEPRESSOR MECHANISM OF CLONIDINE [J]
  823. Changes of β-endorphin and DYNORPHIN A in plasmaand cerebrospinal fluid in patients with bleedingstrokes [J]
  824. Almost complete protection of DYNORPHIN-(1–8) hydrolysis in ileal and striatal membrane preparations by peptidase inhibitors
  825. Endorphins and the control of pain: Anatomical studies of enkephalin and DYNORPHIN
  826. The Effects of DYNORPHIN Peptides on Human Natural Killer Cell Activity In Vitro
  827. The Effect of Arginine Vasopressin on β-endorphin and DYNORPHIN A_ (1-13) Contents in Cerebral Ischemic Regions of Mongolian gerbils [J]
  828. Effects of DYNORPHIN A and CCK-8 on synaptosomal 45Ca uptake of the rat spinal cord
  829. E-2078, a potent, selective and stable DYNORPHIN analog with preferential activity for the kappa-opioid receptor subtype on the mouse vas deferens neuroeffector …
  830. STRUCTURE-ACTIVITY RELATIONSHIP OF DYNORPHIN-LIKE PEPTIDES AND THEIR MODULATION OF OPIOID ACTIVITY.
  831. Changes of plasma DYNORPHIN levels before and after percutaneous balloon mitral commissurotomy in patients with mitral stenosis.
  832. DYNORPHIN-related peptides in central and peripheral tissues: distribution and possible functions
  833. Interactions between DYNORPHIN A-(1–13) and morphine: In vivo effects on EEG, in vitro effects on tritium-morphine binding, and correlations between them in naive …
  834. CHANGES OF PLASMA DYNORPHIN LEVELS BEFORE AND AFTER PERCUTANEOUS BALLOON MITRAL COMMISSUROTOMY IN PATIENTS WITH MITRAL …
  835. THE EFFECT OF DYNORPHIN A-(1-13) ON IMMUNGREACTIVE SUBSTANCE P CONTENT IN SPINAL CORD AND ITS INTERACTION WITH THE EFFECT OF …
  836. Influence of DYNORPHIN A (1-17) on calmodulin level and activity of PDE in spinal cord of rats
  837. Immunocytochemistry and insitu hybridization identify changes in neuronal DYNORPHIN levels in a rat model of peripheral inflammation
  838. Histamine release induced by DYNORPHIN (1-13) from rat mast cells
  839. REGULATION OF HYPOTHALAMIC B-ENDORPHIN AND DYNORPHIN RELEASE BY CORTICOTROPIN-RELEASING FACTOR (CRF)
  840. Observations on the ontogeny and phylogeny of pro-DYNORPHIN
  841. ANATOMICAL AND BIOCHEMICAL STUDIES OF DYNORPHIN
  842. PHARMACOLOGICAL PROPERTIES OF DYNORPHIN
  843. PHARMACOLOGICAL PROPERTIES OF DYNORPHIN
  844. CHANGES IN IMMUNOREACTIVE SUBSTANCE DYNORPHIN A1-13 LEVELS IN PITUITARY AND BRAIN AREAS IN BURNED RATS
  845. Modulation of DYNORPHIN B release by cholecystokinin in the neostriatum and substantia nigra of rat
  846. DYNORPHIN A (1-17) causes motor dysfunction and decreases adenylyl cyclase-cAMP level of spinal cord in rat
  847. DYNORPHIN: DIFFERENTIAL INTERACTIONS WITH OPIATES AND PEPTIDES IN NAIVE AND MORPHINE TOLERANT MICE
  848. Effect of Endometriosis Pill Mo. 2 on β-Endometriosis and DYNORPHIN of Endometriosis
  849. A Study of the Effects of Dopaminergic Manipulations and Stress on DYNORPHIN Concentrations in Midbrain and Forebrain Regions of Rat Brain
  850. PERIPHERAL INFLAMMATION AND DYNORPHIN RELEASE IN THE RAT SPINAL CORD
  851. Relationship between endogenour opioids and the cardiovascular system: DYNORPHIN measurement in the human heart: β-endorphin plasmatic levels assay during …
  852. Effects of intrasubarachnoid space injection of anti DYNORPHIN A1-13 serum or nor-BNI on the recovery of spinal cord injury in rats
  853. Synthesis and biological activity of DYNORPHIN A-(1-13) analogs
  854. A study on the effect of DYNORPHIN A-(1-13) ICV injection on water, sodium and potassium excretion of rats
  855. Isoforms of a DYNORPHIN B converting enzyme isolated by column electrophoresis in agarose suspension.
  856. INVESTIGATIONS ON DYNORPHIN STRUCTURALLY-RELATED () PIOID PEPTIDES.
  857. Differential Effects of Selective Brain Lesions on Hypothalamic and Pituitary Ir-DYNORPHIN
  858. DYNORPHIN and enkephalin mRNAs in the rat forebrain by in situ hynridization histochmistry
  859. CHANGES OF BRAIN IMMUNOREACTIVE DYNORPHIN CONTENT FOLLOWING AMYGDALOID-KINDLED AND RECCURENT SEIZURES
  860. Kappa opioid agonist properties of DYNORPHIN and its peptide fragments
  861. Analgesie activity and opioid receptor binding of DYNORPHIN
  862. Origins, precise pathways, distribution and co-existence of ChAT-, VIP-NPY-CGRP-, SP-, and DYNORPHIN B-positive nerves in rat cerebral vessels. Comparison with …
  863. Effects of Foot-shock, Cold and Scalding on DYNORPHIN B Neurons in Rat Hypothalamus
  864. Expression of DYNORPHIN A and neuropeptide Y in target specific neurons of the rat superior cervical ganglion.
  865. Interaction of iv DYNORPHIN A (1-13) with kappa and mu agonists in a thermal antinociception assay in rhesus monkeys
  866. EFFECTS OF STIMULATING THE CENTRAL END OF VAGUS ON β-ENDORPHIN AND DYNORPHIN B CONTENTS IN THE CENTRAL NERVOUS SYSTEM
  867. Evaluation of DYNORPHIN A (1-13) and E-2078, a DYNORPHIN Analogue, and their Effects in Morphine-Treated Rhesus Monkeys Using Directly Observable Signs, Drug …
  868. DYNORPHIN-induced neurotoxicity in the mammalian spinal cord
  869. Synthesis and Opioid Activity of DYNORPHIN A (1-13) Analogs Substituted at Positions 2 and 4
  870. Opioids and cytosolic calcium in rat anterior pituitary: DYNORPHIN preparation showed LHRH-like action due to contamination
  871. Characterization of the analgesic role of DYNORPHIN A, an endogenous opioid peptide
  872. STUDIES ON THE CLINICAL PHARMACOLOGY OF KAPPA OPIOID RECEPTOR AGONISTS (SPIRADOLINE MESYLATE, NALOXONE, DYNORPHIN).
  873. The Membrane-Mediated Conformation of DYNORPHIN A-(1-13)-Peptide as Studied by Nuclear Magnetic Resonance Spectroscopy, Circular Dichroism …
  874. Effects of E2078, a new DYNORPHIN derivative, on pituitary-adrenocortical functions in dogs
  875. DYNORPHIN: INTRATHECAL INJECTION PRODUCES POTENT ANALGESIC EFFECT
  876. Responses of somatostatin, beta-endorphin and DYNORPHIN A to A glucose load in two groups of women with polycystic ovarian syndrome
  877. THE CHANGES OF THE CONTENTS OF VASOPRESSIN AND DYNORPHIN IN SUB-STANTIA NIGRA OF RATS EXPOSED TOHYPERBARIC OXYGEN
  878. DYNORPHIN and atriopeptin may be involved in the depressor mechanism of clonidine
  879. Solid phase synthesis of DYNORPHIN analogues as probes of Kappa opioid receptors
  880. Biochemical and pharmacological studies of the metabolism of DYNORPHIN 1-8
  881. Solution syntheses of two enkephalin-containing peptides, peptide E and DYNORPHIN (1-24), using Nin-(2, 4, 6-triisopropylphenylsulfonyl) tryptophan.
  882. Effects of DYNORPHIN1−13 on Opiate Binding and Dopamine and GABA Uptake in a Cat Model of Stroke
  883. The Dynamic Changes of DYNORPHIN in Plasma of Bumed Patients
  884. The Effect of Arginine Vasopressin on?-endorphin and DYNORPHIN A_ (1-13) Contents in Cerebral Ischemic Regions of Mongolian gerbils
  885. Synthesis and opioid activity of DYNORPHIN analogues with the modifications in the message sequence
  886. Mechanisms of DYNORPHIN-induced paralysis
  887. The Relationship Between DYNORPHIN A and Craniocerebral Injury: An Experimental Study
  888. Cerebrospinal Fluid Activity of DYNORPHIN-Converting Enzyme at Term Pregnancy
  889. Comparison and optimization of chromatographic conditions for separation of cyclic DYNORPHIN A analogues from linear byproducts
  890. OPIOID MODULATION OF THE RELEASE OF LUTEINIZING HORMONE (PITUITARY, CELL CULTURE, DYNORPHIN, MET-ENKEPHALIN)
  891. Synthesis and opioid activity of DYNORPHIN a analogues
  892. The Effects of Neutral Mucopolysaccharide on the Contents of β-endorphin and DYNORPHIN A_ (1~ 13) in Cerebral Ischemic Regions of Mongolian Gerbils
  893. DYNORPHIN-immunoreactive neurons in the central nervous system of the rat
  894. The localization of DYNORPHIN A_ (1-13) immunoreactive neurons in chicken brain
  895. Nitric Oxide Synthase Expression and DYNORPHIN-induced Spinal Cord Injury in Rats
  896. Synthesis and opioid activity of conformationally constrained DYNORPHIN A analogues
  897. Absence of Δ-9-tetrahydrocannabinol dysphoric effects in DYNORPHIN-deficient mice
  898. Differential biotransformation of DYNORPHIN A (1–17) and DYNORPHIN A (1–13) peptides in human blood, ex vivo
  899. The dysphoric component of stress is encoded by activation of the DYNORPHIN κ-opioid system
  900. Stress increases DYNORPHIN immunoreactivity in limbic brain regions and DYNORPHIN antagonism produces antidepressant‐like effects
  901. Orexin (hypocretin) neurons contain DYNORPHIN
  902. Single intrathecal injections of DYNORPHIN A or des-Tyr-DYNORPHINs produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone
  903. Kisspeptin neurons in the arcuate nucleus of the ewe express both DYNORPHIN A and neurokinin B
  904. DYNORPHIN promotes abnormal pain and spinal opioid antinociceptive tolerance
  905. The DYNORPHIN/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors
  906. Pronociceptive actions of DYNORPHIN maintain chronic neuropathic pain
  907. Role of DYNORPHIN and enkephalin in the regulation of striatal output pathways and behavior
  908. Regulation of gonadotropin-releasing hormone secretion by kisspeptin/DYNORPHIN/neurokinin B neurons in the arcuate nucleus of the mouse
  909. Sustained morphine exposure induces a spinal DYNORPHIN-dependent enhancement of excitatory transmitter release from primary afferent fibers
  910. Minireview: kisspeptin/neurokinin B/DYNORPHIN (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion
  911. Spinally administered DYNORPHIN A produces long-lasting allodynia: involvement of NMDA but not opioid receptors
  912. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter DYNORPHIN in ventral tegmental area
  913. Neurokinin B and DYNORPHIN A in kisspeptin neurons of the arcuate nucleus participate in generation of periodic oscillation of neural activity driving pulsatile …
  914. Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal DYNORPHIN in nerve-injured rats
  915. DYNORPHIN and the pathophysiology of drug addiction
  916. The kisspeptin/neurokinin B/DYNORPHIN (KNDy) cell population of the arcuate nucleus: sex differences and effects of prenatal testosterone in sheep
  917. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal DYNORPHIN
  918. Inhibition of cAMP response element-binding protein or DYNORPHIN in the nucleus accumbens produces an antidepressant-like effect
  919. DYNORPHIN, stress, and depression
  920. Concomitant loss of DYNORPHIN, NARP, and orexin in narcolepsy
  921. Distinct subpopulations of nucleus accumbens DYNORPHIN neurons drive aversion and reward
  922. CRF1-R activation of the DYNORPHIN/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior
  923. Coexpression of DYNORPHIN and neurokinin B immunoreactivity in the rat hypothalamus: morphologic evidence of interrelated function within the arcuate nucleus
  924. DYNORPHIN A activates bradykinin receptors to maintain neuropathic pain
  925. Evidence that DYNORPHIN plays a major role in mediating progesterone negative feedback on gonadotropin-releasing hormone neurons in sheep
  926. Cytokine involvement in DYNORPHIN-induced allodynia
  927. The role of the DYNORPHIN–κ opioid system in the reinforcing effects of drugs of abuse
  928. DYNORPHIN acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal cord
  929. Differential target-dependent actions of coexpressed inhibitory DYNORPHIN and excitatory hypocretin/orexin neuropeptides
  930. Effect of the endogenous κ opioid agonist DYNORPHIN A (1–17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in …
  931. The endomorphin-1/2 and DYNORPHIN-B peptides display biased agonism at the mu opioid receptor
  932. Kisspeptin, neurokinin B, and DYNORPHIN act in the arcuate nucleus to control activity of the GnRH pulse generator in ewes
  933. κ-opioid receptor/DYNORPHIN system: genetic and pharmacotherapeutic implications for addiction
  934. DYNORPHIN activates quorum sensing quinolone signaling in Pseudomonas aeruginosa
  935. Running and cocaine both upregulate DYNORPHIN mRNA in medial caudate putamen
  936. The DYNORPHIN/κ-opioid receptor system and its role in psychiatric disorders
  937. Regulation of arcuate neurons coexpressing kisspeptin, neurokinin B, and DYNORPHIN by modulators of neurokinin 3 and κ-opioid receptors in adult male mice
  938. DYNORPHIN opioid peptides enhance acid-sensing ion channel 1a activity and acidosis-induced neuronal death
  939. Regulation of Kiss1 and DYNORPHIN gene expression in the murine brain by classical and nonclassical estrogen receptor pathways
  940. The dopamine D1-D2 receptor heteromer localizes in DYNORPHIN/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia
  941. Methionine-enkephalin-and DYNORPHIN A-release from immune cells and control of inflammatory pain
  942. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and DYNORPHIN) neurons: a novel hypothesis on the mechanism of …
  943. Arcuate kisspeptin/neurokinin B/DYNORPHIN (KNDy) neurons mediate the estrogen suppression of gonadotropin secretion and body weight
  944. Orexin (hypocretin)/DYNORPHIN neurons control GABAergic inputs to tuberomammillary neurons
  945. Region selective up-regulation of μ-, δ-and κ-opioid receptors but not opioid receptor-like 1 receptors in the brains of enkephalin and DYNORPHIN knockout mice
  946. … increases DYNORPHIN a concentrations in cerebrospinal fluid and preproDYNORPHIN messenger ribonucleic acid levels in a subset of DYNORPHIN neurons in the sheep
  947. A Microdialysis Profile of DYNORPHIN A1–8 Release in the Rat Nucleus Accumbens Following Alcohol Administration
  948. Cellular sites for DYNORPHIN activation of κ-opioid receptors in the rat nucleus accumbens shell
  949. Colocalization of progesterone receptors in parvicellular DYNORPHIN neurons of the ovine preoptic area and hypothalamus
  950. … , a C 19-diterpenoid alkaloid, attenuates chronic neuropathic pain through stimulating ERK/CREB signaling pathway-mediated microglial DYNORPHIN A …
  951. DYNORPHIN controls the gain of an amygdalar anxiety circuit
  952. DYNORPHIN, dysphoria, and dependence: the stress of addiction
  953. Role for kisspeptin/neurokinin B/DYNORPHIN (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature
  954. Repeated ethanol administration induces short-and long-term changes in enkephalin and DYNORPHIN tissue concentrations in rat brain
  955. Palatability-induced hyperphagia increases hypothalamic DYNORPHIN peptide and mRNA levels
  956. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of DYNORPHIN and orexin in the …
  957. DYNORPHIN/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders
  958. Endogenous DYNORPHIN in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors
  959. KNDy (kisspeptin/neurokinin B/DYNORPHIN) neurons are activated during both pulsatile and surge secretion of LH in the ewe
  960. Morphine acts on spinal DYNORPHIN neurons to cause itch through disinhibition
  961. L-DOPA-induced dyskinesia is associated with regional increase of striatal DYNORPHIN peptides as elucidated by imaging mass spectrometry
  962. Colocalisation of DYNORPHIN a and neurokinin B immunoreactivity in the arcuate nucleus and median eminence of the sheep
  963. Potent regulation of microglia‐derived oxidative stress and dopaminergic neuron survival: substance P vs. DYNORPHIN
  964. DYNORPHIN A as a potential endogenous ligand for four members of the opioid receptor gene family
  965. Projection-target-defined effects of orexin and DYNORPHIN on VTA dopamine neurons
  966. Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to DYNORPHIN A (1–13) or MK-801 in a nerve-ligation model of peripheral …
  967. Stress-induced activation of the DYNORPHIN/κ-opioid receptor system in the amygdala potentiates nicotine conditioned place preference
  968. Hippocampal DYNORPHIN B injections impair spatial learning in rats: a κ-opioid receptor-mediated effect
  969. … transcript peptide projections in the ventral midbrain: Colocalization with γ‐aminobutyric acid, melanin‐concentrating hormone, DYNORPHIN, and synaptic interactions …
  970. DYNORPHIN/kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction
  971. Delayed kindling development after rapidly recurring seizures: relation to mossy fiber sprouting and neurotrophin, GAP-43 and DYNORPHIN gene expression
  972. Targeting DYNORPHIN/kappa opioid receptor systems to treat alcohol abuse and dependence
  973. DYNORPHIN is a downstream effector of striatal BDNF regulation of ethanol intake
  974. NMR structure and dynamics of the agonist DYNORPHIN peptide bound to the human kappa opioid receptor
  975. Translocation of DYNORPHIN neuropeptides across the plasma membrane: a putative mechanism of signal transmission
  976. Desipramine reduces stress-activated DYNORPHIN expression and CREB phosphorylation in NAc tissue
  977. Behavioral stress may increase the rewarding valence of cocaine-associated cues through a DYNORPHIN/κ-opioid receptor-mediated mechanism without …
  978. DYNORPHIN–still an extraordinarily potent opioid peptide
  979. Sensitization to the behavioral effects of cocaine: modulation by DYNORPHIN and κ-opioid receptor agonists
  980. Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or DYNORPHIN antiserum
  981. Sex differences and phases of the estrous cycle alter the response of spinal cord DYNORPHIN neurons to peripheral inflammation and hyperalgesia
  982. DYNORPHIN B and spinal analgesia: induction of antinociception by the cannabinoids CP55, 940, Δ9-THC and anandamide
  983. Mechanisms of induction of persistent nociception by DYNORPHIN
  984. DYNORPHIN is expressed primarily by GABAergic neurons that contain galanin in the rat dorsal horn
  985. Roles of nucleus accumbens CREB and DYNORPHIN in dysregulation of motivation
  986. Neuropathic pain: the paradox of DYNORPHIN
  987. Distinct mechanisms for activation of the opioid receptor-like 1 and κ-opioid receptors by nociceptin and DYNORPHIN A
  988. DYNORPHIN A1–13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation …
  989. Striatal and ventral pallidum DYNORPHIN concentrations are markedly increased in human chronic cocaine users
  990. Low degree of overlap between kisspeptin, neurokinin B, and DYNORPHIN immunoreactivities in the infundibular nucleus of young male human subjects challenges the …
  991. Suppression of morphine withdrawal by electroacupuncture in rats: DYNORPHIN and κ-opioid receptor implicated
  992. Kisspeptin/Neurokinin B/DYNORPHIN (KNDy) cells as integrators of diverse internal and external cues: evidence from viral-based monosynaptic tract-tracing in …
  993. Imaging mass spectrometry reveals elevated nigral levels of DYNORPHIN neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson’s disease
  994. DYNORPHIN A (1–13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons
  995. Endogenous DYNORPHIN protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice
  996. Involvement of κ/DYNORPHIN system in WIN 55,212-2 self-Administration in mice
  997. … of the hypothalamic arcuate nucleus release GABA, communicate with dopaminergic and other arcuate neurons, and respond to DYNORPHIN, met-enkephalin, and …
  998. Electrophysiological and morphological evidence for synchronized GnRH pulse generator activity among Kisspeptin/neurokinin B/DYNORPHIN A (KNDy) neurons in …
  999. Different alcohol exposures induce selective alterations on the expression of DYNORPHIN and nociceptin systems related genes in rat brain
  1000. Morphometry of a peptidergic transmitter system: DYNORPHIN B‐like immunoreactivity in the rat hippocampal mossy fiber pathway before and after seizures
  1001. Activation of alpha7 acetylcholine receptors reduces neuropathic pain by decreasing DYNORPHIN A release from microglia
  1002. Comparison of the structure-activity relationships of nociceptin and DYNORPHIN A using chimeric peptides
  1003. DYNORPHIN-kappa opioid receptor signaling partly mediates estrogen negative feedback effect on LH pulses in female rats
  1004. DYNORPHIN and epilepsy
  1005. Involvement of DYNORPHIN B in the antinociceptive effects of the cannabinoid CP55, 940 in the spinal cord
  1006. DYNORPHIN B is an agonist of nuclear opioid receptors coupling nuclear protein kinase C activation to the transcription of cardiogenic genes in GTR1 embryonic stem …
  1007. Caspase-3 activity is reduced after spinal cord injury in mice lacking DYNORPHIN: differential effects on glia and neurons
  1008. Generation of DYNORPHIN knockout mice
  1009. Structure–activity analysis of DYNORPHIN A toxicity in spinal cord neurons: intrinsic neurotoxicity of DYNORPHIN A and its carboxyl-terminal, nonopioid metabolites
  1010. Aconitum-derived bulleyaconitine A exhibits antihypersensitivity through direct stimulating DYNORPHIN A expression in spinal microglia
  1011. DYNORPHIN and stress‐related peptides in rat locus coeruleus: Contribution of amygdalar efferents
  1012. Role of the DYNORPHIN/kappa opioid receptor system in the motivational effects of ethanol
  1013. Structures that delineate orphanin FQ and DYNORPHIN A pharmacological selectivities
  1014. Experience-dependent myelination following stress is mediated by the neuropeptide DYNORPHIN
  1015. Ultrastructural localization of DYNORPHIN in the dentate gyrus in human temporal lobe epilepsy: a study of reorganized mossy fiber synapses
  1016. The emerging role of spinal DYNORPHIN in chronic pain: a therapeutic perspective
  1017. DYNORPHIN regulates D1 dopamine receptor‐mediated responses in the striatum: Relative contributions of pre‐and postsynaptic mechanisms in dorsal and ventral …
  1018. Bullatine A stimulates spinal microglial DYNORPHIN A expression to produce anti-hypersensitivity in a variety of rat pain models
  1019. Cannabinoid modulation of DYNORPHIN A: correlation to cannabinoid-induced antinociception
  1020. The role of nociceptin and DYNORPHIN in chronic pain: Implications of neuro–glial interaction
  1021. DYNORPHIN exerts both postsynaptic and presynaptic effects in the globus pallidus of the rat
  1022. Nonopioid actions of intrathecal DYNORPHIN evoke spinal excitatory amino acid and prostaglandin E2 release mediated by cyclooxygenase-1 and-2
  1023. A comparison between microwave irradiation and decapitation: basal levels of DYNORPHIN and enkephalin and the effect of chronic morphine treatment on DYNORPHIN …
  1024. DYNORPHIN: friend or foe?
  1025. Minocycline prevents DYNORPHIN-induced neurotoxicity during neuropathic pain in rats
  1026. Alcohol-induced plasticity in the DYNORPHIN/kappa-opioid receptor system
  1027. Development and characterization of functionalized niosomes for brain targeting of DYNORPHIN-B
  1028. The role of DYNORPHIN and the kappa opioid receptor in the symptomatology of schizophrenia: a review of the evidence
  1029. Enkephalin and DYNORPHIN mRNA expression are associated with resilience or vulnerability to chronic social defeat stress
  1030. Big DYNORPHIN as a putative endogenous ligand for the κ‐opioid receptor
  1031. DYNORPHIN-kappa opioid receptor activity in the central amygdala modulates binge-like alcohol drinking in mice
  1032. Kappa-opioid receptors, DYNORPHIN, and cocaine addiction: a positron emission tomography study
  1033. Effect of ethanol on hypothalamic opioid peptides, enkephalin, and DYNORPHIN: relationship with circulating triglycerides
  1034. Effects of acute and chronic social defeat stress are differentially mediated by the DYNORPHIN/kappa-opioid receptor system
  1035. Hypothalamic reproductive endocrine pulse generator activity independent of neurokinin B and DYNORPHIN signaling
  1036. Modulation of neurotransmitter release in the basal ganglia of the rat brain by DYNORPHIN peptides
  1037. Intrathecally administered big DYNORPHIN, a proDYNORPHIN-derived peptide, produces nociceptive behavior through an N-methyl-D-aspartate receptor mechanism
  1038. The role of dopamine, DYNORPHIN, and CART systems in the ventral striatum and amygdala in cocaine abuse
  1039. High-affinity interaction of (des-Tyrosyl) DYNORPHIN A (2-17) with NMDA receptors
  1040. The DYNORPHIN/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?
  1041. DYNORPHIN counteracts orexin in the paraventricular nucleus of the thalamus: cellular and behavioral evidence
  1042. Dietary fat stimulates endogenous enkephalin and DYNORPHIN in the paraventricular nucleus: role of circulating triglycerides
  1043. Kappa opioid receptor and DYNORPHIN signaling in the central amygdala regulates alcohol intake
  1044. Stress-induced reinstatement of nicotine preference requires DYNORPHIN/kappa opioid activity in the basolateral amygdala
  1045. Prenatal ethanol induces an anxiety phenotype and alters expression of DYNORPHIN & nociceptin/orphanin FQ genes
  1046. Chemical probes unravel an antimicrobial defense response triggered by binding of the human opioid DYNORPHIN to a bacterial sensor kinase
  1047. Molecular simulation of DYNORPHIN A-(1− 10) binding to extracellular loop 2 of the κ-opioid receptor. A model for receptor activation
  1048. The kappa opioid receptor and DYNORPHIN co-localize in vasopressin magnocellular neurosecretory neurons in guinea-pig hypothalamus
  1049. DYNORPHIN uses a non-opioid mechanism to potentiate N-methyl-D-aspartate currents in single rat periaqueductal gray neurons
  1050. Mouse strains that lack spinal DYNORPHIN upregulation after peripheral nerve injury do not develop neuropathic pain
  1051. Big DYNORPHIN, a proDYNORPHIN-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice
  1052. DYNORPHIN and the kappa 1 ligand [3H] U69, 593 binding in the human epileptogenic hippocampus
  1053. The role of the DYNORPHIN/κ opioid receptor system in anxiety
  1054. DYNORPHIN A elicits an increase in intracellular calcium in cultured neurons via a non-opioid, non-NMDA mechanism
  1055. DYNORPHIN activation of kappa opioid receptor promotes microglial polarization toward M2 phenotype via TLR4/NF-κB pathway
  1056. Effects and interactions of tachykinins and DYNORPHIN on FSH and LH secretion in developing and adult rats
  1057. [2′,6′-Dimethyltyrosine]DYNORPHIN A(1−11)-NH2 Analogues Lacking an N-Terminal Amino Group:  Potent and Selective κ Opioid Antagonists
  1058. DYNORPHIN selectively augments the M-current in hippocampal CA1 neurons by an opiate receptor mechanism
  1059. Effects of DYNORPHIN A (1-13) on carbon monoxide-induced delayed amnesia in mice
  1060. Increased spinal DYNORPHIN levels and phospho-extracellular signal-regulated kinases 1 and 2 and c-Fos immunoreactivity after surgery under remifentanil anesthesia …
  1061. Expression of Fos-related antigens, oxytocin, DYNORPHIN and galanin in the paraventricular and supraoptic nuclei of lactating rats
  1062. Intraplantar injection of a cyclooxygenase inhibitor ketorolac reduces immunoreactivities of substance P, calcitonin gene-related peptide, and DYNORPHIN in the dorsal …
  1063. Differential regulation of the human κ opioid receptor by agonists: etorphine and levorphanol reduced DYNORPHIN A-and U50, 488H-induced internalization and …
  1064. Bulleyaconitine A inhibits visceral nociception and spinal synaptic plasticity through stimulation of microglial release of DYNORPHIN A
  1065. Immunohistochemical characterization of the arcuate kisspeptin/neurokinin B/DYNORPHIN (KNDy) and preoptic kisspeptin neuronal populations in the hypothalamus …
  1066. Lappaconitine, a C18-diterpenoid alkaloid, exhibits antihypersensitivity in chronic pain through stimulation of spinal DYNORPHIN A expression
  1067. Spinal astrocytes produce and secrete DYNORPHIN neuropeptides
  1068. Drug seeking and relapse: new evidence of a role for orexin and DYNORPHIN co-transmission in the paraventricular nucleus of the thalamus
  1069. Long‐term ethanol effects on acute stress responses: modulation by DYNORPHIN
  1070. Spinal DYNORPHIN and bradykinin receptors maintain inflammatory hyperalgesia
  1071. Differential regulation of GAD67, enkephalin and DYNORPHIN mRNAs by chronic‐intermittent L‐dopa and A2A receptor blockade plus L‐Dopa in dopamine …
  1072. Does DYNORPHIN play a role in the onset of puberty in female sheep?
  1073. Evidence that DYNORPHIN acts upon KNDy and GnRH neurons during GnRH pulse termination in the ewe
  1074. Pronociceptive actions of DYNORPHIN via bradykinin receptors
  1075. Identification of arodyn, a novel acetylated DYNORPHIN A-(1− 11) analogue, as a κ opioid receptor antagonist
  1076. DYNORPHIN-containing axons directly innervate noradrenergic neurons in the rat nucleus locus coeruleus
  1077. DYNORPHIN and enkephalin opioid peptides and transcripts in spinal cord and dorsal root ganglion during peripheral inflammatory hyperalgesia and allodynia
  1078. DYNORPHIN and its role in alcohol use disorder
  1079. Cathepsin L participates in DYNORPHIN production in brain cortex, illustrated by protease gene knockout and expression
  1080. Upregulated DYNORPHIN opioid peptides mediate alcohol-induced learning and memory impairment
  1081. DYNORPHIN‐based “release on demand” gene therapy for drug‐resistant temporal lobe epilepsy
  1082. Co-localization of mu opioid receptor is greater with DYNORPHIN than enkephalin in rat striatum.
  1083. Changes in rat melanin-concentrating hormone and DYNORPHIN messenger ribonucleic acids induced by food deprivation
  1084. Ifenprodil blocks the excitatory effects of the opioid peptide DYNORPHIN 1–17 on NMDA receptor-mediated currents in the CA3 region of the guinea pig hippocampus
  1085. Immunoelectron microscopic observation of the subcellular localization of kisspeptin, neurokinin B and DYNORPHIN A in KNDy neurons in the arcuate nucleus of the …
  1086. Cocaine dysregulates DYNORPHIN modulation of inhibitory neurotransmission in the ventral pallidum in a cell-type-specific manner
  1087. Acute nicotine changes DYNORPHIN and proDYNORPHIN mRNA in the striatum
  1088. Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of DYNORPHIN-mediated κ-opioid receptor and …
  1089. Involvement of DYNORPHIN and kappa opioid receptor in yohimbine-induced reinstatement of heroin seeking in rats
  1090. … differentially reduces aconitine-induced anti-hypersensitivity and acute neurotoxicity: Involvement of spinal microglial DYNORPHIN expression and implications …
  1091. Elevated mutant DYNORPHIN A causes Purkinje cell loss and motor dysfunction in spinocerebellar ataxia type 23
  1092. DYNORPHIN A (1–17) induces apoptosis in striatal neurons in vitro through α-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor-mediated cytochrome C …
  1093. Suppressed prolactin response to DYNORPHIN A1–13 in methadone-maintained versus control subjects
  1094. Region-specific bioconversion of DYNORPHIN neuropeptide detected by in situ histochemistry and MALDI imaging mass spectrometry
  1095. Synthesis and Opioid Activity of Conformationally Constrained DYNORPHIN A Analogues. 2. Conformational Constraint in the “Address” Sequence,
  1096. Central changes in nociceptin DYNORPHIN B and Met-enkephalin-Arg-Phe in different models of nociception
  1097. Epilepsy, CNS viral injury and DYNORPHIN
  1098. Neuropathic plasticity in the opioid and non-opioid actions of DYNORPHIN A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat …
  1099. Involvement of the DYNORPHIN/KOR system on the nociceptive, emotional and cognitive manifestations of joint pain in mice
  1100. Opposing roles of cotransmission of DYNORPHIN and hypocretin on reward and motivation
  1101. Protracted withdrawal from ethanol and enhanced responsiveness stress: regulation via the DYNORPHIN/kappa opioid receptor system
  1102. Paraventricular DYNORPHIN A neurons mediate LH pulse suppression induced by hindbrain glucoprivation in female rats
  1103. DYNORPHIN A (1–17) biotransformation in striatum of freely moving rats using microdialysis and matrix‐assisted laser desorption/ionization mass spectrometry
  1104. Potentiation of NMDA receptor-mediated responses by DYNORPHIN at low extracellular glycine concentrations
  1105. Analgesia-producing mechanism of processed Aconiti tuber: role of DYNORPHIN, an endogenous κ-opioid ligand, in the rodent spinal cord
  1106. Mechanism and site of action of big DYNORPHIN on ASIC1a
  1107. Melatonin‐induced T‐helper cell hematopoietic cytokines resembling both interleukin‐4 and DYNORPHIN
  1108. Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide DYNORPHIN A(1–17) in the unilateral 6‐OHDA rat model of Parkinson’s disease
  1109. DYNORPHIN peptides differentially regulate the human κ opioid receptor
  1110. A midbrain DYNORPHIN circuit promotes threat generalization
  1111. DYNORPHIN activation of kappa opioid receptor protects against epilepsy and seizure-induced brain injury via PI3K/Akt/Nrf2/HO-1 pathway
  1112. Topical application of DYNORPHIN A (1–17) antiserum attenuates trauma induced alterations in spinal cord evoked potentials, microvascular permeability disturbances …
  1113. Basal levels and alcohol-induced changes in nociceptin/orphanin FQ, DYNORPHIN, and enkephalin levels in C57BL/6J mice
  1114. Neonatal handling in rats induces long-term effects on DYNORPHIN peptides
  1115. Kappa opioid receptor endocytosis by DYNORPHIN peptides
  1116. DYNORPHIN A (1–13) and responsiveness of the newborn rat to a surrogate nipple: Immediate behavioral consequences and reinforcement effects in conditioning
  1117. Effects of corticotropin-releasing hormone receptor antagonists on the ethanol-induced increase of DYNORPHIN A1-8 release in the rat central amygdala
  1118. DYNORPHIN-mediated antinociceptive effects of L-arginine and SIN-1 (an NO donor) in mice
  1119. [Nα-BenzylTyr,cyclo(d-Asp5,Dap8)]- DYNORPHIN A-(1−11)NH2 Cyclized in the “Address” Domain Is a Novel κ-Opioid Receptor Antagonist
  1120. The relationship between housing and social rank on cortisol, β-endorphin and DYNORPHIN (1–13) secretion in sows
  1121. Both DYNORPHIN A (1-17)[Des-Tyr1] DYNORPHIN A (2-17) inhibit adenylyl cyclase activity in rat caudate putamen.
  1122. NMR and structural model of DYNORPHIN A (1− 17) bound to dodecylphosphocholine micelles
  1123. C2 spinal cord stimulation induces DYNORPHIN release from rat T4 spinal cord: potential modulation of myocardial ischemia-sensitive neurons
  1124. Screening of 109 neuropeptides on ASICs reveals no direct agonists and DYNORPHIN A, YFMRFamide and endomorphin-1 as modulators
  1125. DYNORPHIN inhibits basal forebrain cholinergic neurons by pre‐and postsynaptic mechanisms
  1126. Possible involvement of DYNORPHIN A-(1–17) release via μ1-opioid receptors in spinal antinociception by endomorphin-2
  1127. DYNORPHIN and κ-opioid receptor dysregulation in the dopaminergic reward system of human alcoholics
  1128. Structure–activity relationship studies of DYNORPHIN A and related peptides
  1129. Exposure to cocaine alters DYNORPHIN-mediated regulation of excitatory synaptic transmission in nucleus accumbens neurons
  1130. Direct inhibition of arcuate proopiomelanocortin neurons: a potential mechanism for the orexigenic actions of DYNORPHIN
  1131. Analgesic roles of peripheral intrinsic met-enkephalin and DYNORPHIN A in long-lasting inflammatory pain induced by complete Freund’s adjuvant in rats
  1132. Postnatal maturation of spinal DYNORPHIN circuits and their role in somatosensation
  1133. Progesterone-receptive β-endorphin and DYNORPHIN B neurons in the arcuate nucleus project to regions of high gonadotropin-releasing hormone neuron density in the …
  1134. Prostaglandin E2 release evoked by intrathecal DYNORPHIN is dependent on spinal p38 mitogen activated protein kinase
  1135. Age-related alterations in hypothalamic kisspeptin, neurokinin B, and DYNORPHIN neurons and in pulsatile LH release in female and male rats
  1136. Role of brain DYNORPHIN in nitrous oxide antinociception in mice
  1137. Release of endogenous DYNORPHIN opioids in the prefrontal cortex disrupts cognition
  1138. Effects of moxibustion on DYNORPHIN and endomorphin in rats with chronic visceral hyperalgesia
  1139. DYNORPHIN A increases substance P release from trigeminal primary afferent C-fibers
  1140. Hippocampal DYNORPHIN immunoreactivity increases in response to gonadal steroids and is positioned for direct modulation by ovarian steroid receptors
  1141. Characterizing the site and mode of action of DYNORPHIN at hippocampal mossy fiber synapses in the guinea pig
  1142. Decoy peptides that bind DYNORPHIN noncovalently prevent NMDA receptor-mediated neurotoxicity
  1143. Effect of chronic treatment with morphine, midazolam and both together on DYNORPHIN (1–13) levels in the rat
  1144. Structure-activity relationships of nociceptin and related peptides: comparison with DYNORPHIN A
  1145. Somatodendritic DYNORPHIN release: orchestrating activity patterns of vasopressin neurons
  1146. Effects of Ovariectomy and Sex Hormone Replacement on Numbers of Kisspeptin-, Neurokinin B-and DYNORPHIN A-immunoreactive Neurons in the Arcuate Nucleus of …
  1147. Neurotensin and DYNORPHIN Bi-Directionally modulate CeA inhibition of oval BNST neurons in male mice
  1148. Pronociceptive role of DYNORPHINs in uninjured animals: N-ethylmaleimide-induced nociceptive behavior mediated through inhibition of DYNORPHIN degradation
  1149. Structure and dynamics of DYNORPHIN peptide and its receptor
  1150. Electroacupuncture relieves labour pain and influences the spinal DYNORPHIN/κ-opioid receptor system in rats
  1151. Decreased DYNORPHIN A (1–17) in the spinal cord of spastic rats after the compressive injury
  1152. Pre-emptive intrathecal Mk-801, a non-competitive N-methyl-D-aspartate receptor antagonist, inhibits the up-regulation of spinal DYNORPHIN mRNA and hyperalgesia in …
  1153. DYNORPHIN A-Mediated Reduction in Multiple Calcium Currents Involves a Goα-Subtype G Protein in Rat Primary Afferent Neurons
  1154. Differential sensitivity of recombinant N-methyl-D-aspartate receptor subunits to inhibition by DYNORPHIN.
  1155. Antibodies to DYNORPHIN A (1–17) Attenuate Closed Head Injury Induced Blood–Brain Barrier Disruption, Brain Edema Formation and Brain Pathology in the Rat
  1156. DYNORPHIN immunoreactive fibers contact GnRH neurons in the human hypothalamus
  1157. DYNORPHIN A, kappa opioid receptors and the antinociceptive efficacy of asimadoline in streptozotocin-induced diabetic rats
  1158. DYNORPHIN and proDYNORPHIN mRNA changes in the striatum during nicotine withdrawal
  1159. DYNORPHIN induced magnetic ordering in lipid bilayers as studied by 31P NMR spectroscopy
  1160. Neonatal injury evokes persistent deficits in DYNORPHIN inhibitory circuits within the adult mouse superficial dorsal horn
  1161. Characterization of kappa opioid receptor mediated, DYNORPHIN-stimulated [35S] GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an …
  1162. Secondary structure transitions and aggregation induced in DYNORPHIN neuropeptides by the detergent sodium dodecyl sulfate
  1163. Glucocorticoids stimulate hypothalamic DYNORPHIN expression accounting for stress-induced impairment of GnRH secretion during preovulatory period
  1164. Central injection of neuropeptide Y modulates sexual behavior in male rats: interaction with GnRH and kisspeptin/neurokinin B/DYNORPHIN
  1165. Inhibition of DYNORPHIN-converting enzymes prolongs the antinociceptive effect of intrathecally administered DYNORPHIN in the mouse formalin test
  1166. Loss of DYNORPHIN-mediated inhibition of voltage-dependent Ca2+ currents in hippocampal granule cells isolated from epilepsy patients is associated with mossy fiber …
  1167. Identification of DYNORPHIN a from zebrafish: a comparative study with mammalian DYNORPHIN A
  1168. A Novel N-Terminal Cyclic DYNORPHIN A Analogue cycloN,5[Trp3,Trp4,Glu5] DYNORPHIN A-(1−11)NH2 That Lacks the Basic N-Terminus
  1169. The role of kisspeptin/neurokinin B/DYNORPHIN neurons in pathomechanism of vasomotor symptoms in postmenopausal women: from physiology to potential …
  1170. Pronociceptive effects of spinal DYNORPHIN promote cannabinoid-induced pain and antinociceptive tolerance
  1171. Transcriptional profile of spinal DYNORPHIN-lineage interneurons in the developing mouse
  1172. Viral risk factor for seizures: pathobiology of DYNORPHIN in herpes simplex viral (HSV-1) seizures in an animal model
  1173. Plasma DYNORPHIN A concentration reflects the degree of pruritus in chronic liver disease: a preliminary report
  1174. Discovery of amphipathic DYNORPHIN A analogues to inhibit the neuroexcitatory effects of DYNORPHIN A through bradykinin receptors in the spinal cord
  1175. Warming moxibustion relieves chronic visceral hyperalgesia in rats: relations to spinal DYNORPHIN and orphanin-FQ system
  1176. Alterations in GAD67, DYNORPHIN and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson’s disease
  1177. DYNORPHIN peptides: antagonists of melanocortin receptors
  1178. DYNORPHIN/KOP and nociceptin/NOP gene expression and epigenetic changes by cocaine in rat striatum and nucleus accumbens
  1179. DYNORPHIN knockout reduces fat mass and increases weight loss during fasting in mice
  1180. Occlusal disharmony transiently impairs learning and memory in the mouse by increasing DYNORPHIN A levels in the amygdala
  1181. Contribution and interaction of kinin receptors and DYNORPHIN A in a model of trigeminal neuropathic pain in mice
  1182. Relationship of spinal DYNORPHIN neurons to δ-opioid receptors and estrogen receptor α: anatomical basis for ovarian sex steroid opioid antinociception
  1183. Knock-down’of spinal CB1 receptors produces abnormal pain and elevates spinal DYNORPHIN content in mice
  1184. Effect of morphine on DYNORPHIN B and GABA release in the basal ganglia of rats
  1185. The effect of paracetamol on nociception and DYNORPHIN A levels in the rat brain
  1186. Classical conditioning in the fetal rat: Reinforcing properties of DYNORPHIN A (1–13).
  1187. Effects of DYNORPHIN A (1–13) on opiate withdrawal in humans
  1188. DYNORPHIN in pro-opiomelanocortin neurons of the hypothalamic arcuate nucleus
  1189. Inhaled [D-Ala2]-DYNORPHIN 1-6 Prevents Hyperacetylation and Release of High Mobility Group Box 1 in a Mouse Model of Acute Lung Injury
  1190. Regulation of prepubertal DYNORPHIN secretion in the medial basal hypothalamus of the female rat
  1191. Different domains of the ORL1 and κ-opioid receptors are involved in recognition of nociceptin and DYNORPHIN A
  1192. Prenatal testosterone exposure decreases colocalization of insulin receptors in kisspeptin/neurokinin B/DYNORPHIN and agouti‐related peptide neurons of the adult …
  1193. DYNORPHIN-A immunoreactive terminals on the neuronal somata of rat mesencephalic trigeminal nucleus
  1194. Amygdala DYNORPHIN/κ opioid receptor system modulates depressive-like behavior in mice following chronic social defeat stress
  1195. Metabolism of DYNORPHIN A (1-13)
  1196. Compartment-specific opioid receptor signaling is selectively modulated by different DYNORPHIN peptides
  1197. Projection neurons in lamina III of the rat spinal cord are selectively innervated by local DYNORPHIN-containing excitatory neurons
  1198. Molecular dynamics simulations predict a tilted orientation for the helical region of DYNORPHIN A (1–17) in dimyristoylphosphatidylcholine bilayers
  1199. Orphanin FQ, but not DYNORPHIN A, accelerates colonic transit in rats
  1200. The α9/α10-containing nicotinic ACh receptor is directly modulated by opioid peptides, endomorphin-1, and DYNORPHIN B, proposed efferent cotransmitters in the inner …
  1201. Electrospray ionization mass spectrometric and liquid chromatographic–mass spectrometric studies on the metabolism of synthetic DYNORPHIN A peptides in brain …
  1202. Sex, pain, and opioids: interdependent influences of sex and pain modality on DYNORPHIN-mediated antinociception in rats
  1203. Distribution of preproDYNORPHIN mRNA and DYNORPHIN-a immunoreactivity in the sheep preoptic area and hypothalamus
  1204. DYNORPHIN Neuropeptides Decrease Apparent Proton Affinity of ASIC1a by Occluding the Acidic Pocket
  1205. Conopeptide-derived κ-opioid agonists (Conorphins): potent, selective, and metabolic stable DYNORPHIN A mimetics with antinociceptive properties
  1206. Spinal cord DYNORPHIN expression increases, but does not drive microglial prostaglandin production or mechanical hypersensitivity after incisional surgery in rats
  1207. Local inhibitory effects of DYNORPHIN A-(1–17) on capsaicin-induced thermal allodynia in rhesus monkeys
  1208. Novel signaling of DYNORPHIN at κ-opioid receptor/bradykinin B2 receptor heterodimers
  1209. DYNORPHIN-A (1–17) decreases nitric oxide release and cytotoxicity induced with lipopolysaccharide plus interferon-γ in murine macrophage cell line J774
  1210. Involvement of DYNORPHIN in immobilization stress-induced antinociception in the mouse
  1211. Nitric oxide synthase inhibitors in? uence DYNORPHIN A (1–17) immunoreactivity in the rat brain following hyperthermia
  1212. Thioperamide, a histamine H3 receptor antagonist, suppresses NPY-but not DYNORPHIN A-induced feeding in rats
  1213. Activation of Transient Receptor Potential Vanilloid 1 Channels in the Nucleus of the Solitary Tract and Activation of DYNORPHIN Input to the Median Preoptic …
  1214. The Opioid Peptide DYNORPHIN a Induces Leukocyte Responses via Integrin Mac-1 (αMβ2, CD11b/CD18)
  1215. Temporal changes in spinal cord expression of mRNA for substance P, DYNORPHIN and enkephalin in a model of chronic pain
  1216. Structure and orientation of DYNORPHIN bound to lipid bilayers by 13C solid-state NMR
  1217. Left vagal stimulation induces DYNORPHIN release and suppresses substance P release from the rat thoracic spinal cord during cardiac ischemia
  1218. Distribution and regulation of gonadotropin-releasing hormone, kisspeptin, RF-amide related peptide-3, and DYNORPHIN in the bovine hypothalamus
  1219. DYNORPHIN mRNA Expression in Dorsal Horn Neurons After Traumatic Spinal Cord Injury: Temporal and Spatial Analysis Using In Situ Hybridization
  1220. Effects of systemically administered DYNORPHIN A (1–17) in rhesus monkeys
  1221. Antinociceptive effects of DYNORPHIN peptides in a model of inflammatory pain
  1222. DYNORPHIN A toxicity in striatal neurons via an α-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor mechanism
  1223. Contribution of DYNORPHIN and orexin neuropeptide systems to the motivational effects of alcohol
  1224. DYNORPHIN A1–17-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats
  1225. Design, synthesis, and pharmacological activities of DYNORPHIN A analogues cyclized by ring-closing metathesis
  1226. N-Alkylated derivatives of [d-Pro10] DYNORPHIN A-(1-11) are high affinity partial agonists at the cloned rat κ-opioid receptor
  1227. Isoflurane attenuates DYNORPHIN‐induced cytotoxicity and downregulation of Bcl‐2 expression in differentiated neuroblastoma SH‐SY5Y cells
  1228. Effects of the κ-opioid DYNORPHIN A (1–13) on learning and memory in mice
  1229. Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the κ-opioid receptor does not affect DYNORPHIN A (1− 13) affinity and function
  1230. Micellar electrokinetic chromatography separations of DYNORPHIN peptide analogs
  1231. DYNORPHIN A (1–8) analog, E-2078, is stable in human and rhesus monkey blood
  1232. Enkephalin and DYNORPHIN neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats
  1233. Topical application of DYNORPHIN A (1-17) antibodies attenuates neuronal nitric oxide synthase up-regulation, edema formation, and cell injury following focal trauma to …
  1234. Dynamic interactions between orexin and DYNORPHIN may delay onset of functional orexin effects: a modeling study
  1235. A novel acetylated analogue of DYNORPHIN A-(1− 11) amide as a κ-opioid receptor antagonist
  1236. Effects of aging on hyperalgesia and spinal DYNORPHIN expression in rats with peripheral inflammation
  1237. [Pro3]Dyn A(1−11)-NH2:  A DYNORPHIN Analogue with High Selectivity for the κ Opioid Receptor
  1238. Characterization of the high affinity [3H] nociceptin binding site in membrane preparations of rat heart: correlations with the non-opioid DYNORPHIN binding site
  1239. Pre-emptive DYNORPHIN and N-methyl-D-aspartate glutamate receptor antagonism alters spinal immunocytochemistry but not allodynia following complete peripheral …
  1240. Endogenous opioid DYNORPHIN is a potential link between traumatic brain injury, chronic pain and substance use disorder
  1241. Reproductive status-dependent DYNORPHIN and neurokinin B gene expression in female Damaraland mole-rats
  1242. Opioid receptor blockade in rat nucleus tractus solitarius alters amygdala DYNORPHIN gene expression
  1243. Possible involvement of DYNORPHIN A release via μ1-opioid receptor on supraspinal antinociception of endomorphin-2
  1244. Relationship between NOC/oFQ, DYNORPHIN, and COX-2 activation in impaired NMDA cerebrovasodilation after brain injury
  1245. Acute ‘binge’cocaine administration elevates DYNORPHIN mRNA in the caudate putamen of C57BL/6J but not 129/J mice
  1246. Inhibition of glutamate carboxypeptidase II (NAALADase) protects against DYNORPHIN A-induced ischemic spinal cord injury in rats
  1247. Effects of Modifications of Residues in Position 3 of DYNORPHIN A(1−11)-NH2 on κ Receptor Selectivity and Potency
  1248. Photoperiodic co‐regulation of kisspeptin, neurokinin B and DYNORPHIN in the hypothalamus of a seasonal rodent
  1249. Alterations in proDYNORPHIN gene expression and DYNORPHIN levels in different brain regions after chronic administration of 14-methoxymetopon and oxycodone-6 …
  1250. DYNORPHIN 1-17 and its N-terminal biotransformation fragments modulate lipopolysaccharide-stimulated nuclear factor-kappa B nuclear translocation …
  1251. DYNORPHIN A analogs for the treatment of chronic neuropathic pain
  1252. Ovarian sex steroid-dependent plasticity of nociceptin/orphanin FQ and opioid modulation of spinal DYNORPHIN release
  1253. A direct chemical interaction between DYNORPHIN and excitatory amino acids
  1254. CB1 receptor antagonism prevents long-term hyperexcitability after head injury by regulation of DYNORPHIN-KOR system and mGluR5 in rat hippocampus
  1255. Chronic Oestradiol Reduces the Dendritic Spine Density of KND y (Kisspeptin/Neurokinin B/DYNORPHIN) Neurones in the Arcuate Nucleus of Ovariectomised Tac2 …
  1256. DYNORPHIN-(1–8) inhibits the release of substance P-like immunoreactivity in the spinal cord of rats following a noxious mechanical stimulus
  1257. Rational design of DYNORPHIN A analogues with δ-receptor selectivity and antagonism for δ-and κ-receptors
  1258. Genetic association analyses and meta-analysis of DYNORPHIN-Kappa Opioid system potential functional variants with heroin dependence
  1259. Separation of DYNORPHIN peptides by capillary electrochromatography using a polydiallyldimethylammonium chloride gold nanoparticle‐modified capillary
  1260. Long‐lasting antinociceptive effects of a novel DYNORPHIN analogue, Tyr‐D‐Ala‐Phe‐Leu‐Arg ψ (CH2NH) Arg‐NH2, in mice
  1261. DYNORPHIN and the hypothalamo-pituitary-adrenal axis during fetal development
  1262. Lateralized response of DYNORPHIN a peptide levels after traumatic brain injury
  1263. DYNORPHIN release by the lateral olivocochlear efferents may inhibit auditory nerve activity: a cochlear drug delivery study
  1264. Protopanaxadiol alleviates neuropathic pain by spinal microglial DYNORPHIN A expression following glucocorticoid receptor activation
  1265. DYNORPHIN, won’t you myelinate my neighbor?
  1266. Improvement by DYNORPHIN A (1-13) of galanin-induced impairment of memory accompanied by blockade of reductions in acetylcholine release in rats.
  1267. Expression of hypothalamic kisspeptin, neurokinin B, and DYNORPHIN A neurons attenuates in female Zucker fatty rats
  1268. DYNORPHIN and GABAA Receptor Signaling Contribute to Progesterone’s Inhibition of the LH Surge in Female Mice
  1269. Effects of E-2078, a stable DYNORPHIN A (1–8) analog, on sedation and serum prolactin levels in rhesus monkeys
  1270. Priming with L-DOPA differently affects DYNORPHIN and substance P mRNA levels in the striatum of 6-hydroxydopamine-lesioned rats after challenge with dopamine D1 …
  1271. Close apposition of DYNORPHIN-positive nerve fibres to lymphocytes in the liver suggests opioidergic neuroimmunomodulation
  1272. DYNORPHIN A (1–8) analog, E-2078, crosses the blood-brain barrier in rhesus monkeys
  1273. Changes of plasma level of neurotensin, somatostatin, and DYNORPHIN A in pilots under acute hypoxia
  1274. κ Opioid Receptor-DYNORPHIN Signaling in the Central Amygdala Regulates Conditioned Threat Discrimination and Anxiety
  1275. Effects of peptidase inhibitors on anti-nociceptive action of DYNORPHIN-(1–8) in rats
  1276. Chronic tooth pulp inflammation causes transient and persistent expression of Fos in DYNORPHIN-rich regions of rat brainstem
  1277. Effects of surgery and/or remifentanil administration on the expression of pERK1/2, c-Fos and DYNORPHIN in the dorsal root ganglia in mice
  1278. Redox manipulation of NMDA receptors in vivo: alteration of acute pain transmission and DYNORPHIN-induced allodynia
  1279. Human pharmacology of the opioid neuropeptide DYNORPHIN A (1–13)
  1280. Lithium attenuates the effects of DYNORPHIN A (1–13) on inositol 1, 4, 5-trisphosphate and intracellular Ca2+ in rat ventricular myocytes
  1281. DYNORPHIN activation of kappa opioid receptor reduces neuronal excitability in the paraventricular nucleus of mouse thalamus
  1282. DYNORPHIN A enhances mitogen-induced proliferative response and interleukin-2 production of rat splenocytes
  1283. Structure− Activity Relationships of DYNORPHIN A Analogues Modified in the Address Sequence
  1284. DYNORPHIN block of N-methyl-D-aspartate channels increases with the peptide length
  1285. Synthesis and Opioid Activity of [d-Pro10]DYNORPHIN A-(1−11) Analogues with N-Terminal Alkyl Substitution
  1286. Mechanism of the DYNORPHIN-induced dualistic effect on free intracellular Ca2+ concentration in cultured rat spinal neurons
  1287. Short-term withdrawal from repeated exposure to cocaine during adolescence modulates DYNORPHIN mRNA levels and BDNF signaling in the rat nucleus accumbens
  1288. Enzymatic conversion of DYNORPHIN A in the rat brain is affected by administration of nandrolone decanoate
  1289. Structure–Activity Relationships of [des-Arg7]DYNORPHIN A Analogues at the κ Opioid Receptor
  1290. Evaluation of DYNORPHIN and kappa-opioid receptor level in the human blood lymphocytes and plasma: Possible role as a biomarker in severe opioid use disorder
  1291. Spinal release of immunoreactive DYNORPHIN A (1− 8) with the development of peripheral inflammation in the rat
  1292. Protection against DYNORPHIN-(1–8) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon
  1293. Promotion of the unfolding protein response in orexin/DYNORPHIN neurons in sudden infant death syndrome (SIDS): elevated pPERK and ATF4 expression
  1294. Dual role for nitric oxide in DYNORPHIN spinal neurotoxicity
  1295. Solution structure of DYNORPHIN A (1–17): a NMR study in a cryoprotective solvent mixture at 278 K 1
  1296. A genetic polymorphism of the endogenous opioid DYNORPHIN modulates monetary reward anticipation in the corticostriatal loop
  1297. The endogenous opioid DYNORPHIN is required for normal bone homeostasis in mice
  1298. Levels of immunoreactive DYNORPHIN A1-13 during development of morphine dependence in rats.
  1299. Estradiol treatment prevents injury induced enhancement in spinal cord DYNORPHIN expression
  1300. Nonopioid motor effects of DYNORPHIN A and related peptides: structure dependence and role of the N-methyl-D-aspartate receptor
  1301. Central orexin A affects reproductive axis by modulation of hypothalamic kisspeptin/neurokinin B/DYNORPHIN secreting neurons in the male Wistar rats
  1302. A diminution of Δ9-tetrahydrocannabinol modulation of DYNORPHIN A-(1–17) in conjunction with tolerance development
  1303. Interaction of Extracellular Loop II of κ-Opioid Receptor (196–228) with Opioid Peptide DYNORPHIN in Membrane Environments as Revealed by Solid State Nuclear …
  1304. Evidence that pubertal status impacts kisspeptin/neurokinin B/DYNORPHIN neurons in the gilt
  1305. Design, Synthesis, and Biological Activities of Cyclic Lactam Peptide Analogues of DYNORPHIN A(1−11)-NH2
  1306. The role of endogenous DYNORPHIN in ethanol-induced state-dependent CPP
  1307. Testicular lactate dehydrogenase and sorbitol dehydrogenase activity after intratesticular injection of DYNORPHIN and morphine in male rats.
  1308. Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by DYNORPHIN A (1–13), an endogenous κ-opioid receptor …
  1309. DYNORPHIN A (2-13) improves mecamylamine-induced learning impairment accompanied by reversal of reductions in acetylcholine release in rats
  1310. Involvement of kappa/DYNORPHIN system in the development of tolerance to nicotine‐induced antinociception
  1311. Substance P N-terminal fragment SP (1–7) attenuates chronic morphine tolerance and affects DYNORPHIN B and nociceptin in rats
  1312. A solid‐phase synthetic strategy for the preparation of peptide‐based affinity labels: synthesis of DYNORPHIN A analogs
  1313. Des-tyrosine1 DYNORPHIN A-(2–13) improves carbon monoxide-induced impairment of learning and memory in mice
  1314. nociceptive behavior induced by the endogenous opioid peptides DYNORPHINs in uninjured mice: evidence with intrathecal N‐ethylmaleimide inhibiting DYNORPHIN …
  1315. DYNORPHIN-independent spinal cannabinoid antinociception
  1316. Antinociceptive effect produced by intracerebroventricularly administered DYNORPHIN A is potentiated by p-hydroxymercuribenzoate or phosphoramidon in the mouse …
  1317. DYNORPHIN A-(1-13) and (2-13) improve β-amyloid peptide-induced amnesia in mice
  1318. DYNORPHIN neurotoxicity induced nitric oxide synthase expression in ventral horn cells of rat spinal cord
  1319. Regulation of spinal DYNORPHIN 1-17 release by endogenous pituitary adenylyl cyclase-activating polypeptide in the male rat: relevance of excitation via disinhibition
  1320. Modulation of feeding behavior and metabolism by DYNORPHIN
  1321. Functional Characterization of Spinocerebellar Ataxia Associated DYNORPHIN A Mutant Peptides
  1322. DYNORPHIN mRNA-expressing neurons in the rat paraventricular hypothalamic nucleus project to the spinal cord
  1323. Effects of orchidectomy and testosterone replacement on numbers of kisspeptin‐, neurokinin B‐, and DYNORPHIN A‐immunoreactive neurones in the arcuate nucleus of …
  1324. Acute subjective effects of DYNORPHIN A (1-13) infusion in normal healthy subjects
  1325. Glucose stimulation of pancreatic β-cell lines induces expression and secretion of DYNORPHIN
  1326. Modification of amphipathic non-opioid DYNORPHIN A analogues for rat brain bradykinin receptors
  1327. Antianalgesic action of DYNORPHIN A mediated by spinal cholecystokinin
  1328. In vitro biotransformation of DYNORPHIN A (1-17) is similar in human and rhesus monkey blood as studied by matrix-assisted laser desorption/ionization mass …
  1329. Distinct DYNORPHIN expression patterns with low- and high-dose estrogen treatment in the arcuate nucleus of female rats†,‡
  1330. Contribution of spinal μ1-opioid receptors and DYNORPHIN B to the antinociception induced by Tyr-D-Arg-Phe-Sar
  1331. Temporal change of hippocampal enkephalin and DYNORPHIN mRNA following trimethyltin intoxication in rats: effect of anticonvulsant
  1332. Bulleyaconitine A Inhibits Morphine-Induced Withdrawal Symptoms, Conditioned Place Preference, and Locomotor Sensitization Via Microglial DYNORPHIN A …
  1333. Pharmacokinetics of intravenous DYNORPHIN A (1–13) in opioid‐naive and opioid‐treated human volunteers
  1334. DYNORPHIN A (1–8) inhibits oxidative stress and apoptosis in MCAO rats, affording neuroprotection through NMDA receptor and κ-opioid receptor channels
  1335. DYNORPHIN A (1–13) Analgesia in Opioid-Treated Patients with Chronic Pain
  1336. Region-specific changes in proDYNORPHIN mRNA and ir-DYNORPHIN A levels after kindled seizures
  1337. The PC12 rat pheochromocytoma cell line expresses the proDYNORPHIN gene and secretes the 8 kDa DYNORPHIN product
  1338. Improving the Utility of a DYNORPHIN Peptide Analogue Using Mannosylated Glycoliposomes
  1339. Non-opioid nociceptive activity of human DYNORPHIN mutants that cause neurodegenerative disorder spinocerebellar ataxia type 23
  1340. DYNORPHIN A processing enzyme: tissue distribution, isolation, and characterization
  1341. Structural model of a cyclic DYNORPHIN A analog bound to dodecylphosphocholine micelles by NMR and restrained molecular dynamics
  1342. Opiate modulation of DYNORPHIN conversion in primary cultures of rat cerebral cortex
  1343. The Effects of C-Terminal Modifications on the Opioid Activity of [N-BenzylTyr1]DYNORPHIN A-(1−11) Analogues
  1344. DYNORPHIN displaces binding at the glycine site of the NMDA receptor in the rat striatum
  1345. The opioid peptide DYNORPHIN suppresses pituitary‐ovary axis in the tilapia Oreochromis mossambicus
  1346. Penetration of DYNORPHIN 1–13 across the blood-brain barrier
  1347. The efficacy of DYNORPHIN fragments at the κ, μ and δ opioid receptor in transfected HEK cells and in an animal model of unilateral peripheral inflammation
  1348. Pretreatment with antiserum against DYNORPHIN, substance P, or cholecystokinin enhances the morphine-produced anti-allodynia in the sciatic nerve ligated mice
  1349. The effect of a paracetamol and morphine combination on DYNORPHIN A levels in the rat brain
  1350. Positioning and stabilization of DYNORPHIN peptides in membrane bilayers: the mechanistic role of aromatic and basic residues revealed from comparative MD …
  1351. Kisspeptin, Neurokinin B, and DYNORPHIN Expression during Pubertal Development in Female Sheep
  1352. … root of Aconitum carmichaelii Debeaux exerts antinociceptive effect in Complete Freund’s Adjuvant-induced mice: roles of DYNORPHIN/kappa-opioid system …
  1353. Increased release of immunoreactive DYNORPHIN A1–17 from the spinal cord after intrathecal treatment with endomorphin-2 in anesthetized rats
  1354. Role of the non-opioid DYNORPHIN peptide des-Tyr-DYNORPHIN (DYN-A2− 17) in food intake and physical activity, and its interaction with orexin-A.
  1355. Constitutive and inducible nitric oxide synthases after DYNORPHIN-induced spinal cord injury
  1356. Characterization of immunoreactive DYNORPHIN B and β-endorphin in human plasma
  1357. Dipeptidyl peptidase IV (DPPIV) enzyme activity on immature T-cell line R1. 1 is down-regulated by DYNORPHIN-A (1–17) as a non-substrate inhibitor
  1358. Structure–activity relationships of non-opioid [des-Arg7]-DYNORPHIN A analogues for bradykinin receptors
  1359. DYNORPHIN A inhibits NMDA receptors through a pH-dependent mechanism
  1360. Role of vasopressin in altered pial artery responses to DYNORPHIN and β-endorphin following brain injury
  1361. Dysregulation of Nociceptin/Orphanin FQ and DYNORPHIN Systems in the Extended Amygdala of Alcohol Preferring Marchigian Sardinian (msP) Rats
  1362. Systemic effects of E-2078, a stabilized DYNORPHIN A (1–8) analog, in rhesus monkeys
  1363. Increased spinal DYNORPHIN contributes to chronic nicotine-induced mechanical hypersensitivity in the rat
  1364. Calcium influx into phospholipid vesicles caused by DYNORPHIN neuropeptides
  1365. Perturbations of model membranes induced by pathogenic DYNORPHIN A mutants causing neurodegeneration in human brain
  1366. Levels of DYNORPHIN peptides in the central nervous system and pituitary gland of the spontaneously hypertensive rat
  1367. Single-nucleus characterization of adult mouse spinal DYNORPHIN-lineage cells and identification of persistent transcriptional effects of neonatal hindpaw incision
  1368. Building 3D-structural model of kappa opioid receptor and studying its interaction mechanism with DYNORPHIN A (1-8).
  1369. Altered levels of synapsin I, dopamine transporter, DYNORPHIN A, and neuropeptide Y in the nucleus accumbens and striatum at post-puberty in rats treated neonatally …
  1370. Effect of diet-induced obesity on kisspeptin-neurokinin B-DYNORPHIN A neurons in the arcuate nucleus and luteinizing hormone secretion in sex hormone …
  1371. DYNORPHIN modulates ocular hydrodynamics and releases atrial natriuretic peptide via activation of κ-opioid receptors
  1372. Immunohistochemical mapping of pro-opiomelanocortin-and pro-DYNORPHIN-derived peptides in the alpaca (Lama pacos) diencephalon
  1373. Kainic acid-induced sprouting of DYNORPHIN-and enkephalin-containing mossy fibers in the dentate gyrus of the rat hippocampus
  1374. Synthesis of novel basic head‐to‐side‐chain cyclic DYNORPHIN A analogs: Strategies and side reactions
  1375. Gucy2d selectively marks inhibitory DYNORPHIN neurons in the spinal dorsal horn but is dispensable for pain and itch sensitivity
  1376. Comparative studies of the neuro-excitatory behavioural effects of morphine-3-glucuronide and DYNORPHIN A (2-17) following spinal and supraspinal routes of …
  1377. Cholecystokinin-8S increases DYNORPHIN B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes
  1378. Stabilized DYNORPHIN derivatives for modulating antinociceptive activity in morphine tolerant rats: effect of different routes of administration
  1379. Pharmacological Characterization of Human κ/μ Opioid Receptor Chimeras that Retain High Affinity for DYNORPHIN A
  1380. The role of N-methyl-D-aspartate receptors in the release of adrenocorticotropin by DYNORPHIN A1–13
  1381. Differential effects of N-peptidyl-O-acyl hydroxylamines on DYNORPHIN-induced antinociception in the mouse capsaicin test
  1382. Lateralization of DYNORPHIN gene expression in the rat striatum
  1383. Synthesis and Opioid Activity of Side-Chain-to-Side-Chain Cyclic DYNORPHIN A-(1− 11) Amide Analogues Cyclized between Positions 2 and 5. 1. Substitutions in …
  1384. Climatic modulation of neurotransmitter release in amphibian neuromuscular junctions: role of DYNORPHIN-A
  1385. Non-opioid DYNORPHIN binding site on secretory vesicles of a pituitary-derived cell line
  1386. The neuropeptide FF analogue, 1DMe, reduces in vivo DYNORPHIN release from the rat spinal cord
  1387. The regulation of hippocampal DYNORPHIN by neural/neuroendocrine pathways: models for effects of aging on an opioid peptide system
  1388. Metabolism of DYNORPHIN A1–13 in human CSF
  1389. DYNORPHIN A1–13 stimulates ovine fetal pituitary-adrenal function through a novel nonopioid mechanism
  1390. Inhibitory effects of DYNORPHIN 3-14 on the lipopolysaccharide-induced toll-like receptor 4 signalling pathway
  1391. Expression of c-fos mRNA is increased and related to DYNORPHIN mRNA expression following excitotoxic spinal cord injury in the rat
  1392. DYNORPHIN modulates dopamine D1-receptor mediated turning behavior in 6-hydroxydopamine-lesioned rats
  1393. Identification of stabilized DYNORPHIN derivatives for suppressing tolerance in morphine-dependent rats
  1394. DYNORPHIN A 1–17 biotransformation in inflamed tissue, serum and trypsin solution analysed by liquid chromatography–tandem mass spectrometry
  1395. Kappa-opioid receptor-mediated modulation of innate immune response by DYNORPHIN in teleost Channa punctatus
  1396. DYNORPHIN A (2–17) attenuates the unconditioned but not the conditioned effects of opiate withdrawal in the rat
  1397. Membrane interaction of disease-related DYNORPHIN A variants
  1398. Further studies on possible DYNORPHIN involvement in the ovulatory luteinizing hormone surge in the proestrous rat
  1399. Regarding “DYNORPHIN is a downstream effector of striatal BDNF regulation of ethanol intake”
  1400. Unraveling the mechanism of action of the GnRH pulse generator: a possible role for kisspeptin/neurokinin B/DYNORPHIN (KNDy) neurons
  1401. In vivo microdialysis study on changes in septal DYNORPHIN and β-endorphin activities in active and hibernating Columbian ground squirrels
  1402. Interspecies comparison of in vitro plasma degradation of DYNORPHIN A 1-13.
  1403. Role of neurokinin B and DYNORPHIN A in pituitary gonadotroph and somatolactotroph cell lines
  1404. Maternal cocaine treatment alters DYNORPHIN and enkephalin mRNA expression in brains of fetal rhesus macaques
  1405. Relevance of the Kappa DYNORPHIN System to Schizophrenia and Its Therapeutics
  1406. Different modulation of cholinergic neuronal systems by DYNORPHIN A (1–13) in carbon monoxide-exposed mice
  1407. Dopaminergic regulation of striatonigral tachykinin and DYNORPHIN gene expression: a study with the dopamine uptake inhibitor GBR-12909
  1408. DYNORPHIN‐phospholipid membrane interactions: Role of phospholipid head‐group and cholesterol
  1409. URE, an initiator (Inr)-like site, suppresses the promoter of the rat DYNORPHIN gene
  1410. Alanine scan of the opioid peptide DYNORPHIN B amide
  1411. Gastric acid secretion by central injection of DYNORPHIN A-(1–17), an endogenous ligand of κ-opioid receptor, in urethane-anesthetized rats
  1412. Influence of ovarian sex steroids on spinal methionine-enkephalin release: comparison with DYNORPHIN reveals asymmetrical regulation
  1413. Interactions of DYNORPHIN A and related peptides with cardiac ouabain binding sites
  1414. Identification of synaptic metabolites of DYNORPHIN A (1‐8) by electrospray ionization and tandem mass spectrometry
  1415. Discovery of stable non-opioid DYNORPHIN A analogues interacting at the bradykinin receptors for the treatment of neuropathic pain
  1416. Conformation effects of CpG methylation on single-stranded DNA oligonucleotides: analysis of the opioid peptide DYNORPHIN-coding sequences
  1417. Identification of bikunin as an endogenous inhibitor of DYNORPHIN convertase in human cerebrospinal fluid
  1418. Alteration of DYNORPHIN and secretogranin II in the prolactin immunoreactive neurons of the rat lateral hypothalamus upon osmotic stimulation
  1419. Methamphetamine alters proDYNORPHIN gene expression and DYNORPHIN A levels in rat hypothalamus.
  1420. Specificity of the DYNORPHIN‐Processing Endoprotease: Comparison with Prohormone Convertases
  1421. Altered opioid‐mediated control of the spinal release of DYNORPHIN and met‐enkephalin in polyarthritic rats
  1422. Effect of DYNORPHIN A1-13 on hypoxia-ischemic brain injury in neonatal rats
  1423. DYNORPHIN A analogs containing a conformationally constrained phenylalanine derivative in position 4: Reversal of preferred stereochemistry for opioid receptor …
  1424. Site and mechanism of action of DYNORPHIN A-(1–13) andN-methyl-d-aspartate on ACTH release in fetal sheep
  1425. Regulation of DYNORPHIN gene expression by κ-opioid agonist treatment
  1426. DYNORPHIN A (6-12) analogs suppress thermal edema
  1427. Neurokinin B receptor agonist and DYNORPHIN receptor antagonist stimulated luteinizing hormone secretion in fasted male rodents
  1428. Delta-opioid agonist SNC80 can attenuate the development of DYNORPHIN A-induced tactile allodynia in rats
  1429. … of universal cysteines in the binding sites of three opioid receptor subtypes by disulfide-bonding affinity labeling with chemically activated thiol-containing DYNORPHIN A …
  1430. Interactions of DYNORPHIN A-(1–13) and Nociceptin with Cardiac D2 Binding Sites: Inhibition of Ischemia-evoked Release of Noradrenaline from Synaptosomal …
  1431. Role of DYNORPHIN in hypoxic pulmonary hypertension
  1432. Pharmacological characterization of β-endorphin-and DYNORPHIN A1–17-induced feeding using G-protein α-subunit antisense probes in rats
  1433. Effects of DYNORPHIN on rat entopeduncular nucleus neurons in vitro
  1434. Cisplatin-induced long-term DYNORPHIN A-immunoreactivity in cell somata of rat area postrema neurons
  1435. Dopaminergic regulation of postnatal development of DYNORPHIN neurons in rat striatum
  1436. Direct detection of neuropeptide DYNORPHIN A binding to the second extracellular loop of the κ opioid receptor using a soluble protein scaffold
  1437. Affinity labelling of frog brain opioid receptors by DYNORPHIN (1–10) chloromethyl ketone
  1438. DYNORPHIN A (1–13) Alleviated Stress-Induced Behavioral Impairments in Mice
  1439. Diet restriction increases enkephalin-and DYNORPHIN-like immunoreactivity in rat brain and attenuates long-term retention of passive avoidance
  1440. Influence of DYNORPHIN on estradiol-and cervical stimulation-induced prolactin surges in ovariectomized rats
  1441. Methamphetamine-lnduced Changes in AP-1 Binding and DYNORPHIN in the Striatum: Correlated, Not Causally Related Events?
  1442. Assessment of complex peptide degradation pathways via structured multicompartmental modeling approaches: The metabolism of DYNORPHIN A1–13 and related …
  1443. Structure–activity relationships of DYNORPHIN analogs substituted in positions 2 and 3
  1444. Nonpeptide Analogues of DYNORPHIN A (1− 8): Design, Synthesis, and Pharmacological Evaluation of κ-Selective Agonists
  1445. Opioid binding profile of morphiceptin, Tyr-MIF-1 and DYNORPHIN-related peptides in rat brain membranes
  1446. c-Fos antisense oligodeoxynucleotide offsets behavioral nociceptive responses and both up-regulations of c-Fos protein and DYNORPHIN a (1-8) in dorsal horn: a study …
  1447. Effects of the Substitution of Phe4 in the Opioid Peptide [d-Ala8]DYNORPHIN A-(1−11)NH2
  1448. DYNORPHIN regulates the phagocytic activity of splenic phagocytes in wall lizards: involvement of a κ-opioid receptor-coupled adenylate-cyclase–cAMP–PKA pathway
  1449. Polyethylene glycol-induced hypovolemia affects the expression of MCH mRNA, but not DYNORPHIN or secretogranin II mRNAs, in the rat lateral hypothalamus
  1450. An HPLC/RIA method for DYNORPHIN A1-13 and its main metabolites in human blood
  1451. Interactions of lipid bilayers with corticotropin, DYNORPHIN, and enkephalin peptides
  1452. Chick auditory terminals contain DYNORPHIN-like immunoreactivity.
  1453. Differential time course of effects of κ-opioid agonist treatment on DYNORPHIN a levels and κ-opioid receptor density
  1454. Altered secondary structure of DYNORPHIN A associates with loss of opioid signalling and NMDA-mediated excitotoxicity in SCA23
  1455. DYNORPHIN up-regulation in the dentate granule cell mossy fiber pathway following chronic inhibition of GluN2B-containing NMDAR is associated with increased CREB …
  1456. A novel soluble protein factor with non-opioid DYNORPHIN A-binding activity
  1457. Double deletion of orexigenic neuropeptide Y and DYNORPHIN results in paradoxical obesity in mice
  1458. Supraspinal flumazenil inhibits the antianalgesic action of spinal DYNORPHIN A
  1459. Systemic administration of DYNORPHIN A-(1–13) markedly improves cycloheximide-induced amnesia in mice
  1460. In major depression, increased serum DYNORPHIN and kappa opioid receptor levels are positively associated with mu opioid receptor levels and immune activation and …
  1461. Effects of TCM Preparation Tifukang on Blood Lacate, beta-Endorphin, Leu-Enkephalin and DYNORPHIN A_ (1-13) in the Rat of Fatigue Induced by Exercise [J]
  1462. Differential Mechanisms of Ovine Fetal Pituitary Stimulation by a Selective κ-Opioid Agonist and by DYNORPHIN
  1463. Ibogaine pretreatment dramatically enhances the DYNORPHIN response to cocaine
  1464. ORL1 and opioid receptor preferences of nociceptin and DYNORPHIN A analogues with Dmp substituted for N-terminal aromatic residues
  1465. Direct inhibition of hypothalamic proopiomelanocortin neurons by DYNORPHIN A is mediated by the μ‐opioid receptor
  1466. Analgesic effect of DYNORPHIN A (1~ 13) and its antagonistic effect on morphine analgesia in rat brain in the cold water tail flick test assay
  1467. Studies of the release of immunoreactive galanin and DYNORPHIN A (1–8) in the spinal cord of the rat
  1468. Blockade of non-opioid excitatory effects of spinal DYNORPHIN A at bradykinin receptors
  1469. Design of potent DYNORPHIN A-(1 9) analogues devoid of supraspinal motor effects in mice
  1470. Perivascular expression and potent vasoconstrictor effect of DYNORPHIN a in cerebral arteries
  1471. Evaluation of an on‐capillary copper complexation methodology for the investigation of in vitro metabolism of DYNORPHIN A 1–17
  1472. Cyclic non-opioid DYNORPHIN A analogues for the bradykinin receptors
  1473. Variation in hippocampal DYNORPHIN b-immunoreactive mossy fiber terminal fields of apomorphine-(un) susceptible rats
  1474. DYNORPHIN-dependent reduction of excitability and attenuation of inhibitory afferents of NPS neurons in the pericoerulear region of mice
  1475. Effects of extracellular pH on the DYNORPHIN A inhibition of N‐methyl‐D‐aspartate receptors expressed in Xenopus oocytes
  1476. Pituitary Contents of Beta-Endorphin, DYNORPHIN, Substance P, Cholecystokinin and Somatostatin in Rats with Streptozotocin-lnduced Diabetes
  1477. Neurokinin A, calcitonin gene-related peptide, and DYNORPHIN A (1–8) in spinal dorsal horn contribute to descending inhibition evoked by nociceptive afferent …
  1478. Allodynia and hyperalgesia produced by specific inhibition of spinal c-fos expression: lack of correlation with DYNORPHIN content
  1479. Responses of somatostatin, beta-endorphin and DYNORPHIN A to a glucose load in two groups of women with polycystic ovarian syndrome
  1480. DYNORPHIN stimulates corticotropin release from mouse anterior pituitary AtT-20 cells through nonopioid mechanisms
  1481. DYNORPHIN B induces lateral asymmetric changes in feline spinal cord reflexes
  1482. A non-opioid pathway for DYNORPHIN-caused spinal cord injury in rats
  1483. Evidence for a DYNORPHIN-mediated inner ear immune/inflammatory response and glutamate-induced neural excitotoxicity: an updated analysis
  1484. DYNORPHIN a peptides
  1485. Influence of intrastriatal infusion of DYNORPHIN fragments on overflow of acetylcholine and dopamine in the rat brain
  1486. Use of receptor chimeras to identify small molecules with high affinity for the DYNORPHIN A binding domain of the κ opioid receptor
  1487. Effect of three peptidase inhibitors on antinociceptive potential and toxicity with intracerebroventricular administration of DYNORPHIN A (1–17) or (1–13) in the rat
  1488. A Simple Method for Controlling the Degree of PEGylation of DYNORPHIN A (1–13)
  1489. Decreased DYNORPHIN levels and increased kappa opioid receptor binding in male rats with isolation-induced hypertension
  1490. The Relevance of Oxytocin & DYNORPHIN in COVID-19: Towards a Prophylactic Treatment
  1491. Involvement of DYNORPHIN A in the inhibition of morphine physical dependence by N-nitro-L-arginine in rats.
  1492. Aging changes of neurotensin-like and DYNORPHIN-like neurons in the central nucleus of amygdala of the rat anti-aging effect of radix achyranthis bidentatae …
  1493. Changes in DYNORPHIN immunoreactivity but unaltered density of enkephalin immunoreactive neurons in basal ganglia nuclei of genetically dystonic hamsters
  1494. Role of tryptophan‐14 in the interaction of DYNORPHIN A (1‐17) with micelles
  1495. The Role of DYNORPHIN and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach
  1496. Effects of halothane, ketamine and nitrous oxide on DYNORPHIN mRNA expression in dorsal horn neurons after peripheral tissue injury
  1497. New developments in kisspeptin, neurokinin B and DYNORPHIN A regulation of gonadotropin-releasing hormone pulsatile secretion
  1498. OPTOGENETIC STIMULATION OF LATERAL HYPOTHALAMIC OREXIN/DYNORPHIN INPUTS IN THE VENTRAL TEGMENTAL AREA POTENTIATES MESOLIMBIC …
  1499. The gene expression of DYNORPHIN, Enkephalin, c-FOS in the neuropathic rat
  1500. Comparison of cysteine and serine protease inhibitors on DYNORPHIN B-induced antinociception in the mouse capsaicin test
  1501. Evaluation of DYNORPHIN and kappa-opioid receptor level in the human blood lymphocytes andplasma: Possible roleasabiomarker insevere opioid use disorder
  1502. The relationship between DYNORPHIN A 1~ 13 and brain edema after collagenase induced intracerebral hemorrhage in rats [J]
  1503. DYNORPHIN convertases and their functions in CNS
  1504. Vasopressin contributes to DYNORPHIN modulation of hypoxic cerebrovasodilation
  1505. Development of highly potent and ective DYNORPHIN A analogues as new medicines
  1506. Development of DYNORPHIN-like immunoreactive auditory nerve terminals in the chick
  1507. Delineation of insula DYNORPHIN and kappa opioid receptor circuit elements in alcohol consumption
  1508. The permeation of DYNORPHIN A 1–6 across the blood brain barrier and its effect on bovine brain microvessel endothelial cell monolayer permeability
  1509. The Oxytocin DYNORPHIN Axis
  1510. … DECREASES FORMALIN-INDUCED BEHAVIORAL RESPONSES AND BOTH OF THE ELEVATED c-Fos PROTEIN AND DYNORPHIN A (1~ 8) EXPRESSIONS IN …
  1511. Connections between GABAergic neurons and Metenkephalin, Leu-enkephalin,# beta#-endorphin or DYNORPHIN immunoreactive terminals in the periaqueductal gray …
  1512. Mephedrone alters basal ganglia and limbic DYNORPHIN systems
  1513. Effect of peptidase inhibitors on DYNORPHIN A (1-17) or (1-13)-induced antinociception and toxicity at spinal level
  1514. DYNORPHIN administered to newborn rats modulates morphogenesis of the heart
  1515. Effects of DYNORPHIN A (1-13) on Lipid Peroxidation and the Activity of Antioxidant Enzymes in Immobilization Stress of Different Durations
  1516. Activation of the kappa opioid receptor/DYNORPHIN system alters stress and threat responding during acute withdrawal from intermittent alcohol drinking in male …
  1517. Effect of DYNORPHIN and excitatory amino acid on spinal cord injury in rats
  1518. Effect and significance of DYNORPHIN on changes of excitatory amino acid after spinal cord injury in rats [J]
  1519. Effect of DYNORPHIN A (1-17) on proliferation and IL-2, IL-4, IFN-γ production by peripheral blood mononuclears
  1520. The DYNORPHIN/kappa-opioid system of the brain as a promising target for therapy for dependence on psychoactive substances
  1521. Glutamate Involved in Rats with Spinal Cord Injury Induced by DYNORPHIN A (1-17)
  1522. Role of KNDy neurons expressing kisspeptin, neurokinin B, and DYNORPHIN A as a GnRH pulse generator controlling mammalian reproduction
  1523. Various modifications of the amphipathic DYNORPHIN A pharmacophore for rat brain bradykinin receptors
  1524. Effect of DYNORPHIN A 1-13 on astrocyte swelling induced by glutamate [J]
  1525. Retracted: DYNORPHIN inhibits NEP activity in R1.1 mouse thymoma cells
  1526. Synthesis of DYNORPHIN B Analogues by Solid-Phase Method
  1527. Synthesis and pharmacological evaluation of DYNORPHIN A analogs constrained in the “message” sequence
  1528. Photoperiod affects distribution of DYNORPHIN A in the brain of Siberian hamster
  1529. Dopaminergic Involvement in Improving Effects of DYNORPHIN A‐(1‐13) on Galanin‐Induced Impairment of Passive Avoidance Learning in Mice
  1530. DYNORPHIN A inhibits nociceptin-converting enzyme from the rat spinal cord
  1531. Effects of DYNORPHIN A (1-17) on motor function and spinal intracellular messenger systems in rat.
  1532. The Development of Analytical Methods for Investigations of DYNORPHIN A 1-17 Metabolism in the Central Nervous System and Peripheral Tissues and Transport at the …
  1533. Conformational Analysis of DYNORPHIN A (1–13) Using Hydrogen—Deuterium Exchange and Tandem Mass Spectrometry
  1534. Stress‐induced dysphoria is encoded by the DYNORPHIN‐Kappa Opioid system
  1535. SUN-LB50 Increased In Vivo Pulsatile LH Secretion and Hypothalamic Kisspeptin, NKB, and DYNORPHIN RNA Levels in a PCOS-Like Mouse Model
  1536. DYNORPHIN/Kappa-Opioid Receptor System Modulation of Cortical Circuitry.
  1537. DYNORPHIN A is a competitive, partial agonist at the bradykinin receptors
  1538. Structure-Activity Relationships of Arodyn, a Novel DYNORPHIN A-(1–11) Analogue
  1539. DYNORPHIN A 1-13 can reduced brain edema following collagenase induced intracerebral hemorrhage in rats [J]
  1540. Nociceptin and DYNORPHIN A (1-17) produce antianalgesia through independent systems in mice
  1541. Comparison with Naloxone of Two DYNORPHIN a Analogues with K-and δ-Opioid Antagonist Activity
  1542. CLINICAL SIGNIFICANCE OF DYNORPHIN A CHANGE IN CEREEBRAL SPINAL FLUIO AND PLASMA IN PATIENTS FOLLOWING ACUTE SPINAL CORD INJURY [J …
  1543. Study of the receptor mechanism of DYNORPHIN-induced loss of spinal reflex
  1544. Dendritic DYNORPHIN Release in the Hippocampal Formation
  1545. Effect of DYNORPHIN A (1-13) on lymphocyte proliferation and Th1/Th2 cytokine expression
  1546. Effect of DYNORPHIN A 1-13 on Hypoxia Ischemic Brain Injury in Neonatal Rats
  1547. The effect of the electroacupunture on labor analgesia and DYNORPHIN regulation impact
  1548. Kappa opioid receptor antagonist and N-methyl-D-aspartate receptor antagonist affect DYNORPHIN-induced spinal cord electrophysiologic impairment
  1549. DYNORPHIN A (1–17) induces apoptosis in striatal neurons in vitro through AMPA/kainate receptor-mediated cytochrome c release and caspase-3 activation
  1550. Changes in Neuronal Pulse Activity of Bulbar Cardiovascular Center after Administration of DYNORPHIN A 1-13
  1551. DYNORPHIN a Induces Membrane Permeabilization by Formation of Proteolipidic Pores
  1552. Effects of terguride on protein and mRNA expressions of dopamine D2 receptor and DYNORPHIN in different brain regions of rats after heroin self administration
  1553. Spinal DYNORPHIN and neuropathic pain
  1554. Immunohistochemical identification of DYNORPHIN A and Kappa opioid receptor-1 in the digestive system of scallop Chlamys farreri
  1555. The Research of Using Point Massage on Effect Ofpuerpera′ s DYNORPHIN Level and Analgesia
  1556. Endogenous DYNORPHIN in emotional control and stress response
  1557. Effects of DYNORPHIN A (1-13) on DNA Synthesis and Free Radical Oxidation in Respiratory Organs of Newborn Albino Rats Pretreated with NG-Nitro-L-Arginine Methyl …
  1558. DYNORPHIN/α-neo-endorphin
  1559. Rabbit polyclonal to DYNORPHIN B
  1560. The relation between DYNORPHIN A_ (1-13) and the cerebral edema following experimental acute brain trauma in rats [J]
  1561. Glutamatergic effects of DYNORPHIN peptides on cultured oligodendrocytes
  1562. Role of sympathetic nervous system in protective effects of selective k-opiate receptor agonist DYNORPHIN A 1–13 on the incidence of cardiac arrhythmia during …
  1563. Neuroendocrine Role of Kisspeptin-Neurokinin B-DYNORPHIN Pathway in Male Fertility and its Correlation with Melatonin
  1564. Correlation between motor paralysis and neurotoxicity induced by intrathecal DYNORPHIN A (1-17) in rats
  1565. MK-801 suppresses DYNORPHIN A (1-17)-induced facilitation of nociceptive responses to formalin in rats
  1566. Expression of Kisspeptin, Neurokinin B, and DYNORPHIN During Pubertal Development in Female Sheep
  1567. Distribution of DYNORPHIN-ir neurons and coexisting of DYNORPHIN-ir and arginine-vasopressin-ir in rat hypothalamus
  1568. Effect of intrathecal administration of DYNORPHIN A (1-17) on the dendrites of two kinds of motoneurons in rat
  1569. … zhiyang recipe for treatment of patients with senile pruritus of blood-deficiency and Gan-hyperactive syndrome type and its impact on stem cell factor and DYNORPHIN
  1570. Effects of high dose of DYNORPHIN on NMDA receptor and NOS activities in spinal cord of rats
  1571. Role of neuronal nitric oxide synthase in DYNORPHIN spinal neurotoxicity and analgesia in rats
  1572. DYNORPHIN-Kappa Opioid Receptor Activity in the Central Amygdala Modulates Binge-Like Alcohol Drinking in Mice
  1573. Mechanisms Underlying the Adverse Consequences of Stress: A Role for the DYNORPHIN/Kappa Opioid Receptor System, p38α MAPK, and the Serotonin …
  1574. Correction: DYNORPHIN activates quorum sensing quinolone signaling in pseudomonas aeruginosa
  1575. Effects of DYNORPHIN A1-17 on the activities, immunoreactivities and mRNA expression of cNOS and iNOS in rat spinal cord and their mechanisms
  1576. Dualistic effect of DYNORPHIN on high potassium-induced increase of intracellular free calcium concentration in cultured rat spinal neurons
  1577. Physical and computational methods of investigating the relationship between stress, cognition, and behavior in the context of the KOR-DYNORPHIN system
  1578. Aladan scanning: The structure-activity relationship of DYNORPHIN A
  1579. Delineation of DYNORPHIN and kappa opioid receptor circuit elements in alcohol consumption
  1580. Effects of three peptidase inhibitors on antinociceptive action of DYNORPHIN (1-13) and DYNORPHIN (1-17) by intrathecal administration in rats: 9AP3-3
  1581. DYNORPHIN activates quorum sensing quinolone signaling in Pseudomonas aeruginosa
  1582. Mechanism and Binding Site of the ASIC1A-Big DYNORPHIN Interaction
  1583. Development of DYNORPHIN-immunoreactivity in the chick cochlear nucleus
  1584. Influence of obesity and type 2 diabetes on the number of kisspeptin-, neurokinin B-and DYNORPHIN A-immunoreactive neurons in the arcuate nucleus of female rats
  1585. Effect of a DYNORPHIN A analog, E2078, on phospholipid membrane properties
  1586. Synthesis and biological evaluation of DYNORPHIN analogs and, Caco-2 permeability of opioid macrocyclic tetrapeptides
  1587. Synthetic strategies for the preparation of affinity label DYNORPHIN A (1–11) amine analogues
  1588. Adolescent forced swim stress increases social anxiety-like behaviors and alters the DYNORPHIN/kappa opioid receptor system in the basolateral amygdala of males
  1589. Cocaine effects on striatal DYNORPHIN and CART neuropeptides: association to mood disorder
  1590. … of helical opioid glycopeptide agonists: the study of the structure-activity relationship and transport of glycopeptides related to beta-endorphin and DYNORPHIN
  1591. Kisspeptin/Neurokinin B/DYNORPHIN (KNDy) Peptide mRNA Expressions in Intact Female Goats Induced Metabolic Stress Condition by Fasting
  1592. Effects of Diet-Induced Obesity on Hypothalamic Kisspeptin-Neurokinin-DYNORPHIN (KNDy) Neurons and Luteinizing Hormone Secretion in Sex Hormone-Primed Male …
  1593. … DURING LATE GESTATION INCREASES ETHANOL INTAKE AND THE EXPRESSION OF PRO-ENKEPHALIN AND PRO-DYNORPHIN MRNAS IN RAT INFANTS
  1594. Erratum: J Reprod Dev, Vol. 59, No. 3, p. 266–272, DYNORPHIN-Kappa Opioid Receptor Signaling Partly Mediates Estrogen Negative Feedback Effect on LH Pulses in …
  1595. DUAL-TARGETING THE DYNORPHIN/KAPPA OPIOID RECEPTOR AND DOPAMINE SYSTEMS FOR TREATMENT OF COCAINE USE DISORDER
  1596. efficacy of DYNORPHIN fragments at the κ, μ and δ opioid receptor in transfected HEK cells and in an animal model of unilateral peripheral inflammation
  1597. Effects of the DYNORPHIN/Kappa Opioid Receptor System on Stress Reactions After Intermittent Alcohol Drinking and Withdrawal in Female C57BL/6J Mice
  1598. Cloning and Expression of DYNORPHIN-32 in E. coli and Analgesic Tests in Mice Models.
  1599. Bulleyaconitine A inhibits morphine physical and psychological dependence via DYNORPHIN A expression
  1600. Is On-Demand DYNORPHIN Destined to Be in Demand to Decrease Seizures?
  1601. The Pronociceptive Activity of Spinal DYNORPHIN A is not due to Sensitization of Wide Dynamic Range Neurons
  1602. Delayed kindling development after rapidly recurring seizures: Relation to messy fiber sprouting and neurotrophin, GAP-43 and DYNORPHIN gene expression
  1603. The Role of DYNORPHIN Signaling in the Central Amygdala on Binge-like Drinking and Anxiety-like Behaviors.
  1604. Role of DYNORPHIN/Kappa Opioid Receptor Activity within the Extended Amygdala in Binge Alcohol Drinking
  1605. ERRATUM FOR “DYNORPHIN and GABAA Receptor Signaling Contribute to Progesterone’s Inhibition of the LH Surge in Female Mice”
  1606. DYNORPHIN Promotes Comorbid Migraine-like Pain in Female Mice with Temporomandibular Joint Disorders
  1607. Investigations into the Role of Orexin (Hypocretin) and DYNORPHIN in Drug Seeking, Reinforcement, and Withdrawal
  1608. DYNORPHIN A (1-17) was Selective tomicro-Opioid Receptor in Agonist-Stimulated [35S] GTPgammaS Binding in Cortical and Thalamic Membranes of Monkey
  1609. High Affinity Binding of DYNORPHIN A‐(2–13) at the Bradykinin‐2 Receptor
  1610. A Expression of DYNORPHIN A (1-8) in Ventral Hippocampus during Induction of Enhanced Seizure Susceptibility
  1611. Levodopa induces dopamine D 3 receptor expression in 6-OHDA denervated striato-nigral pathway: role of substance P and DYNORPHIN in behavioral sensitization
  1612. Effect of Early Acupuncture at Huatuo Jiajipoints on Striatalβ-endorphin and DYNORPHIN Levels in MCAO Rats
  1613. Clonidine-Induced Hyperalgesia Depends on Descending Facilitatory Pathways and on Spinal DYNORPHIN
  1614. Cathepsin L Participates in the Production of the DYNORPHIN Opioid Peptide Neurotransmitter
  1615. DREAM in astrocyte regulates proDYNORPHIN–DYNORPHIN expression and may take part in chronic pain
  1616. Receptor mechanism of DYNORPHIN A in rat secondary spinal cord injuries
  1617. IMMUNOHISTOCHEMICAL LOCALISATION OF DYNORPHIN A (1-8) AND VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) IN HUMAN COLONIC MUCOSA
  1618. DYNORPHIN A (1-13) Improves Carbachol-induced Impairment of Learning Accompanied by Blockage of Reduction in Acetylcholine Release in Rat
  1619. Determining the response of central amygdala DYNORPHIN neurons to stress and pain
  1620. Naloxone, but not DYNORPHIN A, Leu-or Met-Enkephalin, Stimulates Insulin Secretion from Rat Beta Cells
  1621. Effect of morphine dependence and abstinence on the expression of pro-DYNORPHIN mRNA in Sprague-Dawley rats
  1622. Effects of DYNORPHIN A and its receptor antagonist on spinal cord blood flow after spinal cord injury to rats
  1623. A mixture of three peptidase inhibitors increases antinociceptive effects of DYNORPHIN A (1-17) or DYNORPHIN A (1-13) by intracerebroventricularl administration in rats …
  1624. Differential time course of the effects of kappa-opioid agonist treatment on DYNORPHIN A and on k-opioid receptor density
  1625. OPTOGENETIC STIMULATION OF LATERAL HYPOTHALAMIC OREXIN/DYNORPHIN INPUTS IN
  1626. The Role of DYNORPHIN and the Kappa Opioid Receptor in Pulsatile Secretion of Gonadotropin-Releasing Hormone
  1627. The regulation of DYNORPHIN to D_ (1) dopamine receptor responses in the striatum
  1628. The developing changes of DYNORPHIN A (1-13) in rat cortex and the cerebral water content after cerebral ischemia
  1629. Effect of DYNORPHIN A1-13 on C6 glioma cells swelling induced by glutamate
  1630. Study of gene expression of melanin-concentrating hormone and of DYNORPHIN in the rat hypothalamus by multiplex competitive RT-PCR
  1631. Developing and Validating Novel Genetically Encoded Sensors in Animal Behavioral Models to Investigate KOR-DYNORPHIN Interactions
  1632. The changes of DYNORPHIN A (1-8) and the cerebral water content in rat brain after cerebral ischemia
  1633. Effect of Melatonin on the Level of DYNORPHIN in Rat Brain
  1634. … ADMINISTRATION OF PRODYNORPHIN ANTISENSE OLIGODEOXYNUCLEOTIDE SUPPRESSES BOTH PRODUCTION OF DYNORPHIN A IN DORSAL HORN …
  1635. DYNORPHIN-Immunoreactive Fibers Make Direct Contact With GnRH Neurons in the Human Preoptic Area and Hypothalamus
  1636. Effect of DYNORPHIN A 1–13 on DNA synthesis and cAMP level in the myocardium of albino rats during early postnatal ontogeny
  1637. DYNORPHIN A expression in the rat area postrema neurons under the condition of cisplatin-induced delayed emesis
  1638. The comparative distribution of enkephalin, DYNORPHIN and substance P in the human globus pallidus and basal for…
  1639. Studies of DYNORPHIN and cholecystokinin release in the rat spinal cord: implications for opioid action
  1640. Effects and receptor mechanism of DYNORPHIN-induced changes of behavior and spinal cord histology of rat
  1641. Co‐localization of DYNORPHIN with inducible cAMP element repressor (ICER) in the supraoptic nucleus
  1642. CHARACTERIZATION OF THE OPIOID PEPTIDE DYNORPHIN A AS A NOVEL LIGAND FOR LEUKOCYTE INTEGRIN αMβ2 (Mac‐1)
  1643. Uptake of I-125 radiolabelled DYNORPHIN in glioma cell cultures
  1644. The immunomodulation of DYNORPHIN 1-17 and its biotransformation fragments on inflammatory signalling pathways
  1645. Effects of intradermal administration of endogenous opioid peptides, β‐endorphin and DYNORPHIN‐A, on scratching behavior in mice
  1646. DYNORPHIN A modulates acute and chronic opioid effects through a non-opioid system.
  1647. Increased Spinal DYNORPHIN Levels, and pERK1/2 and c-Fos Immunoreactivity after Surgery under Remifentanil Anesthesia in Mice
  1648. Opioid and Non-Opoid Actions of DYNORPHIN A on Spinal Wide Dynamic Range Neurons
  1649. Conformational Analysis of DYNORPHIN A (1-8) using Hydrogen/Deuterium Exchange Coupled with Mass Spectrometry
  1650. The influence of DYNORPHIN A (1-13) on lipid peroxidation and antioxidant enzymes activity in the immobilization stress of different duration
  1651. Age-related alterations in hypothalamic kisspeptin, neurokinin B, and DYNORPHIN neurons and in pulsatile LH release in female and male rats
  1652. Mechanism and site of action of big DYNORPHIN on ASIC1a
  1653. Inhibition of neuropathic pain via DYNORPHIN analog LYS 1044
  1654. Anticonvulsant and neuroprotective actions of endogenous DYNORPHIN
  1655. Research on the change of plasma concentrations of kisspeptin, neurokinin B and DYNORPHIN in girls with idiopathic central precocious puberty
  1656. Inhibiting the bioconversion of DYNORPHIN fragments correlated to L-DOPA induced dyskinesia using on-tissue histochemistry and MALDI imaging mass spectrometry
  1657. Immunohistochemical analysis of DYNORPHIN B levels in the mouse substantia nigra after single doses of cocaine and morphine.
  1658. Early-life stress changes reactivity of reward system in the rats: the role of the DYNORPHIN/kappa-opioid system
  1659. Role of the DYNORPHIN/KOR System in Mediating the Stress Response in Mice
  1660. The role of protein convertases in bigDYNORPHIN and DYNORPHIN A metabolic pathway
  1661. Dual effect of DYNORPHIN A on single-unit spike potentials in rat trigeminal nucleus
  1662. Structure Activity Relationship of Stable DYNORPHIN A-(2-13) Analogues Interacting at the Bradykinin-2 Receptor
  1663. Involvement of DYNORPHIN in anxiogenic effects of estrogen
  1664. Repeated Ethanol Exposure Alters DNA Methylation Status and DYNORPHIN/Kappa-Opioid Receptor Expression in Nucleus Accumbens of Alcohol-Preferring AA Rats
  1665. INTERACTION BETWEEN CENTRAL NOREPINEPHRINE AND DYNORPHIN A (1-17) IN PAIN MODULATION
  1666. Nonopioid actions of DYNORPHIN and neuropathic pain
  1667. Effect of acute ethanol administration on the extracellular concentrations of the opioid peptides [beta]-endorphin, met-enkephalin and DYNORPHIN A₁-₈ at the level of …
  1668. ANALYSIS OF THE SPONTANEOUS RELEASE OF SPINAL DYNORPHIN IN PATIENTS WITH ACUTE OR CHRONIC PAIN
  1669. Potential functions of gonadotropin inhibitory hormone and DYNORPHIN in broiler breeder reproduction
  1670. Localization and Characterization of the Enkephalin and DYNORPHIN expressing interneuron populations in the mouse spinal cord and validation of DREADD …
  1671. DYNORPHIN-converting enzyme
  1672. Astrocytes play a role in chronic pain maintenance through DREAM and DYNORPHIN
  1673. Effects of gonadectomy and testosterone replacement on number of DYNORPHIN-immunoreactive (minusIR) cells in the arcuate nucleus of the hypothalamus in obese …
  1674. Kappa Opioid Receptors, DYNORPHIN and Cocaine Addiction: A Positron Emission Tomography Study
  1675. EFFECTS OF MPTP ON THE ABILITY OF SPATIAL LEARNING MEMORY AND EXPRESSION OF DYNORPHIN IN C57BL/6 MICE
  1676. The membrane interaction of DYNORPHIN A depends on lipid head-group charge
  1677. Investigation of the kisspeptin/neurokinin B/DYNORPHIN (KNDy) neurons by using N-7 cells: immortalized hypothalamic cell line
  1678. EFFECTS OF DYNORPHIN A_ (1-13) ON BRAIN EDEMA FOLLOWING COLLAGENASE-INDUCED INTRACEREBRAL HEMORRHAGE IN RATS
  1679. Pharmacological properties of DYNORPHIN A-(2-17) and structurally related novel peptides
  1680. The opioid peptide DYNORPHIN A: Biophysical studies of peptide–receptor and peptide–membrane interactions
  1681. Dermorphin-DYNORPHIN hybrid analogs: Opioid receptor selection and enzymatic stability
  1682. Spectroscopic studies of DYNORPHIN neuropeptides and the amyloid beta-peptide: The consequences of biomembrane interactions
  1683. Opioid and non-opioid mechanisms of DYNORPHIN A _ (1-13) on hypoxic-ischemic brain injury in neonatal rats
  1684. Effects of DYNORPHIN A 1 17 on the Activities, Immunoreactivities and mRNA Expression of cNOS and iNOS in Rat Spinal Cord and Their Mechanisms
  1685. NMR studies of cyclic DYNORPHIN analologues
  1686. A role for kisspeptin/neurokinin B/DYNORPHIN neurons in initiating and maintaining reproduction
  1687. Synthesis and pharmacological evaluation of DYNORPHIN A analogs constrained in the
  1688. Aladan Scanning: Study of the Structure-Activity Relationship of DYNORPHIN A
  1689. INHIBITORY EFFECTS OF DYNORPHIN-A ON SPINALLY ADMINISTERED BETA-ENDORPHIN-AND GRP-INDUCED SCRATCHING IN NONHUMAN PRIMATES
  1690. Treatment of lumbar intervertebral disk prolapse by estradural injection of mailuoning and its influence on DYNORPHIN A in cerebrospinal fluid
  1691. Design and Synthesis of DYNORPHIN A-(1–11) Analogs with C-Terminal Modifications and Evaluation of their Opioid Activity
  1692. Involvement of the DYNORPHIN/KOR system on the nociceptive, emotional and cognitive manifestations of joint pain in mice
  1693. Docking into Homology Models in tandem with Structure Activity Relationships: Bradykinin B2 Receptor Complexed with Non‐opioid DYNORPHIN A Analogues
  1694. Effect of hyperbaric oxygen therapy on DYNORPHIN content in the brain subjected to hypoxic-ischemic brain injury in neonatal rats
  1695. Strategies for the Synthesis of Novel Head-to-Side Chain Cyclic Peptides: Application to DYNORPHIN A Analogs
  1696. Relationship between Acupuncture Analgesia and Met-Enkephalin or DYNORPHIN
  1697. Molecular mechanisms underlying increased PDYN and DYNORPHIN expression in the prefrontal cortex of alcoholic men
  1698. Amphipathic Non-opioid DYNORPHIN A Analogs to Inhibit Neuroexcitatory Effects at Central Bradykinin Receptors
  1699. Effect of xylazine on the content of beta-endorphin, leucine-enkephalin and DYNORPHIN A in the blood and pituitary of rats
  1700. Systemic effects of E-2078, a stabilized DYNORPHIN A (1–8) analog, in rhesus monkeys
  1701. Lateralized response in DYNORPHIN A peptide levels after traumatic brain injury
  1702. The influence of minocycline on injury-induced changes in DYNORPHIN and nociceptin expression and effects of KOP and NOP receptor ligands in a rat model of …
  1703. DYNORPHIN promotes opioid-induced abnormal pain and antinociceptive tolerance
  1704. Investigating the synaptic regulation of kisspeptin/neurokinin B/DYNORPHIN (KNDy) neurons in a mouse model of polycystic ovarian syndrome
  1705. Pharmacokinetic and pharmacodynamic evaluation of stable DYNORPHIN A (1-13) derivatives
  1706. DYNORPHIN A–Interactions with receptors and the membrane bilayer
  1707. Antinociceptive effects of sensory stimulation involve DYNORPHIN B supraspinally in rats
  1708. 1P103 Interaction of ECL-II of κ-opioid receptor with DYNORPHIN in membrane environments as revealed by solid state NMR, QCM and MD simulation (03. Membrane …
  1709. New Developments in Kisspeptin, Neurokinin B and DYNORPHIN A Regulation of Gonadotropin-Releasing Hormone
  1710. WITHDRAWN: Enkephalin-and DYNORPHIN-release produced by electrical stimulation of different frequencies in rat brain slices
  1711. A computer simulation of DYNORPHIN A (1-17) induced spinal cord injury
  1712. Elevated DYNORPHIN A levels lead to Purkinje cell loss in spinocerebellar ataxia type 23 mice
  1713. Effects of clomiphene citrate on the expression of kisspeptin DYNORPHIN A and neurokinin B in female Sprague-Dawley rats
  1714. Expression of hypothalamic kisspeptin, neurokinin B, and DYNORPHIN A neurons attenuates in female Zucker fatty rats
  1715. Mechanisms of DYNORPHIN release and action in the hippocampus
  1716. The Role of DYNORPHIN in the Onset of Puberty in Female Lambs
  1717. Conformational polymorphism of single stranded oligonucleotides with the opioid peptide DYNORPHIN-encoding sequences: effect of CpG methylation and human …
  1718. Effect of Acupuncture Treatment on β-Endorphin and DYNORPHIN in the Endometriosis Model of Rats
  1719. Imaging mass spectrometry reveals association of nigral levels of DYNORPHIN peptides and L-DOPA-induced dyskinesia in Parkinson’s disease
  1720. Alterations of striatal DYNORPHIN peptide levels associated with L-DOPA-induced dyskinesia elucidated by imaging mass spectrometry
  1721. 1P-219 Interaction of opioid peptide DYNORPHIN and extracellular loop 2 (ECL-2) of K-opioid receptor as studied by^< 13> C NMR (The 46th Annual Meeting of the …
  1722. Immunoelectron Microscopic Observation of The Subcellular Localization of Kisspeptin, Neurokinin B and DYNORPHIN A in KNDy Neurona in The Arcuate …
  1723. Antinociceptive effect of p-hydroxymercuribenzoate through the spinal DYNORPHIN system
  1724. Effect of inhalational anesthetics on DYNORPHIN mRNA expression in spinal dorsal horn neurons after noxious stimuli
  1725. Levels of immunoreactive DYNORPHIN A_ (1-13) during development of morphine dependence in rats
  1726. AN EXPERIMENTAL STUDY OF MECHANISMS OF DYNORPHIN A_ (1-13) IN HYPOXIC-ISCHEMIC BRAIN INJURY IN NEONATAL RATS
  1727. 3P-174 Interaction of opioid peptide DYNORPHIN with extracellular loop 2 of κ-opioid receptor as studied by^< 13> C NMR (Biol & Artifi memb.: Structure & Property, The …
  1728. DYNORPHIN-induced chronic allodynia: involvement of NMDA receptors, NOS and cytokines
  1729. Brain-derived neurotrophic factor, DYNORPHIN and the homeostatic regulation of ethanol intake
  1730. Kisspeptin neurons in the arcuate nucleus of the ewe express both DYNORPHIN A and neurokinin 
Related Posts

Proanthocyanidins

Inflammation & Obesity

Adipocyte Dedifferentiation (the Reversal of Fat Formation)

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping